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General introduction 
Malaria is an infectious disease that is prevalent in the tropical and some 
temperate areas of the world. About half of the world’s population, living in some 
106 countries and territories, were believed to be at risk of infection with 
malaria parasites in the year 2009 [1]. Current malaria control strategies involve 
preventive measures such as targeting the vector with insecticides, use of 
insecticide-treated bed nets and therapeutic interventions with various drug 
formulations that target the parasite. However, the emergence of insecticide and 
drug-resistant strains of the mosquito vectors and parasites respectively [2-6] 
continue to undermine these control efforts. The greatest risk of disease and 
fatality in Plasmodium falciparum-endemic areas occurs in children under 5 
years and in first-time pregnant women (and their foetuses), with the majority of 
fatal cases occurring in sub-Saharan Africa [1]. The disease, especially in its 
severe forms, has a great economic burden as it usually leaves its victims 
incapacitated and sometimes bed-ridden. The development of an effective 
malaria vaccine therefore remains an important objective for public health and 
safety, as none of the currently available tools has proved fully efficacious. An 
effective malaria vaccine would add to the existing arsenal for the control and 
subsequent elimination of malaria globally. 
 
 
The parasite, disease pathology and symptoms 
Malaria is caused by apicomplexan parasites of the genus Plasmodium and is 
transmitted by female mosquitoes of the genus Anopheles. Four major parasite 
species are known to cause disease in humans, namely Plasmodium falciparum, P. 
vivax, P. ovale and P. malariae. Plasmodium knowlesi, a well-known simian 
parasite species, has also been recently implicated in potentially life-threatening 
human infections [7-10]. Malaria parasites have a complex life cycle that takes 
place within a primary (vertebrate) host and a secondary (insect vector) host 
(Figure 1). Generally, the human-infective sporozoite stage develops within the 
mosquito gut and is injected from the salivary glands into the blood stream when 
the mosquito takes a blood meal. Sporozoites migrate to and develop within liver 
cells, and upon release as free merozoites after 6 – 10 days, enter the blood 
phase where they cyclically invade red blood cells. P. vivax and P. ovale infections 
are unique in that some liver stages develop into dormant stages known as 
hypnozoites which can be later activated to cause disease relapse without new 
infection through mosquito bites. The blood stages of most human Plasmodium 
species have a 48-hour cycle, with P. malariae (72 hours) and P. knowlesi (24 
hours) being exceptions. 
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Figure 1. Life cycle of the human Plasmodium species. The asexual liver (A) and blood (B) 
stages occur in the primary host (humans), while the sexual stages (C) occur in the secondary 
host (mosquito). Source: http://www.uni-tuebingen.de/modeling/Mod_Malaria_Cycle_en.html, 
with slight modification. 
 
 
Some parasites develop into the mosquito-infective male and female gametocyte 
stages in the bloodstream, which after being taken up by mosquitoes during a 
blood meal fertilize and perpetuate the entire cycle.  
Blood stage infection with the parasite is responsible for such non-specific 
clinical symptoms as nausea/vomiting, sweating, headaches, muscular/joint 
pains and fatigue in the vertebrate host. Fever/chills experienced by an infected 
person are associated with the periodic release of toxins/pyrogens and other 
inflammatory mediators alongside merozoites following the synchronous lyses 
of infected red blood cells.  
Of the species known to cause disease in humans, P. falciparum infection is the 
most severe and usually results in disease complications. P. vivax (and P. ovale) 
infections can also cause disease with relapses that are especially difficult to 
treat. While all other species have an erythrocyte developmental age restriction, 
P. falciparum (and P. knowlesi) infects erythrocytes of all ages and can thus attain 
very high parasitaemias in vivo. This, together with the ability of red cells that 
contain developing trophozoites/schizonts to sequester in the microvasculature 
of vital organs by adhering to endothelial cells, and also form rosettes with 
uninfected erythrocytes, makes P. falciparum highly virulent. Cytoadherence and 
red cell rosettes are believed to cause blockage of small blood vessels in vital 
organs such as the brain, resulting in ischaemia. Disease complications include 
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severe anaemia, cerebral malaria, respiratory distress, lactic acidosis, multiple 
organ pigmentation and organ failure, resulting in death in extreme cases. 
Although parasite sequestration and rosetting have been implicated in these 
disease complications, a significant portion of clinical symptoms are also due to 
immuno-pathology resulting from the host’s response to the presence of 
parasites [11,12]. 
 
 
Immunity to malaria  
People living in malaria-endemic areas usually develop natural immunity to 
clinical malaria in an age- and exposure-dependent manner after a number of 
parasite infections [13,14]. Development of immunity is believed to be faster in 
high disease transmission areas compared to low transmission areas [14-16]. 
Infants and young children are most especially susceptible to disease, and 
usually suffer a number of clinical episodes before achieving a level of protection 
from severe disease, although they may continue to harbour parasites and suffer 
mild disease. Even in adults who have had several parasite encounters, acquired 
clinical immunity is believed to be partial and short-lived, and its maintenance 
requires periodic exposure to low-level parasitaemia [14,17].  
The mechanisms underlying protective immunity to parasite infection and 
clinical disease in humans are not fully understood. Studies conducted in vitro, in 
animal models and in humans point to the involvement of both cellular and 
humoral immune effectors in a parasite stage-specific manner [14,18], and 
include both innate and adaptive immune mechanisms. Innate immune 
mechanisms involving monocytes, neutrophils, macrophages, natural killer (NK) 
cells, γδT cells and natural killer T (NKT) cells as well as their soluble secretory 
products have all been shown to play a role in parasite killing and protection 
from disease. These cells either inhibit parasite growth or mediate parasite 
clearance through phagocytosis and cytotoxicity [19-21].  Secreted factors such 
as nitric oxide (NO) kill parasites by inhibiting key enzymes, while factors such 
as TNF-α and IFN-γ augment the parasite killing functions of immune cells in 
pre-erythrocytic and erythrocytic stages [18,21-26]. The innate arm of immunity 
also provides the necessary help to achieve an effective adaptive response, and 
immune effects of the two arms are not mutually exclusive.  
 
Cell-mediated immunity  
Apart from the non-specific effector functions of innate immune cells, parasite 
antigen-specific T cell responses have also been demonstrated. Both CD4+ and 
CD8+ T cell responses are elicited by processed parasite antigenic peptides 
presented in the appropriate MHC context by APCs such as dendritic cells or 
macrophages along with the appropriate co-stimulatory ligations, and these 
responses directly or indirectly kill parasites or inhibit their growth [18,27]. 
Generally, a T helper 1 (Th1)-driven immune response is necessary for initial 
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control of the acute phase of disease, whilst a Th2-type counterbalance becomes 
essential for eventual elimination of the parasite and subsequent resolution of 
disease as well as for curbing immunopathology [17,28]. CD4+ Th1 cells promote 
a more pro-inflammatory response early during infection, while CD4+ Th2 cells 
promote anti-inflammatory responses during the chronic phase of infection or 
during convalescence. While both CD4+ and CD8+ T cell responses are generally 
believed to be important against liver stages of the parasite [18,22,29,30], the 
direct cytotoxic activity of CD8+ T cells may have a limited role in controlling 
blood stage infections since erythrocytes, which harbour the blood stage 
parasites, do not express MHC molecules and cannot present processed parasite 
peptides directly to T cells [31]. CD4+ T cells have however been shown to be 
important for blood stage immunity as through secretion of the appropriate 
cytokines/proteins, they induce nitric oxide synthesis and provide B cells the 
needed help for antibody production and class-switching [23,32-35].  
CD4+ and CD8+ T cell responses are adaptive responses and therefore induce 
memory. T cell memory against malarial antigens has been demonstrated [29,36-
38]. Primed T cells undergo expansion and maturation during the secondary 
response to processed and MHC-presented cognate peptides and yield memory 
and effector T cells. While effector T cells undergo apoptosis after resolution of 
infection, memory T cells persist and are likely to be long-lived since re-exposure 
to parasite antigens after some time results in rapid gain of immunity [39,40]. 
Although other studies have found short-lived malaria-specific T cell responses 
[41,42], the induction of long-term T cell memory is crucial in vaccine design 
since vaccine effectiveness depends on the rapid recall of previously 
encountered antigens. These notwithstanding, protective immunity especially 
against acute malaria may ultimately depend on the maintenance of high levels 
of the relevant effectors rather than on generating effectors from resting 
memory cells [40].  
Regulatory T cells (Tregs) are also important immune effector cells that can 
greatly influence the course of an infection. An appropriate and timely induction 
of Tregs is required to regulate the induced anti-parasite responses and prevent 
excessive immune elaboration. Excessive responses resulting from the lack of 
control of the immune response to parasites may cause serious 
immunopathology, whilst an early induction of regulatory mechanisms may elicit 
tolerance to parasites and render parasite control by the immune system 
ineffective [28,43]. Guilbride et al. [44] have recently suggested that sporozoites 
that remain in the skin following inoculation by the mosquito vector may induce 
parasite-specific regulatory T cells within the skin and these may subsequently 
thwart the development of protective immunity against infection. B cells with 
general immune suppressive/regulatory functions (Bregs) have also been 
described mostly in mice (Reviewed in [45]), but there is very little human data 
and currently no data on the role of Bregs in malaria. 
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Antibody-mediated immunity  
Antibodies are secreted by B cells and have very important effector functions in 
the adaptive immune system. Immature B cells released from the bone marrow 
usually express membrane-bound IgM, and develop into naïve B cells in the 
marginal zone or follicular areas of secondary lymphoid organs such as the 
spleen and lymph nodes as well as secondary lymphoid follicles in inflamed 
tissue (Figure 2). Upon encounter with foreign antigen presented by APC and 
with T cell help, follicular naïve B cells, which are capable of peripheral 
circulation, differentiate into antigen-specific memory B cells or plasma 
cells/precursors. These differentiated cells undergo isotype/subclass switching 
and express IgG, IgA or IgE depending on the antigen stimulus and the cytokine 
signals received from helper T cells. Memory B cells do not secrete antibodies 
but rather express membrane-bound immunoglobulins. Marginal zone B cells are 
non-circulating, develop into short-lived plasma cells without T cell help upon 
antigen contact and do not usually differentiate into memory cells [47,48]. A 
small proportion of antibody-secreting/plasma cells usually resides in secondary 
lymphoid organs and secretes antibodies. The majority of these cells, depending 
on the chemokine receptors they express, migrate as plasma cell precursors 
called plasmablasts either to tissue sites of infection or into the bone marrow 
and actively secrete antibodies specific for the cognate antigen [46]. 
Inflammatory mediators in inflamed tissues act as survival signals, and plasma 
cells in these tissues are short-lived as they undergo apoptosis upon resolution 
of inflammation/infection, while long-lived plasma cells can reside in the bone 
marrow for months to decades [46,49-51]. 
 
 
 
Figure 2. Maturation, activation, differentiation and survival of B-lymphocytes.  
Source: Radbruch et al. [46]. 
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Upon secondary contact with the same or similar antigen in germinal centres of 
secondary lymphoid organs, memory B cells rapidly expand and undergo affinity 
maturation through somatic hypermutation in the variable regions of 
immunoglobulin genes [52,53]. The antibodies rapidly produced after these 
events show higher specificity/affinity for the cognate antigen. Antibodies 
recognise and bind to specific determinants known as epitopes on an antigen. 
Antibody epitopes are usually conformational in nature, although linear epitopes 
occur.  Antibodies specific for one antigen may cross-react with other antigens to 
varying extents if these other antigens share epitopes with the antibody-inducing 
antigen.  
Anti-malarial antibodies play a major role in controlling blood stage 
infection/clinical disease symptoms. This was demonstrated in passive transfer 
experiments decades ago, in which gamma globulins isolated from the 
hyperimmune serum of adults were able to control clinical symptoms and 
parasitaemia in children [54-57]. Anti-malarial antibodies are usually directed 
against free merozoite surface antigens or parasite antigens expressed on the 
surface of infected erythrocytes, and are mainly of the IgG isotype. The extent of 
anti-disease protection has been shown to correlate with levels of antibody 
against asexual stage parasite antigens and is dependent on antibody isotypes, 
with IgG1 and IgG3 being most important in humans [58-65]. In normal healthy 
individuals the total IgG pool consists on average of 67% IgG1, 22% IgG2, 7% 
IgG3 and 4% IgG4 [66]. Predominant expression of IgG1, IgG3 or both subclasses 
in response to malaria infection is believed to be dependent on the type of 
antigen, cumulative exposure to the antigen as well as on the infected person’s 
age [65,67]. High levels of antibodies against pre-erythrocytic parasite antigens 
have also been associated with a reduced risk of developing clinical malaria in 
endemic areas [68,69]. Protective anti-malarial antibodies are known to mediate 
anti-parasite effector functions such as the inhibition of erythrocyte invasion 
[70-72], inhibition of cytoadherence [73,74], neutralisation of parasite toxins 
[75,76]  and participation in antibody-dependent cytotoxicity and antibody-
dependent cellular inhibition [77-79]. 
Despite the crucial role antibodies play in the resolution of infection, anti-
malarial antibodies, either acquired naturally or induced by vaccination are 
rapidly lost after resolution of infection in comparison with other 
infections/immunisations [80]. Short-lived protective responses have been 
partially attributed to immune evasion mechanisms of the parasite. Interference 
with the maturation and antigen presenting functions of dendritic cells, the first 
stage in inducing memory and effector B and T cells, as well as the active deletion 
of malaria-specific memory and effector cells have been demonstrated [81-84]. 
Long-term protection from disease depends on the maintenance of immune 
memory to infection, such that subsequent encounter with parasites induces a 
rapid recall response. There are conflicting reports on the longevity of memory 
to malaria infection in endemic areas. While some researchers have reported 
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short-lived memory and antibody responses in the absence of continued 
exposure to low-level parasitaemia [85-87], others have recently identified 
populations with stable levels of anti-malarial antibodies and memory B cells in 
the absence of recurring infections [88,89]. Some other studies have shown that 
there is an age-dependent transition from short-lived to long-lived antibody 
responses in endemic areas [90,91]. Despite these varied findings, protective 
immunity especially against acute malaria may ultimately depend on the 
maintenance of optimal levels of the relevant effectors (here plasma cells and/or 
antibodies) and/or the time it takes to generate these effectors from memory 
cells relative to parasite growth [40,92]. Ultimately, an effective vaccine against 
malaria may need to address the challenge of short-lived memory/protective 
responses.  
 
Malaria vaccine development 
Vaccines are recognised the world over as important epidemiological control 
tools for disease prevention. The natural acquisition of anti-disease immunity in 
adults living in malaria-endemic areas and the successful treatment of 
susceptible individuals with gamma globulins from semi-immune adults [55-
57,93]  suggests that the development of an antibody-mediated blood stage 
vaccine is feasible. A cost-effective vaccine would form a powerful additional 
component in current malaria control strategies. Malaria vaccine development 
has however proven very challenging because of the parasite’s complex nature 
and the difficulty of correlating naturally acquired immune responses to 
protection against infection and/or disease. Current knowledge of the immune 
system suggests that an effective malaria vaccine would need to induce long-
term CD4+ T cell responses irrespective of the parasite stage being targeted 
[17,33,35,94,95]. For vaccines targeting pre-erythrocytic stages of the parasite, 
complementary responses include CD8+ T cell as well as antibody responses, 
whilst robust antibody responses are mainly required against the erythrocytic 
stages [17,18,27]. An effective vaccine would be expected to achieve in infants, 
children first-time pregnant women and/or naïve adults at least the anti-disease 
immune status of semi-immune adults, though over a shorter period of time. 
One strategy of malaria vaccine development involves immunisation with whole 
parasites (sporozoites) that have been attenuated chemically, genetically or 
through irradiation [96-100]. Attenuation ensures that sporozoites become non-
replicating while maintaining a metabolically active state. This strategy has the 
advantage of not requiring adjuvants and exposes vaccinees to all parasite 
antigens in their native conformation, thus avoiding the selection of one or a few 
antigens since the exact targets of protective immunity are poorly defined. This 
strategy has demonstrated robust induction of both cell and antibody-mediated 
responses in rodent models as well as in humans [96-99]. This strategy, despite 
showing very promising results, has a number of inherent challenges including 
parasite (sporozoite) culturing, isolation, storage and vaccine delivery 
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conditions, which would inflate the cost of production as well as final vaccine 
safety. Despite these challenges, optimization of these conditions and clinical 
development of such vaccination strategies are still progressing.  
Vaccination with merozoites, either emulsified with adjuvant or a low dose of 
live parasites followed by drug cure, represent another whole parasite strategy. 
The effectiveness of this strategy has been demonstrated with challenge studies 
in mice, monkeys and humans [101-107]. Administration of low doses of live P. 
falciparum parasites in human volunteers with subsequent drug cure induced 
sterile T cell-mediated protection that was characterised by production of high 
levels of interferon-gamma (IFN-γ) and increased activity of nitric oxide 
synthase but no detectable levels of interleukin4 (IL-4), IL-10 or malaria specific 
antibodies [107]. As with whole sporozoite vaccines, there are practical 
challenges to this approach, to which solutions are currently being sought. 
Subunit vaccine development, the second general strategy, aims to focus the 
immune response on one or a few parasite antigens that have shown promise as 
vaccine candidates. This strategy has the advantage of using defined and highly 
purified recombinant antigens that allow a practical elucidation of the immune 
mechanisms underlying vaccine effectiveness. It however requires the selection 
of very essential targets that are highly antigenic/immunogenic and vaccination 
may be carried out with adjuvant-formulated antigen, or may be delivered as the 
gene preferably incorporated in a viral vector. Antigens may be specific to the 
pre-erythrocytic, erythrocytic or sexual stages of the developing parasite, or may 
be found in different stages of the parasite’s life cycle. While erythrocytic and 
pre-erythrocytic candidates would prevent disease by targeting parasites before 
or during the asexual blood stage and therefore of benefit to the individual, 
sexual stage candidates are typically transmission-blocking and only have 
community-related benefits.  
Though the main targets of protective immunity to malaria are not clearly 
defined, a limited number of accessible parasite antigens expressed at various 
stages of the parasite’s complex life cycle have been linked with protective 
responses in in vitro studies as well as in murine and simian malaria models 
[108-114]. These antigens were identified, and subsequently characterised, 
through their binding to antibodies purified from hyperimmune sera. A handful 
of these antigens are currently undergoing pre-clinical and clinical testing. 
Prominent amongst these are the variant surface antigens (VSAs) that are 
expressed on the surface of infected red cells. Other prominent antigens are 
either expressed/localized to the parasite surface or associated with the 
parasitophorous vacuole and include circumsporozoite protein (CSP), 
thrombospondin-related anonymous protein (TRAP), the liver stage antigens 
(LSAs), apical membrane antigen 1 (AMA1), the merozoite surface proteins 
(MSPs), Glutamate-rich protein (GLURP), erythrocyte binding antigens (EBA), 
the parasite protein anchor molecule glycosylphosphatidylinositol (GPI) as well 
as the gametocyte/ookinate-specific antigens Pfs25, Pfs28, Pfs48/45 and Pfs230. 
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While some of these antigens are developmental stage-specific (eg. LSA, TRAP), 
others like AMA1, GLURP and EBA-175 are found in multiple developmental 
stages [115-118]. Most of these antigens are believed to be essential for the 
parasite’s survival and/or effective transition from one developmental stage to 
another. Targeting these antigens would therefore kill parasites directly or 
interrupt their life cycle.  
The RTS,S subunit vaccine, comprising the antigenic C-terminal repeat regions of 
P. falciparum CSP fused to the N terminal of the surface antigen of Hepatitis B 
virus is the most clinically advanced malaria vaccine. Development of this 
candidate started over two decades ago, and different adjuvant formulations of 
this candidate have over the years demonstrated a generally good safety and 
tolerability profile. Earlier challenge studies of this candidate formulated with 
SBAS2 (currently known as AS02) in malaria-naïve adult volunteers showed 
protection against sporozoite challenge in 6 out of 7 volunteers [119]. A phase 
IIb trial with AS02A as adjuvant in children 1-4 years showed a 37% reduction in 
prevalence of P. falciparum infection compared to Hepatitis B-vaccinated 
controls, and a vaccine efficacy (time to first clinical episode) of 57.7% over a 6-
month follow-up period [120]. Later analysis of data for all randomized subjects 
showed a 30.5% vaccine efficacy against first time infection and 34% lower P. 
falciparum prevalence in the vaccine group compared to controls over the 45-
month surveillance period [121]. A trial of RTS,S formulated with AS01E in 894 
children aged 5 – 17 months showed vaccine efficacy (against first time 
infection) of 39.2% 12 months after the final vaccination and efficacy of 45.8% in 
a cohort followed-up for 15 months [122]. In the same study vaccine efficacy 
after the first 8 months of follow-up was 53% [123]. Another trial with AS02D 
formulations in 340 newborns/infants demonstrated 65.2% efficacy against first 
infection with P. falciparum 6 months after administration of the last vaccine 
dose [124]. In a phase I/IIb trial of RTS,S formulated with AS02D in 214 
newborns/infants, vaccine efficacy against clinical malaria was estimated at 33% 
over a 4-month follow-up period [125]. Based on these varied yet encouraging 
trial results, RTS,S has been described as a “leaky” vaccine that confers partial 
protection to most or all vaccinees [126,127]. The vaccine’s protective effects are 
believed to be mediated mainly by antibodies and CD4+ T cells to the CSP repeat 
regions, with very little evidence for CD8+ T cell activity [128-130]. The RTS,S 
vaccine formulated in AS01 is currently undergoing phase III multi-site trials in 
Africa, involving about 16,000 infants and children in 11 centres with varying 
transmission intensities. 
 
Antigenic polymorphism and immune evasion 
Most subunit vaccine candidate antigens currently under investigation are 
polymorphic in nature, and this presents a formidable challenge to their 
development as vaccines. Allelic polymorphism is believed to be a host immune 
evasion strategy that renders a functional host response to one parasite variant 
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ineffective against other variants [131-133]. This view is supported by the fact 
that polymorphism usually occurs in portions of the parasite’s conformationally 
intact surface antigens that are likely to be accessible to antibodies in vivo 
[133,134]. Parasites have also been shown to modulate the host’s immune 
system by dampening anti-parasite effector responses and inducing regulatory 
responses in various immune cell types in the skin and other immune cell 
compartments [44,81,135,136], thereby inducing immunosuppression to their 
survival benefit.  
The discovery of potent novel candidate antigens is crucial to the development of 
a vaccine against malaria. The advent of new technologies and the current 
advancement in -omics research makes this ever more feasible. Nevertheless, 
there is the need to better understand and improve on immune responses to 
already known candidates that exhibit antigenic variation and allelic 
polymorphism by tweaking vaccine formulation and delivery systems since most 
of these known candidates naturally elicit functional responses. Two general 
approaches can be employed to ensure that such candidates yield desired 
immune responses. The first is to develop subunit vaccines based on conserved 
and immunogenic parts of candidates such as MSP1, MSP3, GLURP and CSP. The 
second approach involves tackling allelic polymorphism by incorporating a 
number of allelic forms either as fusion proteins or as antigen cocktails in a 
single vaccine. The vaccine candidate AMA1-C1 [137] being developed by NIAID, 
and the DiCo strategy [138] being developed by BPRC Rijswijk are examples of 
multi-allele vaccines for dealing with extensive polymorphism in AMA1. 
 
AMA1, a polymorphic vaccine target  
AMA1 is a type 1 trans-membrane protein that is expressed as an 83 kDa 
precursor protein and initially located in micronemes of the merozoite [139-
142]. This precursor is further processed to a 66 kDa protein by the removal of 
the N-terminal prosequence [141,143,144]. The precise role of AMA1 has not 
been fully elucidated, but it is believed to be involved in the formation of the 
contact junction between parasite membrane and the red cell membrane 
following apical re-orientation and prior to red cell invasion [145,146]. Around 
the time of merozoite release from schizonts, the 66 kDa AMA1 is translocated to 
the merozoite surface where it interacts with other invasion-associated antigens 
like the RON proteins at the point of attachment to the red cell surface 
[140,145,147-152]. Its release from micronemes has been shown to be triggered 
by differences in the ionic environment between the erythrocyte cytosol and the 
intravascular compartment, and is sequentially followed by the release of 
rhoptry antigens [153,154]. The ectodomain of AMA1, which is the vaccine 
target, is shed as 44 and 48 kDa alternate proteins from the merozoite surface 
upon red cell invasion [141,155]. The amino acid sequence of the AMA1 
ectodomain has 16 cysteine residues that are conserved in all known AMA1 
sequences and these form disulphide bonds that result in a structure with three 
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distinguishable but interactive domains (Figure 3). The vaccine potential of 
AMA1 is informed by the fact that antibodies against the ectodomain can 
interfere with AMA1 processing and prevent red cell invasion in vitro 
[71,72,156,157], and this effect requires immunisation with correctly folded 
AMA1 [112,158]. Despite the short exposure time for merozoites in between red 
cell invasions and the low abundance of AMA1 relative to other merozoite 
antigens, anti-AMA1 antibody levels in naturally exposed populations are usually 
high compared to antibodies against other blood stage antigens [159-161]. 
Additionally, a significant proportion of new-borns and infants show relatively 
higher levels of placentally transferred anti-AMA1 antibodies [162]. Antibodies 
to domain I of the molecule are more prevalent than those to domains II and III, 
even though dominant antibody epitopes seem to be dependent on more than 
one domain [163-165]. 
The vaccine potential of AMA1 is limited by allelic polymorphism resulting from 
single amino acid substitutions in an estimated 17% of the 622 amino acid 
positions within the AMA1 molecule (Remarque, unpublished data). A significant 
number of amino acids at polymorphic positions however occur at very low 
frequency. Polymorphism results from non-synonymous single nucleotide 
substitutions within the single ama1 gene locus [131,166-168], a phenomenon 
that has been linked with selective pressure from the host immune system. 
 
 
Figure 3. Ribbon structure of the ectodomain of AMA1. 
The three antigen domains are shown in blue (domain I), yellow (domain II) and red (domain III).  
Source: ESRF website (http://www.esrf.eu/news/spotlight/spotlight19malaria/) 
 
General introduction 
13 
 
The majority of amino acid substitutions occur within domain I of the 
ectodomain and are di- or trimorphic, with a single heptamorphic site at amino 
acid position 197 [133,169,170]. Polymorphic residues have been shown to 
occur predominantly on one surface of the AMA1 molecule, and this suggests 
that this face at the parasite surface is more accessible to antibodies [169,171], 
and/or that antigenic variation on the more conserved surface is subject to 
strong functional constraints. Polymorphism in AMA1 renders a fully functional 
immune response against one parasite strain less effective against strains 
expressing other allelic variants. This has been extensively demonstrated in 
murine models [109,110,172]  and this may also be the case in humans 
[173,174]. Thus the immune response to AMA1, believed to be mainly antibody-
mediated, is to both strain-specific and conserved epitopes [112,163,165]. A 
vaccine strategy based on AMA1 would therefore have to circumvent the 
inherent strain specificity of immune responses to the molecule in order to have 
broad functional benefits. This may be achieved through vaccine formulations 
that incorporate a number of polymorphic alleles, and the AMA1-C1 vaccine 
candidate, developed by the US NIAID and comprising an equimolar mixture of 
AMA1 alleles from the FVO and 3D7 parasite strains [137,175,176]  in an 
example. This strategy of vaccine formulation was also exploited in the in silico 
design of three Diversity-Covering (DiCo) proteins based on 355 published 
unique sequences of AMA1 that were available at the time of design [138]. The 
three antigens expressed in the yeast Pichia pastoris and purified from culture 
supernatants. When formulated as a cocktail with adjuvant, they induce antibody 
responses that show broad AMA1 allele recognition and in vitro inhibition of 
diverse parasite strains. 
 
Aims and outline of thesis 
An effective malaria vaccine will be a valuable and cost-effective addition to 
currently available malaria control tools, and a lot of effort and resources are 
being devoted to finding an effective vaccine. All approaches to malaria vaccine 
development face peculiar challenges, and in addition to discovering novel 
vaccine targets, there is the need to fine-tune immune responses against already 
known and available targets. One such vaccine target is the ectodomain of P. 
falciparum AMA1 (PfAMA1), an essential parasite protein that exhibits extensive 
polymorphism. There are currently 1778 valid published PfAMA1 protein 
sequences (GenBank), from which 649 unique alleles have been identified 
(Remarque, personal communication). This huge diversity begs the question 
whether there are common antigenic determinants to which functional 
antibodies can be induced, since a broad-acting vaccine would need to be 
effective against most or all parasite variants.   
This thesis focuses on strategies for PfAMA1 vaccine formulation that can 
broaden the antibody response and ultimately achieve near universal 
functionality. It addresses issues relating to the fine dissection of antibody 
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responses to PfAMA1 as well as to existing approaches for assessing vaccine 
effectiveness. 
In chapter 2 of this thesis, a competition ELISA protocol with high sensitivity and 
reproducibility for analyzing antibody specificities to allelic variants of PfAMA1 
was developed. This assay, together with in vitro parasite growth inhibition 
assays, was used to show that rabbits immunised with a three-antigen PfAMA1 
cocktail vaccine elicit antibodies that exhibit greater cross-reactivity and broader 
in vitro inhibitory activity than antibodies induced against a single PfAMA1 allele. 
The induction of functional anti-AMA1 antibodies to epitopes shared by a 
number of different PfAMA1 alleles was also established.  
In chapter 3, the antibody responses induced in rabbits against cocktail vaccines 
incorporating three and seven antigens were compared. Data obtained showed 
that a cocktail of three DiCo AMA1 antigens (DiCo mix) induced antibodies with 
similar specificity and functionality as antibodies induced with a seven-antigen 
(DiCo mix + AMA1 of FVO, HB3, 3D7 and CAMP strains of P. falciparum) vaccine 
cocktail. It was also established here that DiCo mix vaccines in three different 
adjuvants induced very similar proportions of antibodies against shared AMA1 
epitopes, irrespective of the adjuvant used for formulation. The absolute levels of 
induced antibodies were however dependent on the choice of adjuvant. This is 
important for the further development of PfAMA1-based vaccines, as adjuvant 
selection for subsequent clinical development will be determined mainly by the 
antibody potentiation (quantity) properties of the adjuvant.  
Data showing that immunisation of rabbits with three different PfAMA1 alleles 
(from the FVO, HB3 and 3D7 parasite strains) either in sequence or as a vaccine 
cocktail, yields antibodies with comparable specificity and functionality is 
presented in chapter 4. Since clinical immunity to malaria develops after 
(sequential) exposure to a diversity of parasites, a vaccine cocktail would be 
expected to induce immunity similar to that acquired through natural infection, 
but over a shorter period of time. The data therefore suggests that acquisition of 
natural immunity involves accumulation of antibodies to shared epitopes with 
time and exposure to variant parasite strains.  
The induction of antibodies with broadened allele recognition and parasite 
inhibition capacity after immunisation with a multi-allele PfAMA1 vaccine was 
confirmed in rhesus monkeys as a more representative model for immunity to 
malaria in humans, and the data is presented in chapter 5.  Different groups of 
monkeys were immunised with DiCo mix formulated in two different adjuvants 
(CoVaccine HT and Montanide ISA51), as well as with a PfAMA1-MSP119 fusion 
protein in Montanide ISA51, with all vaccine formulations demonstrating a 
generally good tolerability profile.  
In chapter 6, the effect of antigenic diversity on the laboratory measurement of 
anti-PfAMA1 antibodies in naturally exposed individuals was investigated. 
Antibody levels in the plasma of infants and children exposed naturally to P. 
falciparum were measured against 4 PfAMA1 allelic variants as well as 3 antigen 
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cocktails and compared. The data showed that humans, especially infants and 
younger children with very few parasite encounters, discriminate between 
different PfAMA1 alleles, just as is the case for other mammalian species. The 
implication of this for the measurement of antibody responses against PfAMA1 
as a polymorphic antigen in vaccine studies and especially in the field has been 
highlighted.  
A general discussion of the key findings in this thesis, the current status of 
malaria vaccine development as well as the vaccine-related implications of 
antigenic diversity in AMA1 that is found naturally in P. falciparum isolates from 
malaria-endemic areas are finally presented in chapter 7.  
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ABSTRACT 
 
Apical Membrane Antigen 1 (AMA1), a merozoite protein essential for red cell 
invasion, is a candidate malaria vaccine component. Immune responses to AMA1 
can protect in experimental animal models and antibodies isolated from AMA1-
vaccinated or malaria-exposed humans can inhibit parasite multiplication in 
vitro. The parasite is haploid in the vertebrate host and the genome contains a 
single copy of AMA1, yet on a population basis a number of AMA1 molecular 
surface residues are polymorphic, a property thought to be primarily as a result 
of selective immune pressure.  After immunisation with AMA1, antibodies more 
effectively inhibit strains carrying homologous AMA1 genes, suggesting that 
polymorphism may compromise vaccine efficacy.  Here, we analyse induction of 
broad strain inhibitory antibodies with a multi-allele Plasmodium falciparum 
AMA1 (PfAMA1) vaccine, and determine the relative importance of cross-
reactive and strain-specific IgG fractions by competition ELISA and in vitro 
parasite growth inhibition assays.  
Immunisation of rabbits with a PfAMA1 allele mixture yielded an increased 
proportion of antibodies to epitopes common to all vaccine alleles, compared to 
single allele immunisation. Competition ELISA with the anti-PfAMA1 antibody 
fraction that is cross-reactive between FVO and 3D7 AMA1 alleles showed that 
over 80% of these common antibodies were shared with other PfAMA1 alleles. 
Furthermore, growth inhibition assays revealed that for any PfAMA1 allele (FVO 
or 3D7), the cross-reactive fraction alone, on basis of weight, had the same 
functional capacity on homologous parasites as the total affinity-purified IgGs 
(cross-reactive + strain-specific). By contrast, the strain-specific IgG fraction of 
either PfAMA1 allele showed slightly less inhibition of red cell invasion by 
homologous strains.  
Thus multi-allele immunisation relatively increases the levels of antibodies to 
common allele epitopes. This explains the broadened cross inhibition of diverse 
malaria parasites, and suggests multi-allele approaches warrant further clinical 
investigation.  
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INTRODUCTION 
Malaria continues to be one of the most important human parasitic diseases, 
with a global estimate of about 247 million clinical cases and almost 1 million 
deaths annually [1]. The greater burden of the disease is caused by Plasmodium 
falciparum in sub-Saharan Africa, where children under 5 years old, pregnant 
women (mostly primigravid) and their foetuses are at the greatest risk. A cost-
effective vaccine would form a powerful additional component in control 
strategies for malaria and a number of Plasmodium antigens expressed at 
different stages of the parasite’s complex life cycle are currently undergoing 
clinical evaluation [2]. 
Among the candidates in clinical testing is Plasmodium falciparum Apical 
Membrane Antigen 1 (PfAMA1), a protein expressed in sporozoites and in 
merozoites of both liver and asexual erythrocytic development stages, the 
vaccine-related properties of which has recently been reviewed [3]. In brief, 
AMA1 is a merozoite membrane protein initially located in micronemes.  Around 
the time of merozoite release from schizonts AMA1 is translocated to the 
merozoite surface, where it is involved in merozoite/red cell interactions 
preceding invasion [4–6].  Anti-AMA1 antibodies can interfere with AMA1 
function and prevent invasion in vitro [7–10], this effect requiring immunisation 
with correctly folded AMA1 [11,12]. The ectodomain of AMA1, which is the 
vaccine target, is shed as 44 and 48 kDa alternate proteins from the merozoite 
surface upon RBC invasion [13].  The amino acid sequence of the ectodomain has 
16 cysteine residues that are conserved in all AMA1 sequences and these form 
disulphide bonds that result in a structure with three distinguishable but 
interactive domains (reviewed in [3]).  
Polymorphism in AMA1 has long been evident [14], thought to be an effect of 
selection exerted by host immune responses [15,16]. Immunisation with one 
allele of AMA1 ectodomain induces antibodies that inhibit homologous parasite 
growth in vitro to a greater extent as compared to heterologous parasites 
[12,17,18]. The induction of functional antibodies has been demonstrated in a 
number of ways, including rodent and primate challenge/passive immunisation 
studies [15,19–21].  In some cases, and particularly with the rodent parasite P. 
chabaudi, antibodies are protective against parasites expressing homologous 
AMA1 but not those expressing heterologous AMA1 alleles [15,22]. Antibodies to 
both conserved and strain-specific PfAMA1 antibody epitopes have been 
observed in malaria-exposed humans [23,24].  
About 10% of amino acid residues of AMA1 are polymorphic, and even when 
appearing distant in the primary structure, may cluster within the tertiary 
structure [25–27]. These polymorphic clusters occur predominantly on one 
surface of the AMA1 molecule, which suggests that this face is accessible to 
antibody at the parasite surface [28]. This points to the significance of strain-
specific epitopes in eliciting protective antibodies [12,17,29], although conserved 
AMA1 epitopes are also targets for inhibitory antibodies [30,31].  
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Antibodies induced by immunisation with a combination of two allelic forms of 
PfAMA1 (FVO and 3D7) inhibit the in vitro growth of both parasite strains to the 
same extent as antibodies raised against the single respective antigens [17], 
although there was no significant gain in growth inhibition against unrelated 
parasite strains. Similar observations from antigen recognition in ELISA have 
been reported in human trials with vaccine candidates incorporating PfAMA1 
proteins from the FVO and 3D7 parasite strains [32–34], and multi-allele 
immunisation  has been proposed as one way of overcoming strain-specificity in 
PfAMA1 responses.  The question remains whether antibodies elicited by a 
multi-allele vaccine would be effective against parasites expressing a relatively 
distant natural PfAMA1 allele from those of the vaccine components.  
An effective PfAMA1 vaccine will be required to overcome allelic diversity. We 
have therefore obtained sera from rabbits immunised separately with the full 
ectodomain PfAMA1 from FVO, 3D7 and HB3 strains, as well as sera from rabbits 
immunised with a mixture of these 3 PfAMA1 alleles, to assess the feasibility and 
mechanism of broadening the antibody response by immunisation with a 
mixture of PfAMA1 alleles. Strain-specific and cross-reactive anti-PfAMA1 
antibody fractions were also used to assess the relative importance and 
contribution of these two IgG fractions to the overall in vitro functional capacity 
of anti-PfAMA1 antibodies. The study was also used to validate the competition 
ELISA methodology for assessing antibody responses to naturally-occurring 
PfAMA1 antigens and establish it as an analytical tool for dissecting humoral 
immune responses to polymorphic antigens. Our data shows the feasibility of 
broadening the functional antibody response to PfAMA1 by immunisation with a 
mixture of three PfAMA1 alleles. Such a vaccine preferentially induces the 
expression of antibodies to epitopes that are common to the vaccine component 
alleles by diluting out responses to the strain-specific epitopes. Common or 
cross-reactive antibodies, in the absence of strain-specific antibodies, are capable 
of inhibiting the in vitro growth of parasites represented by the vaccine PfAMA1 
alleles as well as parasites expressing PfAMA1 alleles not included in the vaccine. 
The data indicates that PfAMA1 multi-allele vaccine strategies should be pursued 
and provide a justification for further clinical investigation. 
 
 
METHODS 
 
Protein production and rabbit immunisations 
The full ectodomain of AMA1 allelic forms from the P. falciparum strains FVO, 
HB3, 3D7 and CAMP were expressed in Pichia pastoris by a similar methodology 
as described elsewhere [35,36].  Potential N-glycosylation sites were removed 
from the PfAMA1 gene sequences by mutagenesis before expression. 
All animals were handled in strict accordance with good animal practice as 
defined by the Belgian national animal welfare regulations, and all animal work 
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was approved by the ethics committee of the Centre d'Economie Rurale (CER 
Groupe, Marloie, Belgium). Rabbit immunisations were done intramuscularly 
(Eurogentec SA, Seraing, Belgium) with 4 doses of PfAMA1 formulated in 
Montanide ISA720 (Seppic, Paris, France) as adjuvant, according to the 
manufacturer’s instructions. New Zealand white rabbits were immunised on 
days 0, 28, 56 and 82, and the final bleed sera collected on day 95 were used in 
this study.  Four groups of 2 rabbits each were immunised as follows: the first 3 
groups received 30 µg/dose of FVO AMA1, 3D7 AMA1 or HB3 AMA1 respectively. 
The 4th group received 30 µg/dose of a mixture (10 ug each) of the 3 PfAMA1 
alleles, also formulated in the same adjuvant.  
 
Antibody purification 
Serum antibodies were purified on Protein A sepharose (GE Healthcare, Etten-
Leur, The Netherlands) columns. Binding and elution buffers (Pierce, Rockford, 
IL) were used according to manufacturer’s protocols. After elution, antibodies 
were concentrated and exchanged into RPMI 1640 using AmicronUltra-15 tubes 
(30-kDa cutoff; Millipore, Ireland). Antibodies were subsequently sterile-filtered 
with 0.22 µm Ultrafree MC centrifugal filter units (Millipore), the concentration 
determined with a Nanodrop ND1000 spectrophotometer (Nanodrop 
Technologies, Wilmington, DE) and stored at -20°C until use. 
3D7-specific AMA1 antibodies were purified from the total serum IgGs (protein A 
purified) of a 3D7-immunised rabbit using a 3D7 AMA1-coupled sepharose 
matrix. The eluted 3D7-specific IgG fraction was further separated into strain-
specific (flow-through) and cross-reactive (eluate) IgGs by passage over an FVO 
AMA-coupled sepharose matrix. Protein A purified anti-FVO AMA1 antibodies 
were also affinity fractionated as has been described for anti-3D7 AMA1, first 
over an FVO AMA1-coupled sepharose matrix, then the eluate over a 3D7 AMA1-
coupled matrix (Figure S1, page 155 of this thesis). The constituent IgG in all 
fractions were confirmed by ELISA and all fractions were concentrated, sterile 
filtered and stored at –20°C until use. 
 
ELISA 
Competition ELISA assays were carried out with AMA1 from 4 different P. 
falciparum strains (FVO, HB3, 3D7 and CAMP) to define specificities of antibodies 
raised against the 3 PfAMA1 vaccine antigens (FVO, 3D7, HB3). An initial 
titration was performed to determine the optimal dilution of purified IgG 
required for the competition assay with each of the 3 vaccine antigens as coating 
antigen. Briefly, 96-well flat bottom Microlon titre plates (Greiner, Alphen a/d 
Rijn, The Netherlands) were coated with 100 µl/well of 1 µg/ml FVO, 3D7 or 
HB3 AMA1 ectodomain at 4°C overnight. Plates were washed 5 times with PBS, 
0.05% Tween 20 (PBS-T) using an automated plate washer (Bio-TEK 
Instruments, Inc, VT) and blocked with 200 µl/well of 3% BSA in PBS-T for at 
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least 1.5 h. IgG samples were titrated 3-fold from 1:10,000 and incubated for 2 h. 
A pool of sera from rabbits immunised with a mixture of the 3 PfAMA1 alleles, 
titrated 2-fold from 1:100,000, was used as standard calibrator on all plates. 
Protein A purified IgG from rabbit pre-immunisation sera, titrated 2-fold from 
1:10,000, was used as negative control on all plates. All samples, standards and 
controls were diluted with 0.5% BSA in PBS-T and added in duplicate (100 
µl/well). After sample incubation, plates were washed and 100 µl/well of 
1:1250-diluted goat anti-rabbit IgG/alkaline phosphatase conjugate (Pierce, 
Rockford, IL) added for 1 h. Plates were then washed, incubated with 100 µl/well 
p-nitrophenyl phosphate (pNPP; Fluka, Poole, UK) as substrate for 30 min. and 
the optical density (OD) at 405 nm read with a 96-well ELISA plate reader 
(BioRad, Japan). ODs were converted to arbitrary units (AUs) by the standard 
curve included on each plate using an excel-based four-parameter logistic 
function, which after correcting for variation approximates the IgG dilution that 
gives an OD of 1.0 to one arbitrary unit (1AU).  
Dilutions that resulted in an AU of 2 were extrapolated for each rabbit 
serum/purified IgG and used for the subsequent antigen competition assay. The 
assay involved co-incubation of different allelic forms of PfAMA1 with the same 
dilution of test IgGs in plates coated entirely with one of the vaccine PfAMA1 
alleles, such that there was competition between the added (competitor) 
antigens and the coated antigen for binding to test IgGs. The procedure was 
similar to that described for the pre-titration, except for the addition of 50 
µl/well rabbit IgG at 2 times the desired dilution (equivalent to an AU of 4) to 50 
µl/well of titrated soluble antigens in coated and blocked plates. Antibodies from 
all rabbits were co-incubated with the 4 PfAMA1 alleles (FVO, HB3, 3D7, CAMP) 
separately, on plates coated with either FVO, HB3 or 3D7 AMA1. The 
competitor/soluble antigens were titrated 3-fold from 30 – 0.005 µg/ml over 9 
duplicate wells, and the 10th sample wells were left without soluble antigen. The 
appropriately diluted IgG sample was then added to all 10 duplicate wells for 
each soluble antigen and after incubation for 2 h, plates were developed as 
described above. 
To further dissect the nature and underlying mechanism of humoral responses 
to the different PfAMA1 alleles, IgG pools made from the single allele 
immunisations, were also compared with IgGs from the single and multi-allele 
immunisations by competition ELISA. 
Duplicate OD values (from residual antibody binding to the coated antigen after 
competition) for wells that had soluble antigens were converted to arbitrary 
units and expressed as a percentage of AU values from wells without soluble 
antigen. The percent residual binding values were then plotted (points) 
alongside the predicted percent values (curves) based on a least squares 
approximation from the following four-parameter logistic function; 
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Y = (100 −Y min)
1+ e(Xmid −X )sc
+ Y min  
where Y is the predicted % residual binding, Ymin  is the maximal depletion at 
infinite soluble antigen concentration (minimum value), X is the soluble antigen 
concentration (log scale), Xmid is the soluble antigen concentration (log scale) at 
which 50% antibody depletion is achieved (midpoint between the maximum and 
minimum  depletion values), and sc is the slope of the curve. Percent antibody 
depletion for any competitor/soluble antigen is therefore the difference between 
100% (binding in the absence of soluble antigen) and the residual binding. 
The competition assay was initially validated by testing anti-FVO AMA1 IgG or 
serum at dilutions equivalent to 0.2, 0.5, 1, 2, 4 and 8 times the titre (1AU) on 
FVO-coated plates (100 ng/well) with the same soluble antigen concentrations 
(3-fold titration from 30 µg/ml over 9 duplicate wells). The assay was shown to 
be reproducible and independent of the antibody source (serum or purified IgG) 
and the dilution provided the OD values in wells with no competitor antigen 
were within the linear portion (ODs of 0.3 – 2.5 over blank) of the standard 
curve. 
 
Antibody avidity measurements 
The binding capacity of antibodies raised by single and mixed allele 
immunisations were determined by avidity ELISA with sodium isothiocyanate 
(NaSCN) elution. Briefly, 96-well flat bottom Microlon titre plates were coated 
with AMA1 allelic antigens as described above, and after blocking, incubated 
with a pre-determined titre (1AU) of sera from immunised rabbits for 1 h. Plates 
were then washed and incubated with an increasing  concentration of NaSCN (0, 
0.25, 0.5, 1.0, 1.25, 1.5, 1.75, 2.0, 2.25, 2.5 and 3.0M) in different duplcate wells 
for 15 min. Plates were again washed and subsequently developed with goat 
anti-rabbit IgG/alkaline phophatase conjugate and pNPP substrate as already 
described. Avidity index, the concentration of NaSCN required for 50% 
dissociation of bound antibodies (relative to duplicate wells without NaSCN) was 
the extrapolated in Microsoft excel for each rabbit serum sample. 
 
Parasite cultures and Growth Inhibition assays 
Protein A and affinity-purified IgG fractions were tested for in vitro activity in 
parasite growth inhibition assays (GIAs) as described elsewhere [18]. All IgGs 
and IgG pools were tested in triplicate on FCR3, NF54, HB3 or CAMP parasite 
strains at a 3-fold serial dilution from 6 mg/ml (protein A purified IgG) or 1 
mg/ml (affinity-purified IgG) in 96-well culture plates. Parasites were cultured 
under standard conditions (an atmosphere of 5% CO2, 5% O2, and 90% N2, 37°C), 
and the PfAMA1 antigen expressed by all parasite strains were verified by PCR 
and restriction fragment length analysis. Parasite cultures were mycoplasma-
free and synchronized with 0.3 M alanine, 10 mM Hepes pH 7.5 before use in an 
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assay. Late trophozoite/early schizont stages at a parasitaemia of 0.3 ± 0.1% and 
2% final haematocrit were used in all assays. The final culture volume was 50 
µl/well and parasites were incubated for 40-45 hrs. Parasite growth was 
assessed by measuring parasite lactate dehydrogenase levels with the 
lactate/diaphorase/APAD substrate system, and plates were read at 655 nm 
after 30 min of development. Parasite growth inhibition was expressed as;  
 
%  inhibition =100 − (A655Sample − A655RBC)(A655SZ − A655RBC)
×100  
 
where A655Sample is the OD655 for any test sample well, A655SZ is the average 
OD655 of schizont control wells included on each plate and A655RBC is the average 
OD655 of RBC control wells. The data was presented as the arithmetic mean % 
inhibition from each sample triplicate. 
 
Statistical analyses 
Residual binding (or minimum) values in competition ELISA, and the 
corresponding confidence intervals were generated by a 4-parameter logistic fit 
with least squares approximation using the R statistical package (R Development 
Core Team, 2008, version 2.8.1). Comparisons between minimum values 
estimated in the non-linear regression were done with Student’s t test; p values < 
0.05 were considered statistically significant. All plots were prepared with the R 
statistical package. Since antibody depletion patterns in ELISA were similar for 
IgG samples from the two rabbits in each immunisation group, data presented 
(ELISA and GIA) are for only one rabbit per group and is therefore of a 
qualitative nature. 
 
 
RESULTS 
 
Competition ELISA validation 
The competition ELISA assay used was based on coating plates with one allele of 
PfAMA1 and mixing test antibody samples with the same or other PfAMA1 alleles 
to determine the degree to which antibody binding to the coating material was 
inhibited.  The assay was reproducible within and between runs and at various 
initial serum/IgG concentrations (CV was generally below 2%, and maximally 
15% for very low OD values).  Antibody depletion patterns were similar 
irrespective of whether serum or protein A-purified IgG samples were used for 
the assay (data not shown). Depletion patterns, plotted as percentages, were 
similar irrespective of the final serum /IgG dilution used provided the OD value 
was within the linear portion of the standard curve. An 8-fold active dilution 
range (0.5 – 4 AU) gave optimal results (Figure S2, page 156 of this thesis). 
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Dilutions above this range (8AU or higher) shifted the curves to the left 
(suggesting less antigen required for depletion compared to dilutions within the 
linear range), and dilutions below the range (0.2AU or lower) shifted curves to 
the right (suggesting more antigen required for depletion compared to dilutions 
within the linear range) (Figure S2). Antibody depletion patterns were also very 
similar for each pair of rabbits immunised with the same antigen, irrespective of 
the original antibody response/titre (data not shown).    
A 4-parameter logistic plot was used to assess the reproducibility and 
robustness of the assay by comparing data from three different assays and at 
three different antibody dilutions using final ODs within the linear portion. A 
statistical comparison of the minimum values, the most informative parameter 
for comparing antibody specificities by this assay, is presented in Table 1 for an 
assay involving co-incubation of 4 different competitor antigens with total IgG 
from an FVO AMA1 immunisation in FVO AMA1-coated plates. For any 
competitor antigen, the minimum value represents the proportion of antibodies 
that do not bind to the competitor antigen, but do bind to the coating antigen. 
This fraction of the test antibodies represents the strain-specific component with 
respect to the competitor antigen, while the fraction depleted by the competitor 
 
Table 1. Residual IgG binding estimates from competition ELISA validation 
 
 
The assay was validated by repeated assessment of anti-FVO AMA1 antibody depletion by FVO, 
HB3, 3D7 and CAMP AMA1 competitor/soluble antigens, on FVO AMA1-coated plates. Values are 
the estimated minimum residual binding and reported as minimum value (95% CI) for each of 
the competitor/soluble antigens.  Assays were performed on three different days with three 
different antibody dilutions (1AU, 2AU, 4AU). 1AU is equivalent to the antibody titre. 
 
 
  Competitor antigen (PfAMA1)  
 FVO HB3 3D7 CAMP 
Expt.1 (1AU) 
4.2 
(-1.8 - 10.2) 
14.2  
(-3.8 - 32.2) 
50.1  
(43.7 - 56.5) 
33.1  
(29.3 - 36.8) 
Expt.1 (2AU) 
3.3  
(-1.9 - 8.5) 
8.4  
(-18.3 - 35.0) 
50.2  
(45.0 - 55.3) 
34.1  
(29.6 - 38.5) 
Expt.2 (2AU) 
3.7  
(-1.3 - 8.6) 
22.4  
(14.8 - 29.9) 
49.9  
(42.0 - 57.9) 
31.6  
(25.5 - 37.6) 
Expt.3 (4AU) 
6.6 
(1.2 – 12.0) 
5.4  
(0.1 - 10.6) 
51.6  
(42.6 - 60.7) 
36.2  
(28.0 - 44.4) 
Mean of all 
Expts. 
4.4  
(0.3 - 8.6) 
13.5  
(6.1 - 20.9) 
50.4  
(44.9 - 55.9) 
33.7  
(29.8 - 37.5) 
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antigen represents antibodies that are capable of binding to both the coated and 
competitor antigens. With the exception of HB3 AMA1, competitor antigens had 
highly consistent minimum values between assays and with different starting 
antibody dilutions. Minimum values for 3D7 and CAMP AMA1 competitor 
antigens were consistently and significantly different from the homologous FVO 
AMA1 competitor antigen. The shape of the HB3 AMA1 competitor antigen curve 
suggested that at higher concentrations, further antibody depletion was possible. 
This was not the case for the other competitor antigens as the minimum values 
had almost reached a plateau at the highest antigen concentration used. As a 
result, relatively wide confidence intervals were obtained for minimum values 
when HB3 AMA1 competed for anti-FVO AMA1 antibodies (Table 1).  
The slope describes an inverse relationship between antibodies not depleted by 
the competitor antigen and the log-concentration of competitor antigen, with a 
higher absolute value representing a steeper curve. At different antibody 
dilutions for FVO, 3D7 and CAMP AMA1 competitor antigens, the slope was fairly 
consistent between assays (-0.26 to -0.52), with most values around -0.40. Xmid, 
like IC50, is the concentration of competitor antigen that results in 50% antibody 
depletion. However, interpretation of this parameter is confounded by the 
different minimum values for the different competitor antigens (Figure S2). 
 
 
Antibodies from multi-allele immunisation have an increased cross-
reactivity 
Once validated, the competition ELISA assay was used to compare the relative 
proportions of cross-reactive and strain-specific antibody fractions induced by 
single and mixed PfAMA1 allele immunisations. Antibody depletion patterns 
revealed significantly increased cross recognition of all heterologous competitor 
antigens by antibodies from the mixed allele immunisation (anti-Combi) 
compared to those from the single allele immunisations (Figure 1, Table 2). This 
implies that there is a higher proportion of antibodies to common epitopes in the 
mixed allele immunisation compared to the proportion in any single allele 
immunisation. For example, recognition and depletion of antibodies by the FVO 
AMA1 competitor antigen increased significantly from 60% (40.2% residual 
binding) for IgGs from the 3D7 AMA1 single allele immunisation to over 80% 
(17.8% residual binding) for anti-Combi antibodies (p<0.0001) in competition 
assays with 3D7 AMA1 as coating antigen (Figure 1A). Similarly, depletion by 
HB3 AMA1 in the same assays was almost 70% (29.9% residual binding) with 
anti-3D7 AMA1 antibodies and up to 95% (5.73% residual binding) with anti-
Combi antibodies (p=0.0006). Depletion by CAMP AMA1, which was not a 
component antigen of the mixed allele vaccine, also increased significantly from 
60% (39.9% residual binding) with anti-3D7 AMA1 antibodies to almost 75% 
(25.7% residual binding) with anti-Combi antibodies (p=0.0008). Similar trends 
of increasing recognition and depletion were observed by comparing antibodies 
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from single allele immunisation with HB3 AMA1 and FVO AMA1 with the mixed 
allele immunisation when assays were performed with the respective PfAMA1 
alleles as coating antigens (Figures 1B and 1C). Depletion of anti-Combi 
antibodies was consistently highest for all competitor antigens when FVO AMA1 
was used as the coating antigen. CAMP AMA1 highly recognized and depleted 
anti-FVO AMA1 antibodies (31.6% residual binding) and least recognized anti-
HB3 antibodies (55.0% residual binding), but relatively similar degrees of anti- 
Combi antibodies were recognized/depleted by CAMP AMA1 irrespective of the 
coating antigen used (Table 2).  
To further assess the nature of antibodies raised in a mixed allele immunisation, 
protein A-purified antibody pools containing anti-FVO/HB3, anti-FVO/3D7 and 
anti-HB3/3D7, as well as a pool of antibodies against all three PfAMA1 alleles 
(anti-FVO/HB3/3D7) were made from antibodies raised in the single allele-
immunised rabbits. These antibody pools were compared to antibodies from 
single and mixed allele immunisations in competition ELISA with FVO, HB3 or 
3D7 AMA1 as coating antigens. Depending on the coating antigen/IgG pool 
combination, there were small changes in depletion by the four native PfAMA1 
alleles compared to the IgGs from single allele immunisations, with mixed 
significance (data not shown). The antibody pools with anti-HB3 IgGs were 
predictably less recognized by CAMP AMA1. Recognition/depletion patterns of 
the pool of three (anti-FVO/HB3/3D7) were intermediate between the observed 
patterns for antibodies from single and mixed allele immunisations (Figure 1). 
Generally, there was the tendency for greater depletion (lower residual binding) 
of anti-Combi antibodies by all competitor antigens compared to the depletion of 
antibodies from the anti-FVO/HB3/3D7 IgG pool (Table 2). This suggests that 
although IgG pooling would result in a decreased proportion of strain-specific 
antibodies, immunisation with the mixed antigens yields even lower levels of 
antibodies to epitopes that are specific to the component vaccine antigens. In 
order to assess the functional capacity of these antibodies in relation to the 
observations made by competition ELISA, growth inhibition assays were 
performed with the FCR3 (one pro-sequence amino acid difference from FVO 
AMA1), HB3, NF54 (with identical AMA1 to clone 3D7) and CAMP strains of P. 
falciparum. In assays with NF54, HB3 and FCR3 parasite strains, growth 
inhibition levels decreased more rapidly with decreasing concentration of 
antibodies against heterologous PfAMA1 alleles (Figure 2). Thus the extent of in 
vitro growth inhibition of any parasite strain was dependent on the antibody 
source (homologous versus heterologous), and generally for heterologous 
parasites, also on the number of amino acid variants between the vaccine and 
parasite AMA1 alleles (see Table 3). For example, the growth of NF54 parasites 
was best inhibited by anti-3D7 AMA1 antibodies and least by anti-FVO AMA1 
antibodies over the 4 dilutions tested, with anti-HB3 AMA1 antibodies yielding 
intermediate inhibition (Figure 2). 
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Figure 1. Competition ELISA with protein A-purified antibodies and antibody pools made 
from single allele immunisations. A) Assay on 3D7 AMA1-coated plates with anti-3D7 AMA1, 
anti-Combi (mixed allele immunisation) and anti-FVO/HB3/3D7 antibody pool. B) Assay on FVO 
AMA1-coated plates with anti- FVO AMA1, anti-Combi and anti-FVO/HB3/3D7 antibody pool. C) 
Assay on HB3 AMA1-coated plates with anti- HB3 AMA1, anti-Combi and anti-FVO/HB3/3D7 
antibody pool. IgG pools were made from antibodies raised in single allele immunisations with 
FVO, HB3 and 3D7 AMA1. All assays were performed with FVO, HB3, 3D7 and CAMP AMA1 
proteins as competitor antigens. All IgGs were used at 2 times the pre-determined antibody titre. 
Plots are representative of at least 2 assay repeats using IgGs from one rabbit per group since the 
depletion patterns were similar for both rabbits in each immunisation group. 
 
 
Most importantly, however, anti-Combi antibodies resulted in growth inhibitions 
that were comparable with that of antibodies from single allele immunisations 
on the respective homologous parasite strains in all cases. Furthermore, the anti- 
Combi antibodies yielded the best growth inhibition of CAMP parasites 
compared to antibodies from the 3 single allele immunisations, even though 
CAMP AMA1 was not included in the mixed allele vaccine. 
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Table 2. Residual IgG binding estimates for antibodies raised in single and  
    multi-allele immunisations.  
 
 
Residual binding values are the predicted minimum values based on the measured values for 
each competitor antigen, and were generated with a four-parameter logistic fit with least squares 
approximation. Values are estimated with the R statistical package and reported as % residual 
binding or minimum value (95%CI). 
§A pool of IgGs from the single allele immunisations with FVO, HB3 and 3D7 AMA1.  
*Negative estimate of residual binding (minimum values have not reached a plateau yet). 
Minimum values cannot be accurately estimated.  
 
  
Coating 
antigen 
IgG 
Sample  Competitor antigen (PfAMA1)  
  FVO HB3 3D7 CAMP 
 anti-FVO 
3.7  
(-1.3 - 7.2) 
22.4  
(14.8 - 29.9) 
49.9  
(42.0 - 57.9) 
31.6  
(25.9 - 37.2) 
FVO 
AMA1 anti-Combi 
3.0  
(-1.3 - 7.2) 
2.9  
(0.1 - 5.8) 
8.0  
(3.1 - 12.9) 
16.8  
(12.6 - 20.9) 
 IgG pool§ 
1.9  
(-7.1 - 10.9) 
-3.2* 
(-15.9 - 9.4) 
18.6  
(12.5 - 24.7) 
25.5  
(14.1 - 36.8) 
  FVO HB3 3D7 CAMP 
 anti-3D7 
40.2  
(36.8 - 43.6) 
29.9  
(19.6 - 40.2) 
3.3  
(-0.8 - 7.4) 
40.0  
(36.0 - 43.8) 
3D7 
AMA1 anti-Combi 
17.8  
(13.4 - 22.2) 
5.7  
(2.4 - 9.0) 
1.9  
(-1.5 - 5.4) 
25.7  
(19.2 - 32.2) 
 IgG pool§ 
29.9  
(18.8 - 40.9) 
-150*  
(-546 - 246) 
-3.0* 
(-11.1 - 5.0) 
34.6  
(28.9 - 40.3) 
  FVO HB3 3D7 CAMP 
 anti-HB3 
52.7 
(46.2 - 59.1) 
2.3  
(-6.0 - 10.5) 
-57.7*  
(-299 - 184) 
55.0  
(43.0 - 67.0) 
HB3 
AMA1 anti-Combi 
15.1 
 (7.6 - 22.5) 
-2.2*  
(-11.7 - 7.4) 
7.5  
(1.5 - 13.5) 
18.8  
(8.2 - 29.5) 
 IgG pool§ 
21.2  
(12.6 - 29.8) 
2.1  
(-2.3 - 6.5) 
3.3  
(-16.8 - 23.4) 
32.9  
(22.1 - 43.7) 
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Figure 2. Growth inhibition levels exhibited by protein A-purified IgGs from single/mixed 
PfAMA1 immunisations and IgG pools. All IgG fractions were tested in a single growth cycle 
assay with FCR3, HB3, NF54 and CAMP strains of P. falciparum. For all strains, assays were 
performed with 0.3 ± 0.1% parasitaemia and a final haematocrit of 2%. IgG samples were tested 
at 4 dilutions (3-fold titration from 6 mg/ml). IgG pools were made from antibodies raised in 
single allele immunisations with FVO, HB3 and 3D7 AMA1. The data presented is representative 
of at least two assay repeats using IgGs from one of the two rabbits per group. 
 
 
The relatively similar ELISA titres of mono-specific antibodies (950,000 for anti-
FVO, 1,150,000 for anti-HB3 and 1,280,000 for anti-3D7 AMA1) on the respective 
homologous PfAMA1 alleles compared to anti-Combi antibodies (1,230,000 on 
FVO, 1,140,000 on HB3 and 1,120,000 on 3D7 AMA1) as measured in protein G-
purified fractions eliminates the possibility of this observation being due to 
higher titres of anti-Combi antibodies. The observed GIA activity cannot also be 
attributed to a better quality of the anti-Combi antibodies since these were 
shown to have antigen-binding capacities in the same order as mono-specific 
antibodies when titres were normalized (Table 4). The current observation may 
therefore be mainly attributed to the induction of a more cross-reactive antibody 
profile and represents a broadened inhibitory capacity of anti-Combi antibodies 
compared to antibodies induced in single allele immunisations.  
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GIAs with the antibody pools were also performed to assess the trends in growth 
inhibition with respect to the varying antibody specificities. Results showed that 
differences in growth inhibition between the pools were dependent on the 
parasite strain/antibody pool combination. 
 
Table 3. Number of amino acid variants between vaccine and Pf  
      parasite AMA1 alleles. 
 
 
 
 
 
 
 
 
 
 
 
Values represent only the differences in domains I, II and III of PfAMA1 ectodomain. Differences 
per domain have been presented in brackets as (domain I, domain II, domain III). 
*The 6 variant amino acids between “homologous” AMA1 alleles (5 for HB3) are due to amino 
acid substitutions introduced to prevent protein glycosylation and cleavage. Substitutions occur 
at positions 162 and 288 in domain I (position 288 only for HB3), positions 373, 422 and 423 in 
domain II, and position 499 in domain III. 
 
 
Table 4. Measured avidity Indices for mono-specific and anti-Combi 
         antibodies against vaccine PfAMA1 alleles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Avidity index of AMA1-specific antibodies was estimated as the concentration of NaSCN required 
to dissociate 50% of AMA1-bound antibodies. The avidity indices of mono-specific antibodies 
were determined against both the immunising (“homologous”) allele and the other two 
“heterologous” alleles.  That for anti-Combi antibodies was determined against all vaccine 
component alleles. 
 
Vaccine 
antigen Parasite strain 
 NF54 HB3 FCR3 CAMP 
3D7 *6  (2,3,1) 29  (15,8,6) 30 (19,8,3) 26   (14,9,3) 
HB3 30 (16,8,6) *5   (1,3,1) 24 (13,7,4) 31  (17,8,6) 
FVO 30 (19,8,3) 23   (12,7,4) *6   (2,3,1) 20  (11,6,3) 
  Avidity Index by capture antigen 
Rb ID (Immunising Ag) FVO HB3 3D7 
1455 (FVO) 1.23 0.91 1.01 
1456 (HB3) 0.89 1.10 0.81 
1459 (3D7) 1.15 1.03 1.38 
1461 (Combi) 1.04 1.06 1.31 
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The anti-FVO/3D7 antibody pool, for example, inhibited the growth of CAMP 
parasites better (Figure 2) than the other double pools (anti-FVO/HB3, anti-
HB3/3D7), even though these pools had similar antibody titres as measured by 
ELISA (data not shown). This is likely due to the fact that HB3 AMA1, being the 
most distant allele from CAMP AMA1 in terms of amino acid residues, shares 
fewer functional epitopes with CAMP AMA1 such that the pools with anti-HB3 
AMA1 antibodies cross-reacted least with CAMP AMA1, resulting in relatively 
lower parasite growth inhibitions. 
Inhibition of all strains by anti-Combi antibodies was higher compared with the 
anti-FVO/HB3/3D7 IgG pool, confirming the induction of higher levels of 
antibodies to common epitopes by multi-allele immunisation. Antibodies to 
common allele epitopes are predominantly induced since strain-specific epitopes 
on each of the vaccine alleles have been diluted out in the vaccine antigen 
mixture, and this translates to a broadened scope of PfAMA1 recognition. The 
functional assay therefore confirms observations made by competition ELISA, 
and shows that mixed allele immunisation predominantly yields antibodies to 
common allele epitopes and low levels of antibodies to strain-specific epitopes. 
High levels of antibodies to the common vaccine allele epitopes are invariably 
required for broad strain inhibition. 
 
Most cross-reactive antibody epitopes are shared by all alleles 
To assess the relative contributions of strain-specific and cross-reactive 
antibodies to overall antigen recognition and parasite inhibition, strain-specific 
and cross-reactive antibody fractions were affinity-purified from total IgGs of 
rabbits immunised with 3D7 AMA1 alone and FVO AMA1 alone. Cross-reactive 
and strain-specific IgG fractions for each of the two PfAMA1 alleles were 
prepared with respect to the other allele (procedure presented schematically in 
Figure S1). Up to 90% of recovered IgGs from anti-3D7 AMA1 antibodies were 
cross-reactive with FVO AMA1, while over 95% of recovered IgGs from anti-FVO 
AMA1 antibodies were cross-reactive with 3D7 AMA1. These IgG fractions were 
compared with the respective un-fractionated affinity-purified anti-3D7 or anti-
FVO IgGs by competition ELISA. The strain-specific fraction of anti-3D7 AMA1 
IgGs had very little reactivity with HB3 and CAMP AMA1 alleles (Figure 3A). 
There was however, an improved recognition and depletion of IgGs in the cross-
reactive fraction by all the heterologous PfAMA1 alleles used (FVO, HB3, CAMP). 
Similar observations were made with anti-FVO AMA1 strain-specific and cross-
reactive IgG fractions, except that the strain-specific fraction of anti-FVO AMA1 
IgG was still highly reactive with HB3 AMA1, and to a lesser extent with CAMP 
AMA1 (Figure 3B). Based on these observations, it is likely that FVO AMA1 may 
induce the production of antibodies that are more cross-reactive in comparison 
with 3D7 AMA1. The affinity-purified antibody fractions were also tested for  
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Figure 3. Competition ELISA with PfAMA1-specific IgG fractions. Anti-3D7 AMA1 IgG was 
affinity-purified from total (Protein A) IgG of one of the 3D7 AMA1-immunised rabbits. A portion 
of this IgG fraction was afterwards fractionated into 3D7 AMA1 strain-specific IgG (flow through) 
and 3D7/FVO cross-reactive IgG (eluate) by passage over an FVO AMA1 affinity matrix. Similar 
specific fractions were made from total IgGs from one of the FVO AMA1-immunised rabbits, first 
over an FVO AMA1 matrix, and then over a 3D7 AMA1 matrix. All IgG fractions were used for 
competition assays at 2 times the pre-determined antibody titre. AMA1 antigens from the 3D7, 
HB3, FVO and CAMP parasite strains were used as competitor antigens in all assays. Assays were 
done using plates coated with 3D7 AMA1 (A) and FVO AMA1 (B), and plots are representative of 
data from at least 2 repeat assays.  
 
 
functional capacity by in vitro growth inhibition assays on FCR3 (FVO), CAMP 
and NF54 (3D7) parasite strains (Figure 4). The cross-reactive fractions alone 
had the same functional capacity on homologous parasites as the respective total 
affinity-purified IgGs when both were tested at the same concentrations.  The 
anti-3D7 cross-reactive fraction showed slightly less inhibition on FCR3 
heterologous parasites over the four antibody concentrations tested as 
compared to the anti-FVO cross-reactive fraction, and the reverse was true for 
the inhibition of NF54 parasites. Furthermore, both cross-reactive fractions 
yielded slightly lower inhibition of CAMP parasites compared to the inhibitions 
observed for same fractions on their respective homologous parasites. By 
contrast, the strain-specific fractions showed slightly less inhibition of red cell 
invasion by homologous parasites compared to the cross-reactive and total 
fractions. Both strain-specific fractions had negligible inhibitory effect on 
heterologous parasites, including the CAMP heterologous strains. These 
observations confirm the need to induce cross-reactive antibodies in overcoming 
allelic diversity to PfAMA1, but also show that the cross-reactive antibody  
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Figure 4. Representative data showing levels of parasite growth inhibition exhibited by 
affinity-purified AMA1-specific IgG fractions. All fractions were tested for functional activity 
on FCR3, NF54 and CAMP strains of P. falciparum. For all strains, assays were done with 0.3 ± 
0.1% parasitaemia and a final haematocrit of 2%. IgG samples were tested at 4 dilutions (3-fold 
titration from 1mg/ml). Anti-FVO and anti-3D7 are the respective total affinity-purified IgGs, anti-
FVO CR and anti-3D7 CR designate the cross-reactive fractions, while anti-FVO spec and anti-3D7 
spec designate the respective strain-specific fractions. 
 
 
fraction from a single PfAMA1 allele immunisation may not be as efficient for 
achieving significant parasite inhibition. 
 
 
DISCUSSION  
Allelic polymorphism in AMA1 is due to single amino acid substitutions and has 
been linked with host immune pressure on the parasite [15,25]. Although this 
makes AMA1 a possible target for natural as well as vaccine induced responses, 
polymorphism presents the practical challenge of developing a broadly effective 
vaccine since immunisation with one AMA1 haplotype appears not to protect 
against parasites expressing relatively distant haplotypes [12]. Preliminary 
analysis of about 745 PfAMA1 amino acid sequences pulled from PubMed 
through GeneBank shows 236 unique AMA1 haplotypes, with an estimated 189 
occurring in domain I alone (unpublished data). An effective vaccine is expected 
to protect against this diversity of parasites globally or at least within a 
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particular endemic region. It is worth noting that while about 10% of amino acid 
residues in the AMA1 ectodomain are polymorphic, most of these residues are 
dimorphic, a few are tri- or tetramorphic, and a single position in domain I (197) 
is heptamorphic [25,28]. Polymorphic residue linkages present within the 
molecule also tend to limit the choice of amino acids in certain polymorphic 
positions [18], providing some level of polymorphic stability. Overcoming 
PfAMA1 polymorphism is therefore a key step in vaccine development, and 
immunisation with a mixture of PfAMA1 alleles has been proposed as one 
possible solution to this challenge [3,17,18,37].  
The aim of the present study was to determine the relative functional 
importance of cross-reactive and strain-specific antibody fractions elicited upon 
immunisation with a particular PfAMA1 allele, and also to assess the feasibility of 
achieving broad strain recognition by antibodies to a multi-allele PfAMA1 
vaccine. We validated a competition ELISA assay for assessing antibody 
specificities providing a highly reproducible and robust methodology for 
dissecting specific antibody responses to immunisation with a PfAMA1-based 
vaccine. The assay was independent of the specific antibody source (serum or 
purified IgG) and the antibody dilution factor when the working OD values fell 
within the linear portion of the standard/calibration curve. The latter 
observation may be explained by the fact that the antigen-antibody complex 
reaction, being reversible, would always have very similar percentage 
proportions of reaction components when it attains a dynamic equilibrium state. 
It is also worthwhile noting that the anti-PfAMA1 antibody depletion patterns 
observed for the various competitor PfAMA1 alleles in competition assays were 
generally predictive of the extent of growth inhibition of the different parasite 
strains by the anti-PfAMA1 antibodies in vitro. 
The major findings of this study are that i) immunisation with a mixture of allelic 
PfAMA1 forms predominantly induces the production of cross-reactive anti-
PfAMA1 antibodies, and ii) the cross-reactive fraction of antibodies to any 
PfAMA1 allele has the same functional capacity (GIA) as the total anti-PfAMA1 
antibodies (cross-reactive + strain-specific) at the same concentration, hence 
induction of antibodies to epitopes that are common to a number of PfAMA1 
alleles will not reduce the inhibitory capacity against parasites expressing any of 
the vaccinating alleles.  
The increased recognition and depletion of anti-Combi antibodies by all 
competitor antigens, including the out-group antigen CAMP, compared to that of 
mono-specific antibodies implies a broadened antibody response (Figure 1). This 
is most likely due to the induction of antibodies predominantly to epitopes that 
are common to the component alleles of the vaccine, and similar observations 
have been made in earlier studies [17,27,37]. Since strain-specific epitopes on 
each vaccine allele are expected to be present at relatively low quantities in the 
mixture, they will have a decreased probability of presentation to the relevant 
immune system effectors compared to common epitopes. Indeed, the levels of 
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antibodies to common epitopes in the mixed allele immunisation, as assessed by 
competition ELISA assays, were constantly higher relative to the levels in 
antibody pools made from the three single immunisations with the same 
antigens (Figure 1). This was confirmed by the growth inhibition patterns 
observed when all antibody fractions were tested against the FCR3, HB3, NF54 
and CAMP parasite strains (Figure 2).  
Recognition and depletion of affinity-purified IgG fractions from FVO and 3D7 
AMA1 mono-specific immunisations provide further evidence for the induction 
of antibodies against common epitopes. Most (≥ 80%) of the cross-reactive 
epitopes between these two PfAMA1 alleles are shared with CAMP and HB3 
AMA1 alleles (Figure 3). Additionally, for the anti-3D7 IgG fraction, affinity 
depletion of anti-FVO cross-reactive antibodies removed up to 80% of antibodies 
reactive to the HB3 and CAMP AMA1 alleles. These observations may possibly 
extend to the many other PfAMA1 alleles not tested in this study. The patterns of 
recognition and depletion of the affinity-purified, cross-reactive fractions closely 
resemble those of antibodies induced by the mixed allele immunisation in ELISA.  
Observations from competition ELISA were confirmed by functional parasite 
growth inhibition assays with the FCR3, NF54, HB3 and CAMP strains of P. 
falciparum. The extent of antigen recognition by these antibody fractions was 
predictive of the degree of functional parasite inhibition observed in vitro. 
Furthermore, assays with affinity-purified anti-PfAMA1 antibodies on FCR3 and 
NF54 parasite strains showed that at the same concentration, the cross-reactive 
fractions had the same growth inhibitory effects as the total anti-PfAMA1 IgGs on 
homologous parasites, while the strain-specific fractions had slightly lower 
inhibitions over the IgG concentrations tested (Figure 4). Thus in the absence of 
the strain-specific fraction of antibodies against any PfAMA1 allele, the cross-
reactive fraction alone is still highly inhibitory against homologous parasites. 
The limited cross inhibition of heterologous parasites by antibodies from single 
allele immunisations may therefore be attributed to the proportions of cross-
reactive and strain-specific antibodies; the cross-reactive antibody fraction may 
not be enough to effectively inhibit heterologous parasite invasion of RBCs to the 
same extent as homologous strain inhibition, which would involve both cross-
reactive and strain-specific antibody activity.  
Cross-reactive antibody fractions of both anti-FVO and anti-3D7 AMA1 IgGs, 
initially derived from mono-specific sera, inhibited the respective heterologous 
strains less effectively in vitro (Figure 4). Since the same concentration of both 
antibody fractions resulted in greater growth inhibition of the respective 
homologous parasites, the current observation may be a potential consequence 
of the affinity purification process, or logically due to avidity differences in 
binding to homologous and heterologous parasite PfAMA1 alleles. This latter 
observation, if confirmed, would imply that the cross-reactive fraction of 
antibodies generated by single allele immunisation may not be as equally good as 
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cross-reactive antibodies induced by multi-allele immunisation in terms of 
functional capacity against heterologous parasites.  
The measured avidity indices for anti-Combi and mono-specific antibodies on the 
immunising antigen(s) as well as for mono-specific antibodies on “heterologous” 
PfAMA1 alleles were comparable (Table 4). Due to antibody titre normalization 
however, the quantity of each mono-specific serum that was used for the avidity 
determination on heterologous alleles was up to 2-fold higher than the quantity 
of mono-specific and anti-Combi antibodies used on the respective homologous 
alleles. Thus cross-reactive antibodies, irrespective of the source, bound the 
allelic PfAMA1antigens to very similar degrees, and the only factor that 
influences the extent of in vitro parasite inhibition was the absolute levels of 
these functional antibodies. These observations, taken together with the fact that 
the functional activity of antibodies is generally linked with their antigen binding 
strength [38,39], support the conclusion that anti-Combi antibodies are most 
likely high-avidity in nature. Additionally, most low-avidity antibodies are likely 
to be lost during affinity purification of PfAMA1-specific antibodies. Depletion 
patterns for the affinity-purified cross-reactive fractions from both anti-3D7 and 
anti-FVO AMA1 antibodies (Figure 3) were however, similar to those of anti-
Combi antibodies (Figure 1) which were Protein A-purified and should therefore 
include any low-avidity AMA1-specific antibodies. The absence of such low-
avidity, cross-reactive antibodies after affinity purification would be expected to 
result in antibody depletion patterns that are rather similar to those of mono-
specific antibodies (Figure 1).  
Considering the data presented, it may be hypothesized that apart from antibody 
specificity, an optimal concentration of antibodies is also necessary in order to 
achieve a good degree of parasite inhibition.  These findings are important for 
two main reasons, that i) there is no loss in in vitro inhibitory capacity by mainly 
inducing antibodies to common epitopes, and ii) the antibodies thus induced will 
also cross-react with epitopes on other PfAMA1 alleles that are similar to those 
on the vaccine’s component alleles to which they were raised. High titres of 
antibodies to such common epitopes imply broadened recognition and inhibition 
of a wide range of parasite strains. Taken together, these results provide 
evidence for the induction of high levels of inhibitory antibodies to common 
epitopes by immunisation with a mixture of PfAMA1 alleles. An added advantage 
of this strategy over a typical multi-antigen or multistage vaccine is the possible 
limitation on the number of different antigens (with very different epitopes) that 
can be practically included in a multistage vaccine formulation without 
compromising effectiveness. Such a multistage vaccine may induce low antibody 
titres to each of a wide variety of antigens/epitopes, some of which may not be 
anti-parasitic enough, such that the overall response will be affected by the 
reduced effective antibody concentration [27,40,41]. A multi-allele strategy with 
a promising antigen like PfAMA1, by comparison, will focus the humoral 
response on relevant epitopes that are common to all constituent alleles. In 
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theory, increasing the number of constituent alleles will reduce the number of 
common/overlapping epitopes and these repeated epitopes will form the bulk of 
all epitopes present in the mixture. This would be expected to translate to 
relatively higher antibody titres against these common epitopes, with the result 
being broad antibody specificity. Duan and others [42] have recently proposed 
such an approach, with a recommended minimum of six PfAMA1 alleles as 
components of a universal vaccine. The number of alleles that can be practically 
included in such a vaccine may however be limited by high costs (of producing 
six different proteins) and/or practical developmental difficulties (of expressing 
fusion proteins with six component antigens), especially if AMA1 is to be 
combined with other highly immunogenic antigen(s) in a multi-antigen vaccine. 
On this basis, the diversity covering approach [18], comprising three synthetic 
and highly divergent PfAMA1-based proteins, appears to be a more practical 
approach to PfAMA1 vaccine development. Being highly divergent sequences, the 
three DiCo antigens are expected to have fewer common/overlapping antibody 
epitopes. These would nevertheless represent the greater proportion of antibody 
epitopes in the DiCo mixture, and would induce high antibody titres upon 
immunisation. It is therefore practically possible and more cost-effective to 
induce a significantly broad humoral response to P. falciparum strains using the 
DiCo proteins, at least as components of a multi-antigen vaccine.  
In summary, the present study has shown that broad functional specificity of 
anti-PfAMA1 antibodies to diverse P. falciparum strains can be achieved by 
multi-allele immunisation. The humoral response is most likely focused on 
epitopes that are common to the constituent alleles, which would form the bulk 
of all epitopes present, and leads to induction of antibodies to these common 
epitopes. The results also show that majority of B cell epitopes are shared by the 
PfAMA1 alleles used in this study, and possibly by many other PfAMA1 alleles. 
Thus antibodies induced against a multi-allele vaccine are also highly likely to be 
effective against parasites expressing diverse PfAMA1 alleles. Of central 
importance to this immunisation strategy is the demonstration of good levels of 
homologous parasite inhibition by cross-reactive anti-PfAMA1 antibodies, 
compared to the total antibody fraction at the same concentration in vitro. This is 
necessary to ensure that in aiming to broaden the antibody response, 
functionality against parasites expressing the vaccine PfAMA1 alleles is not 
compromised.  
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ABSTRACT 
 
 
There is increasing interest in multi-allele vaccines to overcome strain-specificity 
against polymorphic vaccine targets such as Apical Membrane Antigen 1 (AMA1). 
These have been shown to induce broad inhibitory antibodies in vitro and 
formed the basis for the design of three Diversity-Covering (DiCo) proteins with 
similar immunological effects. The antibodies produced are to epitopes that are 
shared between vaccine alleles and theoretically, increasing the number of 
component AMA1 alleles is expected to broaden the antibody response. A 
plateau effect could however impose a limit on the number of alleles needed to 
achieve the broadest specificity. Moreover, production cost and the vaccine 
formulation process would limit the number of component alleles. 
In this paper, we compare rabbit antibody responses elicited with multi-allele 
vaccines incorporating seven (three DiCos and four natural AMA1 alleles) and 
three (DiCo mix) antigens for gains in broadened specificity. We also investigate 
the effect of three adjuvant platforms on antigen specificity and antibody 
functionality.  
Our data confirms a broadened response after immunisation with DiCo mix in all 
three adjuvants. Higher antibody titres were elicited with either CoVaccine HT™ 
or Montanide ISA 51, resulting in similar in vitro inhibition (65 – 82%) of five out 
of six culture-adapted P. falciparum strains. The antigen binding specificities of 
elicited antibodies were also similar and independent of the adjuvant used or the 
number of vaccine component alleles. Thus neither the four extra antigens nor 
adjuvant had any observable benefits with respect to specificity broadening, 
although adjuvant choice influenced the absolute antibody levels and thus the 
extent of parasite inhibition. Our data confirms the feasibility and potential of 
multi-allele PfAMA1 formulations, and highlights the need for adjuvants with 
improved antibody potentiation properties for AMA1-based vaccines.   
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INTRODUCTION 
Malaria is a disease caused by the apicomplexan parasite Plasmodium and 
remains a global scourge despite recent coordinated efforts at control and 
prevention in endemic areas. The development of an effective malaria vaccine 
has become ever more urgent in the face of increasing parasite/vector resistance 
to currently available drugs/insecticides for disease treatment and vector 
control [1–3]. Subunit vaccine development requires the identification of 
immunogenic targets from the wide array of antigens expressed by the parasite. 
A number of antigens expressed by Plasmodium falciparum, the parasite mostly 
responsible for severe forms of malaria, are currently at various stages of pre-
clinical and clinical testing [4–6] with apical membrane antigen 1 (AMA1) being 
an important candidate. The vaccine properties and potential of AMA1 have 
recently been reviewed [7].  
Despite the current global interest in AMA1 as a vaccine component, its potential 
is limited by allelic polymorphism resulting from single amino acid substitutions 
in an estimated 16% of amino acids (100 out of 622 positions in 1294 sequences 
accessed from GenBank) within the AMA1 molecule (Remarque, unpublished 
data). Polymorphism is generally an immune evasion strategy of the parasite 
that renders a fully functional immune response against one parasite strain less 
effective against strains expressing other allele variants, and this has been 
extensively demonstrated for AMA1 in murine models [8–10] as well as in 
clinical trials in malaria-naive populations [11]. This suggests that the immune 
response to AMA1, believed to be mainly antibody-mediated, is to both strain-
specific and conserved epitopes [12–14]. We have previously shown that for any 
PfAMA1 allele, the cross-strain anti-PfAMA1 antibody fraction inhibits the 
homologous parasite strain in vitro to a similar extent as the total antibody 
fraction (strain-specific + cross-reactive) when both are tested at the same 
concentration [15]. On this premise, a universally effective PfAMA1 vaccine 
should have two basic features; i) be able to induce functional responses to 
antibody epitopes that are common to, or conserved in the widest diversity of 
parasite strains possible, and ii) be such that strain-specific epitopes on the 
component alleles are diluted out or eliminated from the epitope repertoire. 
Attempts at achieving such responses have been made through immunisation 
with recombinant vaccines incorporating a number of PfAMA1 alleles [15–17], 
and have been the basis for the in silico design of three Diversity-Covering (DiCo) 
PfAMA1-based proteins with similar immunological effects when mixed in a 
vaccine formulation [18]. The three DiCo proteins, incorporating 80 - 97% of 
AMA1 amino acid diversity found naturally at the time of design, are distinctly 
different from one another and are together expected to elicit functional cross-
strain antibodies. Initial functional assays with protein A-purified rabbit 
antibodies (6 mg/ml) against DiCo mix in Montanide ISA 51 showed an average 
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in vitro inhibition of 70% against the highly diverse FVO, HB3 and 3D7 parasite 
strains [18].  
It seems reasonable to assume that increasing the number of different PfAMA1 
alleles included in such a multi-allele vaccine would further broaden the 
specificity of the expected anti-PfAMA1 antibody response. This idea raises the 
question of how many alleles would be necessary to achieve the broadest 
possible functional antibody response. It should also be noted that the number of 
alleles that can be included in such a vaccine would be limited by the cost of 
producing many different antigens prior to mixing, and the potential inherent 
difficulties with quality assurance/control required for vaccine formulation. 
Another level of complexity would be the appropriate adjuvant system for 
vaccine formulation. Adjuvants are known to modulate the specificity of 
antibodies elicited against some parasite antigens [19,20]. 
In the present study, we further examine the broadened antibody response after 
immunisation of rabbits with a mixture of the three DiCo proteins by 
competition ELISA and in vitro growth inhibition assays (GIAs) with six distinct 
P. falciparum parasite strains. We compare this response with that induced by a 
similar immunisation with a mixture of seven antigens (the three DiCo proteins 
and natural AMA1 alleles from FVO, HB3, 3D7 and CAMP strains of P. falciparum) 
for gains in broadened specificity. We also assess the effect of the choice of 
adjuvant on the antigen specificities of antibodies elicited against the DiCo mix 
vaccine.  
Our data suggests a practical limit to the number of PfAMA1 alleles that need to 
be incorporated in a multi-allele vaccine to achieve broad specificity, and shows 
no adjuvant effect on antigen binding specificity of the elicited antibodies. It also 
highlights a potentially important role for cross-reactive antibodies in naturally 
acquired immunity to malaria, and the need for new adjuvants with improved 
antibody potentiation properties and safety for use in PfAMA1-based subunit 
vaccine development. 
    
 
METHODS 
 
Ethics Statement 
All animals used in this study were handled in strict accordance with good 
animal practices within the respective jurisdictions (German and European 
Union guidelines for BioGenes GmbH, Berlin, and the Belgian national animal 
welfare regulations for Eurogentec SA, Seraing). Rabbit immunisation work at 
BioGenes was under approval from NIH/OLAW (ID number #A5755-01) and 
immunisations at Eurogentec had approval from the ethics committee of the 
Centre d'Economie Rurale (CER Groupe, Marloie, Belgium). 
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Protein production, adjuvants and rabbit immunisations. 
The full ectodomain of the AMA1 allelic forms from P. falciparum strains FVO, 
HB3, 3D7 and CAMP, as well as the in silico-designed DiCo 1, DiCo 2 and DiCo 3 
antigens were expressed as recombinant proteins in Pichia pastoris by a similar 
methodology as described elsewhere [21]. Groups of rabbits were immunised 
with PfAMA1 multi-allele formulations in three different adjuvants. CoVaccine 
HT™, an enhancer of both humoral and cellular immune responses, is a novel 
proprietary vaccine adjuvant from Protherics Medicines Development Limited, a 
BTG Company (London, UK). It is a squalane-based oil-in-water adjuvant that has 
a sucrose fatty acid sulphate ester (SFASE) [22]. Montanide ISA 51 is a water-in-
oil emulsion developed by SEPPIC (Paris, France), containing the naturally 
metabolizable oil Drakeol 6 VR and mannide mono-oleate as emulsifier, and the 
adjuvant promotes antibody formation and significant cytotoxic T-cell activity 
[23,24]. Montanide IMS 4112 VG PR, (one of the Montanide IMS group of 
adjuvants from SEPPIC), is a water-dispersible composition containing 
(undisclosed) immuno-stimulatory organic compounds and excipient [25]. 
The first group of rabbits (Gp 1, n=9) was immunised with a mixture of 7 
antigens (DiCo 1, DiCo 2, DiCo 3, and PfAMA1 allelic antigens from FVO, HB3, 3D7 
and CAMP parasite strains, ~ 7 µg of each antigen, 50 µg total antigen per dose) 
in CoVaccine HT™. The second group (Gp 2, n=8) was immunised with a mixture 
of 3 antigens (~ 17 µg each of DiCo 1, DiCo 2 and DiCo 3, here referred to as DiCo 
mix; 50 µg in total) in CoVaccine HT™. The third group of rabbits (Gp 3, n=8) was 
immunised with DiCo mix (~ 17 µg of each DiCo protein, 50 µg in total) in 
Montanide IMS, and the fourth group (Gp 4, n=5) with DiCo mix (10 µg of each 
DiCo protein, 30 µg in total) in Montanide ISA 51. All immunisations were done 
intramuscularly with 3 full human doses (500 µl/dose) of vaccine on days 0, 28 
and 56, and exsanguination for all groups was on day 70. Vaccine formulation in 
all cases was according to the adjuvant manufacturers’ specifications. For 
CoVaccine HT™, formulation involved mixing 300 µl of antigen at 200 µg/ml with 
300 µl of CoVaccine HT™ with an SFASE concentration of 40 mg/ml. One 500-µl 
dose of the resulting formulation therefore contained 50 µg antigen and 10 mg 
SFASE. Montanide IMS formulation also involved mixing 300 µl of antigen with 
300 µl of adjuvant such that 500 µl of the resulting mixture contained 50 µg of 
antigen. Formulation with Montanide ISA 51 was in a 50/50 (w/w) ratio of 
antigen to adjuvant; 276 µl of antigen at 130 µg/ml was mixed with 324 µl of 
adjuvant and the mixture was emulsified by 20 passages through a 22-gauge 
syringe-coupling piece prior to injection with 500 µl.    
Rabbits in the first three immunisation groups were housed at BioGenes GmbH 
(Berlin, Germany), while the last group (Gp 4) was housed at Eurogentec SA 
(Seraing, Belgium). The second and third group immunisations (Gp 2 and Gp 3) 
were done simultaneously in the same experiment at BioGenes, while the first 
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and fourth (Gp 1 and Gp 4) were done in separate experiments. Final bleed sera 
from the four different immunisation groups were used in the assays described 
here. 
 
Antibody purification  
Antibodies from all groups were purified on Protein G sepharose (GE Healthcare, 
Etten-Leur, The Netherlands) columns. Binding and elution buffers (Pierce, 
Rockford, IL) were used according to manufacturer’s protocols. After elution, 
antibody eluates were filtered (0.22 µm), concentrated and exchanged into RPMI 
1640 using pre-sterilized AmicronUltra-15 tubes (30-kDa cutoff; Millipore, 
Ireland). The concentration of each antibody fraction was subsequently 
determined with a Nanodrop ND1000 spectrophotometer using the IgG molar 
extinction coefficient (Nanodrop Technologies, Wilmington, DE) and stored at -
20°C until use. 
 
ELISA 
Competition ELISA was performed as previously described [15]. Briefly, 96-well 
flat bottom Microlon titre plates (Greiner, Alphen a/d Rijn, The Netherlands) 
were coated with 1 µg/ml (100 µl/well) of the relevant antigen (DiCo 1, DiCo 2, 
DiCo 3, FVO AMA1, HB3 AMA1, CAMP AMA1 or 3D7 AMA1) at 4°C overnight. 
After blocking with 200 µl/well of 3% BSA in PBS-T, 60 µg/ml of each of six 
competitor/soluble antigens (AMA1 from strains FVO, HB3, 3D7 or CAMP, a 
mixture of the 4 AMA1 alleles designated NM, and DiCo mix designated DM) 
were titrated 3-fold over 9 duplicate wells at a 50 µl/well final volume. Fifty 
microlitres/well of a fixed dilution (two arbitrary units or 2AU) of rabbit IgGs 
(titre pre-determined using the relevant capture antigen) was then added to the 
titrated competitor antigens and co-incubated for 2 h. A pool of sera from rabbits 
immunised with a mixture of 3 PfAMA1 alleles (FVO, HB3, 3D7 strains), titrated 
2-fold from 1:100,000, was used as standard calibrator on all plates. After 
sample incubation, plates were developed with 100 µl/well of 1:1250-diluted 
goat anti-rabbit IgG/alkaline phosphatase conjugate (Pierce, Rockford, IL). 
Colour development was with 100 µl/well of p-nitrophenyl phosphate (pNPP; 
Fluka, Poole, UK) for 30 min. and the optical density (OD) at 405 nm determined. 
Measured ODs were converted to arbitrary units (AUs) by the standard curve 
included on each plate and expressed as a percentage of AU values from wells 
without competitor antigen. Residual binding (%) at the highest competitor 
antigen concentration was estimated from AU values based on a least squares 
approximation from the following four-parameter logistic function; 
 
Y = (100 −Y min)
1+ e(Xmid −X )sc
+ Y min  
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where Y is the predicted % residual binding, Ymin  is the maximal depletion at 
infinite soluble antigen concentration (minimum value), X is the soluble antigen 
concentration (log scale), Xmid is the soluble antigen concentration (log scale) at 
which 50% antibody depletion is achieved (midpoint between the maximum and 
minimum  depletion values), and sc is the slope of the curve. Percent antibody 
depletion for any competitor/soluble antigen is therefore the difference between 
100% (binding in the absence of soluble antigen) and residual binding at the 
highest competitor antigen concentration of 30 µg/ml. 
 
Parasite cultures and growth inhibition assays 
Protein G-purified IgG fractions were tested for in vitro activity in parasite 
growth inhibition assays (GIAs). All IgGs were tested in triplicate on FCR3 (one 
amino acid difference in the pro-domain from the FVO strain, with ama1 
GenBank accession no. M34553), NF54 (parent strain of the 3D7 clone with 
ama1 GenBank accession no. U65407), HB3 (accession no. U33277), L32 
(accession no. EF221749), 7G8 (accession no. M34555) and CAMP (accession no. 
M34552) parasite strains at a 2-fold serial dilution from 6 mg/ml in 96-well half 
area cell culture plates (Greiner, Alphen a/d Rijn, The Netherlands). Parasites 
were cultured under standard conditions (an atmosphere of 5% CO2, 5% O2, and 
90% N2, 37°C), and the PfAMA1 antigens expressed by all parasite strains were 
verified by PCR and restriction fragment length analysis. Parasite cultures were 
mycoplasma-free and synchronized with 0.3 M Alanine, 10 mM Hepes pH 7.5 
before use in assays. Late trophozoite/early schizont stages at a parasitaemia of 
0.3 ± 0.1% and 2% final haematocrit were used in all assays. The final culture 
volume was 50 µl/well and parasites were incubated for 42-46 h. Parasite 
growth was assessed by measuring parasite lactate dehydrogenase levels and 
plates were read at 655 nm after 30 min of development. Parasite growth 
inhibition was expressed as;  
 
%  inhibition =100 − (A655Sample − A655RBC)(A655SZ − A655RBC)
×100  
 
where A655Sample is the OD655 for any test sample well, A655SZ is the average 
OD655 of schizont control wells included on each plate and A655RBC is the average 
OD655 of RBC control wells. The data is presented as the arithmetic mean % 
inhibition from each sample triplicate. 
 
Statistical analyses 
Residual antibody binding (Ymin) for each competitor antigen in competition 
ELISA was estimated by a 4-parameter logistic fit with least squares 
approximation using the R statistical package (R Development Core Team, 2009, 
version 2.10.1). The mean % depletion (100-Ymin) and 95% confidence intervals 
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of a competitor antigen on one capture antigen were calculated and compared 
with mean values of the same competitor antigen on other capture antigens 
within the same immunisation group, or with mean values obtained for the same 
competitor antigen in other immunisation groups.  
ELISA antibody titres on seven different capture antigens are presented as 
dotplots superposed with boxplots indicating the median as well as the lower 
and upper quartiles for each immunisation group. GIA data is presented as the 
mean % growth inhibition ± standard error of mean per immunisation group 
against each of the six parasite strains tested. Associations between antibody 
titre and GIA activity for four parasite strains with matching ELISA data were 
estimated with a four-parameter logistic fit.  
The original Gp 1 study involved 98 rabbits immunised with the seven-antigen 
mixture in CoVaccine HT™. ELISA was performed on a random sample of 9 out of 
the 98 available. Since small volumes (~100 µL) of the individual rabbit sera 
were available, only a single antibody sample, representing a pool of IgGs from 
the 98 rabbits, was available for in vitro growth inhibition assay. The growth 
inhibitory capacity of this single sample against three parasite strains (FCR3, 
HB3, NF54) was therefore compared directly with that of IgGs purified from a 
pool of sera from all 8 rabbits immunised with DiCo mix in CoVaccine HT™ (Gp 
2). All plots were prepared with the R statistical package. 
 
 
RESULTS 
 
Three-antigen and seven-antigen immunisations induce antibodies with 
similar specificity profiles. 
Specificity profiles of antibodies from rabbit immunisations with the three-
antigen (DiCo mix, Gp 2) and seven-antigen (DiCo mix + AMA1 alleles from FVO, 
HB3, 3D7 and CAMP strains of P. falciparum, Gp 1) vaccines, both formulated in 
CoVaccine HT™, were determined by a standardized competition ELISA with the 
three DiCo proteins used separately as capture antigens. Initial titrations with 
the separate DiCos as capture antigens showed that antibody titres were higher 
(1.4 – 1.7 times) in the three-antigen immunisation group (Gp 2) compared to 
the seven-antigen immunisation group (Gp 1), and the differences were 
statistically significant when DiCo1 and DiCo 2 were used as capture antigens 
(Figure 1). 
In competition ELISA, antibodies from the three and seven-antigen immunisation 
regimens were co-incubated with four natural PfAMA1 alleles (from 3D7, HB3, 
FVO and CAMP parasite strains) and two different antigen mixtures (DiCo mix or 
DM, and a mixture of the four natural PfAMA1 alleles, designated NM) in coated 
and blocked plates. Antibody depletion by all 6 competitor antigens/mixtures 
was fairly consistent for all rabbits within the same immunisation group when 
assays were done on DiCo 1, DiCo 2 and DiCo 3-coated plates, respectively. 
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Statistical comparison of all rabbit antibodies from the three-antigen (Gp 2, n=8) 
and seven-antigen (Gp 1, n=9) immunisation groups, both formulated in Co-
Vaccine HT, showed no significant difference in mean % antibody depletion by 
all six competitor antigens/mixtures (Table 1, Gps 1 & 2). For both vaccines, 
antibody depletion by the competitor antigen mixtures (DM and NM) was 
between 91% and 99% on all three DiCo capture antigens as was expected 
(Table 1). Of the four natural PfAMA1 competitor antigens,  
HB3 AMA1 depleted the most antibodies (87– 95%) on all the DiCo capture 
antigens, whilst 3D7 AMA1 depleted the least (67 – 82%) (Table 1, Gps 1 & 2). 
The mean % antibody depletion amongst competitor antigens varied most on 
DiCo 2-coated plates compared to DiCo 1- and DiCo 3-coated plates. Mean % 
antibody depletion was least for 3D7 AMA1 (~ 68%) on DiCo 2-coated plates, 
irrespective of whether the antibodies were raised with the three- or seven-
antigen vaccines. 
 
 
Figure 1. Levels of anti-AMA1 antibody elicited with the four multi-allele vaccine 
formulations in rabbits. Gp 1 rabbits were immunised with seven AMA1 antigens (DiCo mix 
and AMA1 from FVO, HB3, 3D7 and CAMP parasite strains) in CoVaccine HT™, and the other 
groups were immunised with DiCo mix in CoVaccine HT™ (Gp 2), Montanide IMS (Gp 3) and 
Montanide ISA 51 (Gp 4) respectively.  Antibody titres were determined by a standardized ELISA 
with DiCo 1, DiCo 2, DiCo 3, FVO, HB3, 3D7 and CAMP AMA1-coated plates. Data is presented on a 
Log2 scale as dotplots with a boxplot superpose indicating the lower and upper quartiles as well 
as the median per immunisation group. Within the same immunisation group, plotting symbols 
represent the antibody titre of individual rabbits on all coating/capture antigens.  
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Table 1. Mean % antibody depletion from DiCo 1, 2 and 3-coated plates. 
 
 
Antibody depletion after competition ELISA, values reported as mean % depletion (95%CI).  
7Ag – vaccine containing DiCo mix + four AMA1 alleles from FVO, HB3, 3D7 and CAMP parasite 
strains;  3Ag –  vaccine containing DiCo mix; NM &DM – competitor antigen mixtures comprising 
natural AMA1 alleles (FVO, HB3, 3D7, CAMP) and DiCo mix, respectively. 
 
Capture 
antigen 
Competitor 
antigen 
Gp 1  
(7Ag/HT)      
n=9 
Gp 2   
(3Ag/HT)      
n=8 
Gp 3 
(3Ag/IMS)    
n=8 
Gp 4 
(3Ag/ISA 51) 
n=5 
DiCo 1 FVO 
84.7 
(81.6 – 87.8) 
83.0 
(79.5 – 86.6) 
77.0 
(71.9 – 82.0) 
77.4 
(73.0 – 81.8) 
 HB3 
93.9 
(91.7 – 96.1) 
90.1 
(88.5 – 91.6) 
90.7 
(87.9 – 93.6) 
83.4 
(76.7 – 90.1) 
 DM 
96.1 
(93.9 – 98.3) 
98.6 
(98.2 – 99.1) 
97.2 
(95.9 – 98.4) 
91.9 
(88.3 – 95.5) 
 CAMP 
87.6 
(84.2 – 90.9) 
86.3 
(84.5 – 88.0) 
78.3 
(74.5 – 82.1) 
77.4 
(71.4 – 83.5) 
 3D7 
75.2 
(72.2 – 78.2) 
76.9 
(73.1 – 80.8) 
69.3 
(65.0 – 73.6) 
61.4 
(54.9 – 68.0) 
 NM 
97.6 
(96.1 – 99.0) 
92.4 
(91.3 – 93.4) 
92.1 
(90.8 – 93.5) 
88.2 
(85.8 – 90.6) 
      
DiCo 2 FVO 
90.0 
(87.2 – 92.8) 
86.4 
(84.2 – 88.6) 
84.8 
(79.4 – 90.2) 
83.6 
(81.2 – 86.1) 
 HB3 
94.0 
(91.8 – 96.2) 
94.4 
(91.1 – 97.8) 
97.1 
(94.8 – 99.4) 
83.7 
(71.6 – 95.7) 
 DM 
96.1 
(93.9 – 98.4) 
97.6 
(96.4 – 98.9) 
98.1 
(96.6 – 99.6) 
92.9 
(90.4 – 95.5) 
 CAMP 
83.0 
(79.6 – 86.4) 
83.5 
(80.1 – 87.0) 
77.9 
(75.3 – 80.5) 
77.3 
(76.1 – 78.6) 
 3D7 
67.6 
(63.3 – 71.9) 
68.3 
(65.9 – 70.6) 
63.6 
(58.7 – 68.5) 
56.6 
(48.3 – 64.9) 
 NM 
95.0 
(93.7 – 96.4) 
92.9 
(91.2 – 94.7) 
95.0 
(92.2 – 97.8) 
88.9 
(85.5 – 92.3) 
      
DiCo 3 FVO 
81.2 
(77.7 – 84.6) 
81.9 
(78.2 – 85.6) 
72.8 
(66.9 – 78.7) 
74.1 
(66.8 – 81.4) 
 HB3 
91.9 
(89.6 – 94.3) 
87.1 
(85.2 – 88.9) 
85.1 
(82.5 – 87.7) 
80.9 
(74.8 – 87.0) 
 DM 
97.3 
(92.2 – 102.2) 
97.8 
(96.4 – 99.3) 
96.8 
(95.4 – 98.2) 
91.0 
(89.1 – 92.9) 
 CAMP 
80.2 
(77.0 – 83.3) 
80.8 
(76.7 – 84.9) 
66.3 
(59.7 – 73.0) 
67.8 
(62.5 – 73.1) 
 3D7 
82.1 
(78.6 – 85.6) 
80.6 
(77.9 – 83.2) 
66.5 
(61.4 – 71.7) 
57.8 
(47.9 – 67.6) 
 NM 
94.2 
(93.1 – 95.4) 
91.4 
(89.0 – 93.7) 
86.5 
(83.6 – 89.4) 
84.0 
(77.6 – 90.4) 
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By contrast, mean % antibody depletion was greatest for FVO AMA1 competitor 
antigen (86.4% and 90.0% respectively for antibodies raised in the three- and 
seven-antigen immunisations) and HB3 AMA1 (94.4% and 94.0%, respectively) 
on DiCo 2-coated plates. 3D7 AMA1 as a competitor antigen depleted most 
antibodies from both immunisation groups (80.6% and 82.1% respectively for 
antibodies raised in the three- and seven-antigen immunisations) on DiCo 3-
coated plates (Table 1, Gps 1 & 2). The 9 antibody samples from the seven-
antigen immunisation in CoVaccine HT™ were randomly selected from a total of 
98 such rabbits, and a pool of antibodies from all 98 rabbits was subsequently 
tested in GIA. The ELISA antibody depletion pattern of this IgG pool was shown 
to be similar to that of the individual antibody samples (data not shown). 
Differences in % antibody depletion amongst the four allelic PfAMA1 competitor 
antigens may be related to the DiCo protein coverage of polymorphism found in 
natural alleles. Alignments of DiCo protein amino acid sequences with those of 
the four natural alleles (Figure 2) reveal that apart from position K376 which 
was mutated in the three DiCo proteins to avoid protein cleavage there are five 
other positions in 3D7 AMA1 that are not present in any of the DiCo proteins. 
CAMP AMA1 sequences have two uncovered positions, HB3 AMA1 has three and 
FVO AMA1 has all amino acid residues represented at least once in the three 
DiCo proteins.  
 
The majority of antibodies raised in three-antigen and seven-antigen 
immunisations recognise shared epitopes in natural PfAMA1 alleles. 
In order to further test the hypothesis that multi-allele vaccines induce high 
proportions of antibodies to epitopes that are shared by the vaccine component 
alleles, the specificities of antibodies elicited by all four vaccine formulations to 
four different PfAMA1 alleles were assessed by competition ELISA. Antibody 
titres were initially determined by a standard ELISA on plates coated with 
PfAMA1 from FVO, HB3, 3D7 and CAMP parasite strains respectively, and titres 
were comparable to those obtained when the same antibodies were titrated on 
the immunising DiCo antigens (Figure 1). In our hands, rabbit immunisations 
with antigen from concentrations of 30 - 100 µg/ml have usually yielded similar 
results, hence the differences in the antigen dose between the first three groups 
and the DiCo mix/Montanide ISA 51 group (Gp 4) may not result in different 
titres. The four PfAMA1 alleles (from FVO, HB3, 3D7 and CAMP parasite strains) 
were used as competitor antigens in subsequent competition ELISA on plates 
coated with FVO and 3D7 AMA1 antigens respectively. 
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Figure 2. Alignment of the protein sequences (aa25-545) of PfAMA1 antigens used in this 
study. DiCo proteins were used to immunise rabbits and as capture antigens in ELISA. Natural 
allele AMA1 proteins were used to immunise rabbits, and as capture and competitor antigens in 
(competition) ELISAs. All proteins were produced in Pichia pastoris and are devoid of N-
glycosylation sites. These have been replaced with amino acid residues that occur in AMA1 
sequences from other malarial species (N162Q, T288V, S373D, N422D, S423K, N499Q). Residue 
162 is unique as it is also a polymorphic residue. Additionally, all DiCo sequences contain a point 
mutation at position 376 (K to R). This was necessary to prevent protein cleavage by P. pastoris 
proteases. 
 
 
In assays performed with FVO AMA1-coated plates, antibodies from all four 
immunisation groups showed the greatest depletion with the homologous FVO 
AMA1 (94 – 98%) and HB3 AMA1 (94 – 97%) as expected (Table 2). CAMP AMA1 
and 3D7 AMA1 depleted 78 – 84% and 67 – 82%, respectively. Likewise, assays 
performed with 3D7 AMA1-coated plates using the same rabbit antibodies 
resulted in 92 – 98% depletion by 3D7 AMA1, 85 – 86.5% depletion by CAMP 
AMA1, 88 – 90.5% depletion by HB3 AMA1 and 81 – 84% depletion by FVO 
AMA1 (Table 2). Between groups, antibody depletion by an individual 
competitor antigen was similar on the same capture antigen, and irrespective of 
the number of immunising antigens (Table 2, Gps 1 & 2) or the adjuvant used in 
vaccine formulation (Table 2, Gps 2, 3 & 4). On average, for all immunisation 
groups, the extent of recognition of FVO-binding antibodies by 3D7 AMA1 
competitor antigen was about 8.8% less than the recognition of 3D7 AMA1-
binding antibodies by FVO AMA1 competitor antigen. These observations 
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indicate that though the majority of antibodies recognise shared epitopes in the 
four natural PfAMA1 alleles, a fraction of antibodies are still strain-specific. This 
may be explained by assuming that some antigen-specific epitopes on any of the 
three DiCo proteins is/are not present on the PfAMA1 alleles of interest. 
Antibodies elicited against such epitopes only recognize the PfAMA1 allele(s) 
that have these epitopes and will not bind to alleles without these strain-specific 
epitopes. Additionally, local distortions of the protein structure resulting from 
changes in amino acids that are in close proximity to, or within these epitopes 
may mean antibodies will have lower binding avidity/affinity for these epitopes. 
This may result in a continuum of binding specificities, such that some antibodies 
will have high avidity for epitopes on some PfAMA1 alleles and lower avidity for 
corresponding, albeit altered epitopes on other alleles. With the exception of FVO 
AMA1, the three other natural PfAMA1 alleles have amino acids that are not 
present in any of the three DiCo proteins (Figure 2).  
 
 
Table 2. Mean % antibody depletion from FVO and 3D7 AMA1-coated  
    plates. 
 
Antibody depletion after competition ELISA, values reported as mean % depletion (95%CI).  
7Ag – vaccine containing DiCo mix + four AMA1 alleles from FVO, HB3, 3D7 and CAMP parasite 
strains; 3Ag –  vaccine containing DiCo mix; NM &DM – competitor antigen mixtures comprising 
natural AMA1 alleles (FVO, HB3, 3D7, CAMP) and DiCo mix, respectively. 
 
 
 
Capture 
antigen 
Competitor 
antigen 
 
Gp 1 
(7Ag/HT)      
n=9 
Gp 2     
(3Ag/HT)      
n=8 
Gp 3     
(3Ag/IMS)      
n=8 
 
Gp 4   
(3Ag/ISA 51) 
n=5 
 
3D7 
AMA1 FVO 
83.9 
(81.6 - 86.2) 
85.4   
(81.8 –89.0) 
81.4   
(78.1 – 84.7) 
82.8   
(79.1 – 86.5) 
 HB3 
90.5   
(89.2 – 91.8) 
89.8   
(88.4 – 91.1) 
90.5   
(88.0 – 93.0) 
88.1   
(85.3 – 91.0) 
 CAMP 
86.4     
 (84.1 – 88.7) 
86.5   
(81.9 – 91.2) 
85.6   
(81.7 – 89.4) 
85.3   
(82.6 – 88.0) 
 3D7 
96.8   
(95.7 – 97.9) 
98.1   
(96.6 – 99.6) 
98.0   
(95.3 – 
100.7) 
92.5   
(90.3 – 94.7) 
      
 
FVO 
AMA1 FVO 
96.1    
(95.3 – 96.8) 
97.5   
(96.3 – 98.7) 
97.5   
(96.4 – 98.6) 
94.3    
(93.0 – 95.6) 
 HB3 
95.0    
(93.9 – 96.0) 
95.7   
(94.5 – 96.8) 
96.3   
(95.5 – 97.1) 
94.1   
(92.7 – 95.6) 
 CAMP 
82.9   
(80.6 – 85.2) 
83.6   
(80.5 – 86.6) 
78.3   
(74.9 – 81.7) 
83.6   
(79.5 – 87.7) 
 3D7 
73.4 
(70.5 – 76.3) 
81.8 
(79.7 – 83.9) 
75.5 
(70.2 – 80.8) 
 
67.7 
(61.8 – 73.7) 
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Epitopes that include these polymorphic amino acids are therefore prime 
candidates that may explain the remnant strain-specificity observed.  
 
The choice of adjuvant determines the quantity but not the antigen 
specificity of elicited antibodies. 
In order to assess the effect of adjuvant on the specificity of elicited responses, 
rabbit antibodies raised against DiCo mix in Co-Vaccine HT (Gp 2, n=8) were 
compared with those raised in separate immunisations with DiCo mix in 
Montanide IMS (Gp 3, n=8) and Montanide ISA 51 (Gp 4, n=5) as adjuvants. 
Antibody titres were dependent on the vaccine adjuvant when titrated in DiCo 1-, 
DiCo 2- or DiCo 3-coated plates. Antibody titres were generally comparable in 
the immunisation groups with Co-Vaccine HT and Montanide ISA 51, whilst titres 
were comparatively lower in the Montanide IMS group (Figure 1, Gps 2, 3 & 4)). 
Additionally, depletion patterns in competition ELISA showed a general, albeit 
insignificant trend of higher % depletions of antibodies against DiCo mix in 
CoVaccine HT™ (Gp 2) by all competitor antigens/mixtures, with 3D7 and CAMP 
AMA1 competitor antigens showing only borderline significance in some 
instances (Table 1, Gps 2, 3 and 4). Depletion of antibodies from the two 
Montanide immunisation groups was also generally comparable except for the 
two competitor antigen mixtures DM and NM. Thus though the choice of an 
adjuvant for immunisation affected the physiological levels of anti-DiCo mix 
antibodies in rabbits, the current data suggests that the adjuvant effect on 
epitope presentation to B cells, and by extension on the antibody specificity, may 
only be marginal. This may however be applicable only to the three adjuvants 
used in this study. 
 
In vitro functional assays with anti-DiCo mix antibodies show similar 
inhibition of multiple P. falciparum strains.   
The functional activity of anti-DiCo mix antibodies from the four immunisation 
groups was determined in vitro on a broad panel of culture-adapted P. falciparum 
strains (FCR3, NF54, HB3, L32, 7G8 and CAMP). Antibodies were tested at a 2-
fold dilution from 6 – 0.75 mg/ml against all parasite strains. At the highest 
concentration tested, antibodies from the seven-antigen immunisation in 
CoVaccine HT™ (Gp 1, n=1, representing a pool with n=98) showed % growth 
inhibition of 75.1%, 81.9%, 87.2%, 88.3%, 89.1% and 93.9% against the L32, 
HB3, NF54, 7G8, FCR3 and CAMP parasite strains, respectively. The single 
sample available for testing in this group however meant these values could not 
be directly compared with the mean % inhibition of the 5 or 8 different rabbit 
IgGs in the other immunisation groups.  The functional activity of this sample 
against three of the six parasite strains (FCR3, HB3, NF54) was therefore 
compared with that of IgGs purified from a serum pool from all 8 rabbits 
immunised with DiCo mix in CoVaccine HT™ (Gp 2) in separate experiments. The 
% inhibition of pooled antibodies from the seven-antigen immunisation were the  
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Figure 3. Growth inhibition of Plasmodium parasites by antibody pools from the 3-antigen 
and 7-antigen immunisation groups. The 7-antigen immunisation group (Gp 1) had only a 
single sample (antibodies purified from a pool of 98 rabbit sera), hence a direct comparison of 
the functional activities of antibodies from the 3 and 7-antigen immunisation groups could not be 
made. The growth inhibitory activity of IgGs purified from a pool of all rabbits immunised with 
DiCo mix (3-antigen, Gp 2) in the same adjuvant (CoVaccine HT™) was therefore compared with 
that of the single Gp 1 sample against the FCR3, HB3 and NF54 parasite strains. Plots represent 
the mean % inhibition ± SEM for replicate measurements for each sample. Filled circles (●) 
represent the Gp 1 pooled sample and the filled squares (■) represent the Gp 2 pooled sample. 
 
 
same as that of the DiCo mix pooled antibodies against NF54 and FCR3 parasite 
strains, but slightly higher than that of DiCo mix pooled antibodies against HB3 
parasites (Figure 3). Moreover, the % inhibition of these three parasite strains by 
the DiCo mix pooled antibodies compared favourably with the corresponding 
mean % inhibition estimated from the measured inhibitions of the individual 
rabbit IgGs to DiCo mix in CoVaccine HT™ (Figures 3 and 4).  
The level of in vitro inhibition was the same for all the three DiCo mix 
immunisation groups (Gp 2, Gp 3 and Gp 4) against five of the six parasite 
strains, with the L32 strain being the exception (Figure 4). At the highest 
concentration tested (6 mg/ml), mean % growth inhibition of antibodies induced 
against DiCo mix in CoVaccine HT™ (Gp 2, n=8) was between 65 and 82% whilst 
that of antibodies against DiCo mix in Montanide ISA 51 (Gp 4, n=5) was between 
65 and 81% against the five strains (Figure 4). Antibodies against DiCo mix in 
Montanide IMS (Gp 3, n=8) had the lowest mean % growth inhibitions (between 
37% and 58%) against all five strains (Figure 4). Although inhibition of the L32 
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strain was generally lower in all immunisation groups (47.3% for Gp 2, 39.5% 
for Gp 3 and up to 50% for Gp 4 at 6 mg/ml total IgG), the trend across 
immunisation groups was similar to that for the other parasite strains. The 
observed lower inhibition of L32 parasites may be explained by the many 
Polymorphic amino acids (R197, D207, I224, N244, P330, R395 and T498) 
within the L32 AMA1 sequence that do not occur in any of the three DiCo 
proteins, aside those in the prodomain, and mutations at N-glycosylation and 
cleavage sites (Figure 5). 
Since the proportions of strain-specific and cross-reactive antibodies as 
measured by competition ELISA were constant across immunisation groups, the 
lower GIA activity of the Montanide IMS group may be explained by the lower 
levels of the relevant cross-reactive antibodies measured in ELISA. Figure 6 
shows that antibody levels against the relevant PfAMA1 alleles correlate with the 
extent of in vitro inhibition of parasite strains that express those alleles. Thus the 
effect of adjuvant on the functionality of elicited antibodies is mainly on the 
quantity of cross-strain antibodies and not the quality of antibodies.  
 
 
Figure 4. Growth inhibition of Plasmodium parasites by antibodies elicited with the three 
DiCo mix vaccines.  Antibodies from all immunisation groups were tested on each of six culture-
adapted strains (7G8, CAMP, FCR3, HB3, L32 and NF54) of P. falciparum. Plots represent the 
mean % inhibition ± SEM for all antibody samples within an immunisation group. Filled circles 
(●) represent Gp 2 (DiCo mix in CoVaccine HT™, n=8), open diamonds (◇) represent Gp 3 (DiCo 
mix in Montanide IMS, n=8) and filled squares (■) represent Gp 4 (DiCo mix in Montanide ISA 51, 
n=5).  
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DISCUSSION 
Antibodies to epitopes that are shared between different PfAMA1 alleles (cross-
reactive/conserved) have been shown to be relevant for broad strain parasite 
inhibition in vitro [16,26,27], and may be potentially important in the field [28]. 
We have previously shown that immunisation with mixed PfAMA1 alleles 
induces a high proportion of such antibodies [15], and this represents an 
important strategy for dealing with allelic polymorphism in key antigenic 
vaccine targets like AMA1. The number of allelic variants of the antigen that are 
needed for a universally functional vaccine however remains a subject of 
discussion. This number will be dependent on the underlying mechanism of 
antibody production upon immunisation with a mixture of slightly different 
immunogens. Our current working hypothesis is that such a formulation will 
have strain-specific epitopes diluted out and this will preferentially enhance the 
presentation of shared epitopes to the relevant antibody-producing effector 
systems in vivo, thereby increasing the breadth of antibody response.   
 
 
 
Figure 5. Alignment of DiCo protein sequences (aa25-545) with those of AMA1 present in 
GIA malaria parasites. AMA1 protein sequences of malaria parasites used for in vitro growth 
inhibition assays were accessed from the GenBank database. The DiCo sequences contain point 
mutations at the cleavage (K376R) and potential N-glycosylation (N162Q, T288V, S373D, N422D, 
S423K, N499Q) sites, and differ from parasite AMA1 sequences at these sites. Amino acids at 51 
polymorphic sites (within aa25-525) also differ between sequences. 
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Our Diversity-Covering approach is premised on this hypothesis, and in 
designing the DiCo proteins, polymorphic amino acids of high frequency (> 10%) 
in naturally occurring PfAMA1 sequences have been incorporated two or three 
times [18].  
Thus the DiCo proteins intrinsically have another level of coverage of 
polymorphism, and are expected to further increase the breadth of antibody 
response. This study compared the proportions of cross-strain antibodies 
elicited in separate rabbit immunisations with three and seven antigens, and also 
assessed the adjuvant effect on antigen-binding specificity of elicited antibodies. 
Data from competition ELISA on plates coated with any one of five AMA1 
antigens (DiCo 1, DiCo 2, DiCo 3, FVO or 3D7) showed that the binding 
specificities of antibodies induced in the seven-antigen immunisation were not 
distinguishable from those induced in the three-antigen immunisation (Gps 1 & 2 
of Table 1 and Table 2).   
 
 
 
Figure 6. Relationship between ELISA antibody titre and in vitro parasite growth 
inhibition. Association of antibody levels with in vitro antibody functionality for three of the four 
immunisation groups (Gps 2, 3 and 4) is shown for parasite strains whose AMA1 allelic antigens 
were available for antibody measurement. In order to obtain an optimal estimate of the 
association, growth inhibition data at all four antibody concentrations tested (6.0, 3.0, 1.5 and 
0.75 mg/ml) for each sample were included. Plots are based on a four-parameter logistic 
function, and each symbol represents individual rabbits in the same immunisation group.  
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Thus the addition of four extra antigens to the three in the DiCo mix vaccine did 
not lead to a detectable increase in the proportion of antibodies against cross-
reactive epitopes. Antibodies induced against a mixture of three PfAMA1 alleles 
have been previously shown to exhibit greater cross-reactivity than antibodies 
against a single allele [15].  
The current data thus suggests a plateau effect and a practical limit on the 
number of alleles that are needed to elicit the broadest antibody response 
possible. Comparison of antibody depletion patterns of the four PfAMA1 
competitor antigens (FVO, HB3, 3D7 and CAMP) showed that the multi-allele 
vaccines least covered the 3D7 and CAMP AMA1 alleles, while HB3 and FVO 
AMA1 had reasonably better coverage (Tables 1 & 2). This was more so when 
assays were performed on DiCo 2 –coated (Table 1) or FVO AMA1-coated (Table 
2) plates, and the observation was irrespective of the number of immunising 
alleles and the adjuvant used. Thus a fraction of antibodies elicited by multi-
allele vaccine formulations is strain-specific. Alignment of the amino acid 
sequences of the three DiCo proteins alongside those of natural PfAMA1 alleles 
(Figure 2) shows that apart from the cleavage site mutation (position K376R), 
there are five amino acids at polymorphic positions within the 3D7 AMA1 
sequence (N34, R39, Y175, E197, P330) that are not present in any of the DiCo 
proteins, while all polymorphic amino acids in FVO AMA1 are present in at least 
one of the three DiCo proteins. Of the five unique amino acids in 3D7 AMA1, two 
in the prodomain (N34 and R39) do not have immunological significance since 
the PfAMA1 prodomain is not present on the merozoite at the time of 
erythrocyte invasion [29,30]. The glutamic acid residue at the heptamorphic hot-
spot position 197 [31] forms part of a cluster of inhibitory epitope residues 
within domain I of the protein [26], and occurs in only 8% of 1294 PfAMA1 
sequences available (Remarque, unpublished data). The two other residues 
(Y175 and P330) are located in other clusters that are also deemed important in 
antigenic escape [26]. Although the seven-antigen vaccine includes 3D7 AMA1, 
there is likely an over-representation of antibody epitopes that are not found 
within 3D7 AMA1. Lower levels of antibodies will thus be elicited against the 
3D7 AMA1-type epitopes, and this fits our working hypothesis. CAMP and HB3 
AMA1 sequences have two (K228 and H407) and three (N34, R39 and K121) 
polymorphic amino acids, respectively, that are not covered in the DiCo 
sequences (Figure 2). Residue K228 is likely to occur within an important 
domain I cluster [26], while residue H407 is in domain II and has not as yet been 
described as part of an important escape cluster. Antibody epitopes that include 
these polymorphic amino acids may therefore be relevant for antigenic escape. 
Residue K121 occurs within domain I and has not yet been described as part of 
an escape cluster. Residues N34 and R39 occur within the prodomain and are 
immunologically not relevant. 
Amino acids at positions 175 and 228 are in close proximity to the conserved 
tyrosine residue at position 251 within the hydrophobic trough of AMA1 [32]. 
Chapter 3 
 
72 
 
This tyrosine residue is believed to be important for interaction with other 
invasion-associated proteins [32].  Residues at positions 330 and 407 cluster 
away from the hydrophobic trough and residue 121 occurs on the more 
conserved face of the molecule. Some of these polymorphic residues have been 
predicted to belong to discontinuous B-cell epitopes within AMA1 (DiscoTope 
method, referenced in [33]). 
Functional antibody assay data supports the observations made with 
competition ELISAs. Antibodies from DiCo mix immunisation groups (Gp 2, Gp 3 
and Gp 4) showed consistent levels of inhibition of five out of six parasite strains 
tested, with the L32 strain being an exception (Figure 4). In addition, anti-DiCo 
mix antibodies elicited with two of the adjuvants (CoVaccine HT™ and Montanide 
ISA 51) consistently showed the greatest inhibition of all strains. These data 
collectively indicate an improved breadth of antibody response compared to 
antibodies from a single allele or two-allele immunisation [15,16]. The data 
shows that strain-specific antibodies, despite being present as determined by 
competition ELISA, did not have any significant functional effects on parasites in 
vitro. Since strain-specific anti-AMA1 antibodies are highly inhibitory against 
homologous strains [9,13,34], it can be concluded that the multi-allele vaccines 
induced only very low titres of these antibodies, confirming our working 
hypothesis.  
The functional activity of the antibody pool from the seven-antigen 
immunisation group compared favourably with a similar pool made from all 
eight sera in the DiCo mix CoVaccine HT™ immunisation group (Figure 3). Thus 
the seven-antigen vaccine does not have significant functional benefits over the 
three-antigen DiCo mix vaccine. Though inhibition of one of the parasite strains 
tested (HB3) was significantly higher for the seven-antigen immunisation pooled 
antibodies compared to the three-antigen pooled immunisation antibodies, this 
singular observation may not have biological significance. 
The lower in vitro inhibition of L32 parasites is likely due to the extent of 
coverage of polymorphism of the L32 AMA1 sequence by the DiCo mix vaccine. 
Apart from mutations at the cleavage (K376R) and N-glycosylation (N162K, 
T288V, S373D, N422D, S423K and N499Q) sites, there are seven polymorphic 
residues (R197, D207, I224, N244, P330, R395 and T498) that are not present in 
any of the three DiCo proteins (Figure 5). Residues at positions 197, 207, 224 
and 244 have already been identified within or in proximity of important 
antigenic escape clusters [26], and it is imaginable that these, in addition to any 
functional epitope(s) that include residues P330, R395 and T498, will contribute 
to significant levels of strain-specific antibodies to L32 parasites.  
Taken together, the data largely suggests parasite inhibition through recognition 
of shared PfAMA1 allele epitopes in these diverse parasites. These functional 
epitopes are likely to occur in AMA1 from many other parasite strains, and 
antibodies to such epitopes may play a key role in naturally acquired immunity 
to malaria [28]. Though partial, clinical immunity is acquired over time after 
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repeated exposure to diverse parasite strains [35–38]. We therefore hypothesize 
that the antibody component of acquired immunity in semi-immune adults 
would be mainly to cross-strain epitopes, in contrast to the alternative model of a 
time-dependent acquisition of a diverse repertoire of strain-specific antibodies 
after repeated exposure to different parasite strains [28]. 
The choice of adjuvant for vaccine formulation has been shown to influence the 
quality and specificity of the elicited cellular and humoral responses [20,39,40]. 
In this study, adjuvant choice determined the levels of elicited antibodies and 
thus the extent of in vitro parasite inhibition observed (Figures 1 and 4). This 
however did not influence antigen specificity as antibodies induced in all four 
immunisation groups had near similar specificity profiles (Tables 1 and 2). This 
observation may be peculiar to DiCo mix as a vaccine candidate since the three 
DiCo proteins were designed to intrinsically cover polymorphism within natural 
PfAMA1 sequences, and any specificity effects of the different adjuvants may 
have been masked by this property of the vaccine candidate. High levels of 
antibody of the right quality are required to counter parasite growth in both in 
vitro and in vivo systems [15,41]. Thus the choice of adjuvant for a DiCo mix 
vaccine, based on the current data, may have little or no effect on the induction of 
the relevant cross-strain antibodies. This is important for this vaccination 
strategy since adjuvant influence on antibody specificity would introduce 
another level of complexity in achieving the ultimate functional cross-strain 
antibodies. 
In summary, we show that the four extra PfAMA1 alleles, when added to DiCo 
mix in a seven-antigen formulation, do not broaden the antigen specificity of 
elicited antibodies further, and that the three DiCo antigens may on their own be 
sufficient to cover PfAMA1 polymorphism. The DiCo mix vaccine elicits 
functional broad-strain antibody responses directed mostly to shared epitopes. 
Though up to three relevant polymorphic amino acids in AMA1 sequences from 
FCR3, HB3, CAMP, NF54 and 7G8 parasite strains were not covered by the DiCo 
antigens, the consistent level of inhibition of these strains by anti-DiCo mix 
antibodies suggest that 100% coverage of polymorphic residues may not be 
necessarily required for a universal vaccine. The lower inhibition of L32 
parasites, which have as many as seven potentially important polymorphic 
residues missing from the DiCo sequences however imply that the DiCo 
approach would need to be constantly reviewed, just as is the case for seasonal 
influenza vaccines. This is necessary to account for increases in the frequency of 
polymorphic amino acids that were low (<10%) at the time of DiCo design, and 
indeed for new polymorphic positions that are likely to evolve in the field. We 
finally demonstrate that different adjuvants elicit anti-DiCo mix antibodies with 
similar antigen specificities, although the absolute levels of elicited antibodies 
differ. This enhances the feasibility of developing an effective multi-allele AMA1-
based vaccine with reduced formulation complexity and warrants further 
development of multi-allele immunisation strategies. We also highlight a 
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potentially important role for cross-strain antibodies in naturally acquired 
immunity to malaria, and the need for novel adjuvants with improved antibody 
potentiation properties and safety for use in AMA1-based subunit vaccine 
development. 
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ABSTRACT 
 
 
Background 
Antibodies to key Plasmodium falciparum surface antigens have been shown to 
be important effectors that mediate clinical immunity to malaria. The cross-
strain fraction of anti-malarial antibodies may however be required to achieve 
strain-transcending immunity. Such antibody responses against Plasmodium 
falciparum apical membrane antigen 1 (PfAMA1), a vaccine target molecule that 
is expressed in both liver and blood stages of the parasite, can be elicited through 
immunisation with a mixture of allelic variants of the parasite molecule. Cross-
strain antibodies are most likely elicited against epitopes that are shared by the 
allelic antigens in the vaccine cocktail.  
 
Methods 
A standard competition ELISA was used to address whether the antibody 
response can be further focused on shared epitopes by exclusively boosting 
these common determinants through immunisation of rabbits with different 
PfAMA1 alleles in sequence. The in vitro parasite growth inhibition assay was 
used to further evaluate the functional effects of the broadened antibody 
response that is characteristic of multi-allele vaccine strategies. 
 
Results 
A mixed antigen immunisation protocol elicited humoral responses that were 
functionally similar to those elicited by a sequential immunisation protocol (p > 
0.05). Sequential exposure to the different PfAMA1 allelic variants induced 
immunological recall of responses to previous alleles and yielded functional 
cross-strain antibodies that would be capable of optimal growth inhibition of 
variant parasites at high enough concentrations.  
 
Conclusions 
These findings may have implications for the current understanding of the 
natural acquisition of clinical immunity to malaria as well as for rational vaccine 
design. 
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BACKGROUND  
Malaria caused by parasites of the Plasmodium spp. continues to be a major 
public health problem with half of the world’s population at risk of infection [1]. 
The greatest risk of disease and fatality in Plasmodium falciparum-endemic areas 
occurs in children under 5 years and in first-time pregnant women. Natural 
immunity to clinical malaria is believed to develop in an age- and exposure-
dependent manner, after repeated infection by a number of (different) parasite 
strains [2-4].  Even in adults who have had several parasite encounters, acquired 
clinical immunity is partial and is believed to be dependent on constant or 
periodic exposure to low-level parasitaemia [3,5].  
The natural ability to acquire immunity to malaria, although partial, is a strong 
indication of the feasibility of developing at least an anti-disease vaccine directed 
against the blood stages of Plasmodium. Antigenic variation in immunogenic 
parasite targets however provides an immune escape route for parasites. 
Polymorphism in such well-known vaccine targets as the Merozoite Surface 
Proteins (MSPs) and Apical Membrane Antigen 1 (AMA1) have been associated 
with host immune pressure on parasites [6-10]. This presents malaria vaccine 
researchers with a formidable challenge since immunisation with one variant of 
these polymorphic antigens induces antibodies that show limited cross-
inhibition/recognition of parasites expressing other allelic variants of the same 
antigen. This has been demonstrated extensively in animal models [11,12] and to 
some extent in human field studies [13-16].  
There is growing interest in multi-allele/multi-antigen malaria vaccines and the 
potential of such vaccines for the induction of broad inhibitory antibody 
responses has been demonstrated [17-19]. The broadened response most likely 
results from diluting out strain-specific epitopes in the antigen mixture, with the 
bulk of remaining epitopes being those that are common to the vaccine 
component alleles [20]. 
The hypothesis that immunisation of rabbits with different PfAMA1 alleles in 
sequence would result in boosting of only antibodies to epitopes that are 
common to all antigens was tested in this study. Antibodies to highly specific 
epitopes would not be boosted, and this is expected to further increase the 
proportion of induced cross-strain antibodies in comparison with antibodies 
induced by a multi-allele vaccine that incorporates the same allelic antigens.  
Such a mechanism of cross-strain antibody production would be based on the 
concept of original antigenic sin (clonal imprinting). Original antigenic sin results 
when prior exposure to one strain/antigen diverts the antibody response to 
shared epitopes following exposure to a second closely related strain/antigen 
such that the newly elicited antibodies still react strongly with the priming 
antigen [21-23]. A sequential immunisation protocol may mimic the 
development of natural clinical immunity and provide some insight into its 
acquisition in the field where over time an individual is exposed (sequentially) to 
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a number of variant parasite strains. The generated data shows that a sequential 
immunisation protocol may not be materially different from a mixed antigen 
protocol with respect to the proportions of elicited strain-specific and cross-
strain antibodies. As expected, antibody production in the sequential 
immunisation groups was through associative immune recall of previous antigen 
encounter. This data is relevant to the current understanding of the acquisition 
of clinical immunity against malaria in endemic areas, as well as for rational 
vaccine design. 
 
 
METHODS 
 
Antigen production, rabbit immunisation and antibody purification 
The full ectodomain of the AMA1 allelic forms from P. falciparum strains FVO, 
HB3, 3D7 and CAMP, as well as the in silico-designed Diversity Covering antigens 
(DiCo 1, DiCo 2 and DiCo 3) [24], were expressed as recombinant proteins in 
Pichia pastoris. The three DiCo proteins were all expressed with the FVO AMA1 
prodomain, and all antigens were mutagenized at up to six potential N-
glycosylation sites within the PfAMA1 ectodomain. The expression, purification 
and characterisation of all antigens were as described previously [25]. 
Rabbit housing and immunisation were at BioGenes GmbH (Berlin, Germany), 
and were in accordance with national and international animal welfare 
regulations. Rabbit immunisation at this facility was under approval from 
NIH/OLAW (ID number #A5755-01). Five groups of rabbits were immunised 
intramuscularly with three doses (30 µg per dose) of different PfAMA1 vaccine 
formulations either in sequence or as an antigen cocktail on days 0, 28 and 56. 
All vaccines were formulated in a modified Freund’s adjuvant (95 % paraffin oil, 
2.4% Tween 40, 0.1% cholesterol and 0.01% lipo-polysaccharide from blue-
green algae) provided by BioGenes, and formulation was according to the 
manufacturer’s protocols. Three of the groups were immunised with PfAMA1 
alleles from the FVO, HB3 and 3D7 strains of P. falciparum in different orders 
(details in Table 1). A fourth group was immunised with three doses of an 
equimolar mixture of these three alleles (designated as NA mix, 10 µg of each 
allele, 30 µg dose), and the last group was immunised with three doses of an 
equimolar mixture of the three DiCo proteins (10 µg of each DiCo, 30 µg dose), 
referred to as DiCo mix (Table 1). Rabbits were exsanguinated on day 70 and 
sera from all five groups were analysed in ELISA while purified antibodies from 
these sera were used in growth inhibition assays described here. Antibodies 
from final bleed sera were purified on Protein G Sepharose (GE Healthcare, 
Etten-Leur, The Netherlands) columns. Binding and elution buffers (Pierce, 
Rockford, IL) were used according to manufacturer’s protocols.  
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Table 1. Schedule indicating the order of PfAMA1 antigen administration  
    to rabbits. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
f (FVO), 3 (3D7) and h (HB3) in groups 1, 2 and 3 indicate the order of antigen administration.  
NA mix – an equimolar mixture of AMA1 antigens from the FVO, HB3 and 3D7 strains of P. 
falciparum, administered at all three immunisation time points. 
DiCo mix – an equimolar mixture of the three Diversity-covering (DiCo) proteins, administered at 
all three immunisation time points. 
 
After elution, antibody eluates were filtered (0.22 µm), concentrated and 
exchanged into RPMI 1640 using pre-sterilized Amicon Ultra-15 tubes (30-kDa 
cutoff; Millipore, Ireland). The concentration of each antibody fraction was 
subsequently determined by a Nanodrop ND1000 spectrophotometer 
(Nanodrop Technologies, Wilmington, DE) using the IgG extinction coefficient, 
adjusted to 12 mg/ml and stored at -20°C until use. 
 
ELISA and growth inhibition assays 
Sera from all rabbits were titrated in a standardized ELISA on plates coated with 
recombinant AMA1 allelic antigens from FVO, HB3 or 3D7 parasite strains. Sera 
were also analysed with a harmonized competition ELISA protocol that has been 
described elsewhere [20]. FVO, HB3 and 3D7 AMA1 proteins were used as 
capture antigens and FVO, HB3, 3D7 and CAMP AMA1 antigens were used as 
competitor antigens in all assays.  
Protein G-purified IgG fractions from final bleed sera were tested for in vitro 
activity in parasite growth inhibition assays (GIAs). All IgGs were tested in 
triplicate on FCR3 (one amino acid difference in the pro-domain from the FVO 
strain, with ama1 GenBank accession no. M34553), NF54 (parent strain of the 
3D7 clone with ama1 GenBank accession no. U65407), HB3 (accession no. 
U33277), 7G8 (accession no. M34555) and CAMP (accession no. M34552) 
 
 
 
Immunisation 
group 
Antigens and immunisation 
*Number 
of rabbits 
 
 
Day 0 Day 28 Day 56 
 
1 (f3h) FVO AMA1 3D7 AMA1 HB3 AMA1 6 
2 (hf3) HB3 AMA1 FVO AMA1 3D7 AMA1 6 
3 (h3f) HB3 AMA1 3D7 AMA1 FVO AMA1 4 
4 (NA mix) NA mix NA mix NA mix 6 
5 (DiCo mix) DiCo mix DiCo mix DiCo mix 6 
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parasite strains at a 2-fold serial dilution from 6 mg/ml in 96-well half area cell 
culture plates (Greiner, Alphen a/d Rijn, The Netherlands). Parasites were 
cultured under standard conditions (an atmosphere of 5% CO2, 5% O2, and 90% 
N2, 37°C), and all parasite strains were verified by PCR and restriction fragment 
length analysis of the PfAMA1 antigen they express. Parasite cultures were 
mycoplasma-free and synchronized with 0.3 M Alanine, 10 mM Hepes, pH 7.5 
before use in assays. Late trophozoite/early schizont stages at a parasitaemia of 
0.3 ± 0.1% and 2% final haematocrit were used in all assays. The final culture 
volume was 50 µl/well and parasites were incubated for 42-46 h. Parasite 
growth was assessed by measuring parasite lactate dehydrogenase levels and 
plates were read at 655 nm after 30 min of development. Parasite growth 
inhibition was expressed as 100 – ((A655Sample - A655RBC)/(A655SZ - A655RBC)) X 
100, where A655Sample is the OD655 for any test sample well, A655SZ is the average 
OD655 of schizont control wells included on each plate and A655RBC is the average 
OD655 of RBC control wells. The data is presented as the arithmetic mean % 
inhibition from each sample triplicate. 
 
Statistical analyses 
All analyses and graphics were made using the R statistical package (R 
Development Core Team, 2009, version 2.10.1). ELISA antibody titres in day 70 
sera were log-transformed and compared between groups by one-way analysis 
of variance (ANOVA) followed by  the pair-wise Tukey Honest Significant 
Difference post hoc test which applies a correction for multiple comparisons. 
Titres are also presented as dotplots superposed with boxplots indicating the 
median, lower and upper quartiles. Residual antibody binding (Ymin) for each 
competitor antigen in competition ELISA was estimated by a 4-parameter 
logistic fit with least squares approximation. The mean % depletion (100-Ymin) 
and corresponding 95% confidence intervals (95% CI) for each competitor 
antigen are presented for all immunisation groups. GIA data is presented as the 
mean % growth inhibition ± standard error of mean per immunisation group 
against the five parasite strains. Associations between antibody titre and the 
corresponding in vitro parasite growth inhibition levels were estimated with a 
four-parameter logistic fit. Differences were considered statistically significant at 
p < 0.05, or when the 95% CI of groups being compared did not overlap. 
One of the 6 rabbits in the first immunisation group (f3h) experienced 
pneumonia during the study and data from this rabbit was excluded from all 
analyses. Rabbits (n = 4) in one of the sequential groups (h3f, Table 1) were 
immunised in a different experiment. 
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RESULTS 
 
Specificity of antibodies elicited with mixed allele and sequential allele 
immunisation protocols 
Antibodies from rabbit sera drawn on day 70 from all five groups were titrated 
against PfAMA1 alleles from FVO, HB3 and 3D7 parasite strains, and the data is 
presented in Figure 1. There were no statistically significant differences for 
comparisons of the log-transformed antibody titres either for any single 
immunisation group against all three capture antigens, or for the different 
immunisation groups against the same capture antigen (P > 0.05, one-way 
ANOVA).  
 
 
Figure 1. Absolute levels of anti-AMA1 antibodies elicited with mixed allele and sequential 
allele protocols in rabbits. Rabbits in groups 1 – 3 were immunised with three PfAMA1 allelic 
antigens (from FVO, HB3 and 3D7 parasite strains) in three different sequences (refer to Table 
1). The fourth group of rabbits was immunised with a cocktail of the three PfAMA1 alleles, while 
the fifth group was immunised with a mixture of the three Diversity covering proteins (DiCo mix) 
at all immunisation time points. All vaccines were formulated with a modified Freund’s adjuvant 
containing a lipo-polysaccharide from blue-green algae as adjuvant.  Antibody titres of sera taken 
on day 70 were determined by a standardized ELISA with 3D7 (left panel), FVO (middle panel) 
and HB3 (right panel) AMA1-coated plates. Data is presented on a Log2 scale as dotplots with a 
boxplot superpose indicating the median, lower and upper quartiles per immunisation group. For 
each capture antigen, plotting symbols represent the antibody titre of individual rabbits within 
an immunisation group. 
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Pair-wise comparison of antibody titres for an immunisation group against any 
two capture antigens, or titres for any two groups against the same capture 
antigen also showed no significant differences (P > 0.05, Tukey HSD). 
Competition ELISA was performed to assess the relative proportions of cross-
reactive and strain-specific antibodies induced against the individual vaccine 
antigens and a fourth PfAMA1 allele (CAMP) that was not a component of any of 
the vaccines. The FVO, HB3 and 3D7 AMA1 allelic proteins were used as capture 
antigens and FVO, HB3, 3D7 and CAMP AMA1 as competitor antigens. Depletion 
(%) of antibodies with the different competitor antigens against each capture 
antigen is presented in Table 2. On each capture antigen, complete depletion of 
antibodies by the homologous competitor antigen was observed as expected. 
Heterologous antibody depletion was however dependent on the number of 
amino acid differences between the capture and competitor antigens (presented 
in Figure 2). For example, depletion was lowest for 3D7 AMA1 competitor 
antigen when FVO AMA1 was used as capture antigen, and lowest for CAMP 
AMA1 when HB3 AMA1 was used as capture antigen (Table 2). 
 
 
 
Figure 2. Protein sequence (aa 25 – 545) alignments for DiCo antigens and parasite AMA1 
alleles. The recombinant AMA1 allelic antigens for FVO, HB3, 3D7 and CAMP used in ELISA differ 
at 6 positions (5 for HB3 AMA1) from the respective parasite sequences presented here. These 
differences (N162Q, T288V, S373D, N422D, S423K, N499Q) were introduced in the recombinant 
antigens to prevent N-glycosylation of the Pichia pastoris-expressed antigens. 
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Table 2. Mean % antibody depletion from FVO, HB3 and 3D7 AMA1-coated   
    plates. 
 
Values reported as mean (95% CI) per immunisation group for the same competitor antigen on 
each coating antigen.  
 
 
Comparison of the three sequential immunisation groups (f3h, hf3 and h3f) 
showed that though there were small differences (based on overlaps in 95% CI, 
Table 2) in the extent of heterologous antibody depletion, no clear trends 
emerged with respect to the order of antigen administration and the capture 
antigen used in assays. The three sequential immunisation groups also showed 
detectable quantities of antibodies that were specific to each of the three vaccine 
PfAMA1 alleles in all polyclonal pools on day 70, despite the fact that each allelic 
antigen was administered at only one of the three time points.  
Coating 
antigen 
Competitor 
antigen  
Gp 1 (f3h)      
n=5 
Gp 2 (hf3)      
n=6 
Gp 3 (h3f)  
 n=4 
Gp 4 (NA 
mix) n=6 
Gp5 (DiCo 
mix)   n=6 
 
 
FVO  FVO 
98.5         
(97.3 – 99.7) 
95.9 
(95.1 – 96.8) 
98.2           
(96.3 – 100.1) 
96.8           
(95.4 – 98.2) 
97.6 
(96.4 – 98.7) 
 
 
AMA1 HB3 
93.2          
(88.1 – 98.3) 
90.4 
(87.0 – 93.8) 
93.2           
(86.0 – 100.4) 
90.6           
(87.4 – 93.9) 
91.3 
(89.7 – 92.9) 
 
 
 
3D7 
84.5         
(77.5 – 91.5) 
75.5 
(74.3 – 76.7) 
76.6           
(65.4 – 87.8) 
70.4           
(64.7 – 76.0) 
77.0 
(69.4 – 84.7) 
 
 
 
CAMP 
78.7         
(73.6 – 83.7) 
70.3 
(65.9 – 74.6) 
74.2           
(64.4 – 84.1) 
70.3           
(64.7 – 74.0) 
84.0 
(82.3 – 85.8) 
       
HB3  FVO 
87.5         
(79.0 – 96.0) 
86.0 
(81.2 – 90.9) 
91.4           
(89.3 – 93.6) 
86.6           
(83.3 – 89.9) 
84.1 
(80.6 – 87.5) 
 
 
AMA1 HB3 
96.1          
(93.6 – 98.5) 
97.5 
(95.4 – 99.6) 
98.2           
(98.1 – 98.4) 
96.7           
(95.0 – 98.4) 
95.6 
(93.7 – 97.4) 
 
 
 
3D7 
86.7         
(82.3 – 91.0) 
84.3 
(75.9 – 92.8) 
77.9           
(70.5 – 85.4) 
73.7           
(66.7 – 80.6) 
74.7 
(70.5 – 78.9) 
 
 
 
CAMP 
76.8          
(73.4 – 80.1) 
68.5 
(62.7 – 74.3) 
74.4           
(70.2 – 78.6) 
66.8            
(60.2 – 73.3) 
81.2 
(78.2 – 84.2) 
       
3D7  FVO 
83.0         
(75.3 – 90.8) 
91.8 
(86.7 – 97.0) 
91.3           
(84.8 – 97.9) 
73.2           
(66.1 – 80.3) 
86.9 
(84.4 – 89.4) 
 
 
AMA1 HB3 
89.3          
(85.2 – 93.4) 
95.9 
(92.7 – 99.1) 
94.1           
(89.2 – 99.0) 
83.6           
(76.1 – 91.1) 
88.7 
(86.2 – 91.2) 
 
 
 
3D7 
100.2         
(96.8 – 103.7) 
98.2 
(95.9 – 100.2) 
96.8           
(94.6 – 99.0) 
95.8           
(94.3 – 97.4) 
97.1 
(95.2 – 99.0) 
 
 
 
CAMP 
79.5         
(71.6 – 87.5) 
82.0 
(77.0 – 87.1) 
85.7           
(77.0 – 94.5) 
71.0           
(66.5 – 75.5) 
89.2 
(86.0 – 92.4) 
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Comparisons across all groups showed that antibody depletion by heterologous 
competitor antigens was generally lowest in the NA mix immunisation group 
compared to the three sequential immunisation groups (f3h, hf3 and h3f, 
Table2). The observed differences were however not always statistically 
significant since 95% CI sometimes overlapped. Antibody depletion by CAMP 
AMA1, an allele that was not in any of the vaccine formulations, was greatest for 
antibodies from the DiCo mix vaccine group compared to the other four groups 
in all assays (Table 2). CAMP AMA1 depletion of anti-DiCo mix antibodies was 
statistically significantly higher than that of anti-NA mix antibodies irrespective 
of the capture antigen, while differences between anti-DiCo mix antibodies and 
the sequential immunisation groups were not always statistically significant 
(Table 2).  
 
 
Functional capacity of antibodies elicited with mixed allele and sequential 
allele immunisation protocols 
Protein G-purified antibodies from day 70 bleeds were used for in vitro growth 
inhibition assays. Antibodies from the three sequential immunisation groups 
(f3h, hf3 and h3f) at 6 mg/ml showed similar mean levels of inhibition of two of 
the three parasites expressing the vaccine alleles (FCR3, p = 0.60; HB3, p = 0.28; 
one-way ANOVA) irrespective of the order of antigen administration (Figure 3). 
Mean inhibition levels against the NF54 strain were however higher for 
antibodies from the f3h group compared to those from the h3f group (p = 0.02, 
Tukey HSD). Pair-wise comparisons of mean growth inhibition levels in any 
sequential immunisation group with that of the NA mix group against any of the 
parasites showed no significant differences (p > 0.05, Tukey HSD) despite the 
weak trend of high antibody depletions from the sequential immunisation 
groups in competition assays (Table 2). Thus it did not matter whether the 
vaccine was administered as a mixture or in sequence the functional outcome in 
vitro was the same.  
Antibodies from the sequential (f3h, hf3 and h3f) and NA mix immunisation 
groups generally showed a reduction in the extent of in vitro inhibition of 
“heterologous” parasite strains (CAMP, 7G8) compared to that of “homologous” 
strains (NF54, FCR3, HB3). Mean inhibition with antibodies from both the f3h 
(Gp 1) and NA mix (Gp 4) immunisations at 6 mg/ml were all higher against 
“homologous” strains (NF54, HB3, FCR3) compared to those against the CAMP 
and 7G8 strains (p < 0.0001, one-way ANOVA). Mean inhibition of antibodies 
from the hf3 group (Gp 2) were however only higher against HB3 strains when 
compared pair-wise with the “heterologous" strains (p = 0.006 for 7G8 and p = 
0.005 for CAMP parasites, Tukey HSD). Antibodies from the h3f group (Gp 3) also 
showed higher mean inhibition against HB3 in comparison with the CAMP strain 
(p = 0.024, Tukey HSD). In contrast, antibodies from the DiCo mix group (Gp 5) 
 
Mixed versus sequential allele immunisation 
 
87 
 
 
Figure 3. Growth inhibition of P. falciparum parasites by antibodies elicited with mixed 
and sequential allele protocols. Protein G-purified antibodies from all immunisation groups 
were tested on each of five culture-adapted strains (7G8, CAMP, FCR3, HB3 and NF54) of P. 
falciparum. Plots represent the mean % inhibition ± SEM for all antibody samples within an 
immunisation group. The filled triangle (▲) plot symbols represent data for group 1 (f3h, n = 5), 
open triangles (△) represent group 2 (hf3, n = 6), open diamonds (◇) represent group 3 (h3f, n = 
4), filled diamonds (◆) represent group 4 (NA mix, n = 6) and filled squares (■) represent group 
5 (DiCo mix, n = 6.  
 
showed a generally consistent level of inhibition of all five parasite strains 
(Figure 3). Mean growth inhibitions ranged from 47.2% against the CAMP strain 
to 66.9% against the HB3 strain at 6 mg/ml total IgG, and these were not 
statistically significantly different (p = 0.55, one-way ANOVA).  
The data generally suggests that effectiveness of the antibody response was 
dependent on the test parasite strain (“homologous” vs. “heterologous”), and the 
absolute levels of elicited antibodies. Higher antibody titres are expected to give 
greater in vitro parasite growth inhibition levels since antibody titres against 
specific alleles correlate well with the level of in vitro inhibition of parasites 
expressing those alleles (Figure 4).  
 
 
DISCUSSION  
An effective malaria vaccine is expected to confer similar or better immunity to 
malaria-susceptible individuals compared to that of adults who are resident in 
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endemic areas, but over a shorter period of time. In semi-immune adults, this 
level of anti-disease immunity is acquired after repeated infection with diverse 
parasite strains [2,3]. Antibodies are key components of anti-disease immunity 
[26,27], and the cross-strain fraction of anti-malarial antibodies may be 
important effectors against parasite strains that express diverse polymorphic 
antigens [7,14,28]. The main objectives of this study were to compare sequential 
and mixed PfAMA1 immunisation protocols for the proportions of functional 
cross-strain antibodies they induce in rabbits, and to further demonstrate the 
specificity broadening effects of such vaccination strategies. 
Statistically similar levels of antibodies were induced with all vaccine 
formulations, irrespective of the order of antigen administration (Figure 1). This 
suggests that the order of antigen exposure may not influence the levels of 
elicited antibodies. For sequential immunisation groups, this shows that  
 
 
Figure 4. ELISA antibody titre correlates with in vitro parasite growth inhibition. 
Association of antibody levels with in vitro antibody functionality is shown for parasite strains 
FCR3 (FVO), HB3 and NF54 (3D7). In vitro inhibition of any parasite strain at 6 mg/ml of purified 
antibody has been plotted against antibody titres measured with the corresponding AMA1 allele. 
Plots are based on a four-parameter logistic function. Filled circles (●) represent animals in 
group 1 (f3h, n = 5), filled triangles (▲) represent group 2 (hf3, n = 6), filled squares (■) 
represent group 3 (h3f, n = 4), open circles (○) represent group 4 (Na mix, n = 6) and open 
triangles (△) represent group 5 (DiCo mix, n = 6).  
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“booster” responses were associative recall responses of previous allele 
vaccinations, and antibodies were mostly to epitopes that are shared by vaccine 
alleles. This is consistent with published data on both cellular and humoral 
immune responses to other polymorphic malaria antigens [7,29-31], and is a 
well-established phenomenon in immune responses to other parasitic and viral 
infections [21,22,32-34].  
Antibody depletion data from competition assays showed marginally higher 
proportions of cross-strain antibodies in some sequential immunisation groups 
compared to the NA mix group (Table 2). Since significance was achieved only in 
some instances and there were no observable trends with respect to capture and 
competitor antigens, the order of antigen administration may only marginally 
influence the ultimate specificity of antibodies on day 70. The three-antigen DiCo 
mix vaccine generally yielded higher proportions of cross-strain antibodies 
compared to the three-antigen NA mix vaccine, especially against the out-group 
competitor antigen CAMP (Table 2). This suggests that the three DiCo antigens 
together present a greater proportion of epitopes that induce broad-reacting 
antibodies, and affirms the specificity broadening properties of the DiCo vaccine 
approach [9,35]. 
The determination of strain-specific antibodies against vaccine alleles in 
sequential immunisation groups on day 70 (Table 2) suggests that immunisation 
with a single allele does induce long-lived responses. This may reflect the 
persistence of strain-specific antibodies that were induced after antigen 
administration on day 0 (first antigen), 28 (second antigen) or 56 (third antigen). 
Alternatively, memory B cells to these specific antibody epitopes in previous 
vaccine alleles could be activated by the altered, corresponding low affinity 
epitopes on subsequently administered PfAMA1 alleles, leading to high affinity 
secondary responses against the cognate epitopes. The latter phenomenon is in 
agreement with the mechanism underlying original antigenic sin, and supports 
the existence of a continuum of antibody specificities [7]. It must be noted that 
the specificity of an antibody for an antigen is directly related to the affinity of 
the antigen-antibody interaction hence an antibody that is “specific” to one 
PfAMA1 allele may indeed have very low affinity for other alleles. 
Data from in vitro growth inhibition assays was consistent with the observations 
in ELISA. The similar inhibition of FCR3, HB3 and NF54 parasite strains by 
purified antibodies from sequential immunisation (f3h, hf3 and h3f) and NA mix 
groups suggests that comparable levels of functional antibodies against all three 
parasite strains were present on day 70, irrespective of the order of antigen 
administration (Figure 3). This confirms the induction of antibodies mostly to 
shared epitopes based on the original antigenic sin phenomenon [7,22].  
The observed higher inhibition of parasite strains expressing the vaccine alleles 
compared to the out-group strains (CAMP, 7G8) may be attributed to the 
generally low levels of antibodies induced in all immunisation groups. A similar 
observation was made in an earlier study where low titres of antibodies elicited 
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against DiCo mix in Montanide IMS resulted in lower in vitro parasite inhibition 
levels compared with the higher antibody levels against DiCo mix in two other 
adjuvants [35]. ELISA antibody titres and parasite inhibition levels in the present 
study are intermediate between those of anti-DiCo mix antibodies elicited in the 
previous study with Montanide IMS on the one hand and CoVaccine 
HT™/Montanide ISA 51 on the other hand. Similar proportions of cross-strain 
antibodies were measured in both studies despite the different absolute 
antibody titres. At such low antibody titres, high avidity strain-specific 
antibodies, which form a small proportion of elicited antibodies, most likely 
augment the functional effects of cross-strain antibodies against the respective 
homologous parasite strains. This fraction of strain-specific antibodies would 
however have very low avidities for AMA1 of the CAMP and 7G8 strains, 
resulting in lower levels of inhibition of these strains (Figure 3). Thus high titres 
of functional cross-strain antibodies are required to optimally inhibit 
“heterologous” strains. At high antibody titres, the additional inhibitory activity 
of any strain-specific antibodies against “homologous” parasites would put the 
overall inhibitory effect in the upper plateau region of the antibody binding-
function curve (Figure 4). A possible limitation here however, is that some 
parasites, here the HB3 strain, may be inherently easier to inhibit than others, 
and this could mask the effect of vaccine responses described. Similar effect has 
been described for D10 parasites, which can be inhibited better with anti-3D7 
AMA1 antibodies compared to inhibition of the homologous 3D7 strain [36,37]. 
Although anti-DiCo mix antibodies least inhibited the three “homologous” 
strains, these antibodies performed as well against the two out-group parasite 
strains as antibodies from all other vaccine formulations. Additionally, unlike the 
other vaccine formulations, anti-DiCo mix antibodies showed consistent 
inhibition of all parasite strains. This consistency, coupled with the significantly 
higher depletion of anti-DiCo antibodies by the out-group CAMP AMA1 
competitor antigen when compared to anti-NA mix antibodies, suggests that 
DiCo mix may have a slight advantage as a vaccine candidate, since AMA1 from 
culture-adapted strains may not necessarily be encountered in the field. 
The current in vitro growth inhibition data may seem inconsistent with our 
earlier published data [20], where rabbit antibodies elicited with a three-antigen 
(FVO, HB3, 3D7 AMA1) vaccine in Montanide ISA720 inhibited a heterologous 
parasite strain (CAMP) to a similar extent as the three “homologous” strains. This 
can however be explained by the fact that data from the earlier study was based 
on a single sample per immunisation group, with antibody titres that were 2-4 
times higher than the average antibody titres in the study under discussion. The 
greater potency of the adjuvant used in the earlier study may partially account 
for the higher titres. Additionally, the earlier study used an immunisation 
protocol (4 vaccine doses on days 0, 28, 56 and 82, exsanguination on day 95) 
that is different from the one used in the current study (3 doses on days 0, 28 
and 56, exsanguination on day 70). The extra booster dose, as well as the longer 
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study period, could account partially for the higher functional antibody titres, 
which were most likely at saturation levels. It must be noted that single allele 
immunisations with FVO, HB3 and 3D7 AMA1 alleles in the previous study also 
resulted in similar antibody titres to that of the three-antigen mixed allele 
vaccine but failed to achieve the same level of in vitro inhibition of heterologous 
parasites as the mixed allele vaccine [20]. Moreover, mixed allele vaccine 
antibodies from both studies showed similar binding specificities for the 
component antigens. Thus high titres of cross-strain antibodies are necessary for 
significant inhibition of variant parasites, and this is consistent with earlier 
published literature in both in vitro and in vivo settings [28,35].  
This data may aid current understanding of the acquisition of clinical immunity 
to malaria in endemic areas. Induction of antibodies to polymorphic antigens in 
the field upon infection with different parasite strains may be through an 
original antigenic sin mechanism, and individuals will most likely accumulate a 
strain-transcending repertoire of antibodies over time. This will also explain why 
clinical testing of a mono-allelic vaccine based on a polymorphic antigen in an 
unexposed population yields antibodies that react better with homologous than 
heterologous antigenic alleles [13] while antibodies taken after a similar trial in a 
malaria-endemic population react equally well with both homologous and 
heterologous vaccine alleles [38]. A mixture of strain-specific and cross-strain 
antibodies are most likely induced in naïve individuals in the former instance 
while previous exposure in the latter results in a boost of responses to epitopes 
that are common to the vaccine and previously encountered alleles.  
In summary, a mixed antigen immunisation protocol is expected to elicit humoral 
responses similar to those elicited by a sequential immunisation protocol, and by 
extension the response induced naturally in individuals in malaria-endemic 
populations. Thus the anti-AMA1 component of a natural immune response can 
be effectively mimicked by immunisation with a cocktail of AMA1 alleles. This 
finding may also apply to the many other polymorphic parasite antigens that are 
currently undergoing clinical evaluation. Additionally, sequential exposure to 
different AMA1 alleles induces immunological recall of responses to previous 
alleles and yields functional cross-strain antibodies that are capable of optimal 
parasite growth inhibitions at high enough concentrations. These findings may 
aid current understanding of the natural acquisition of clinical immunity to 
malaria as well as provide fresh insight into rational vaccine design. 
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ABSTRACT 
 
Background 
Increasing the breadth of the functional antibody response through 
immunisation with Plasmodium falciparum apical membrane antigen 1 (PfAMA1) 
multi-allele vaccine formulations has been demonstrated in several rodent and 
rabbit studies. This study assesses the safety and immunogenicity of three 
PfAMA1 Diversity-Covering (DiCo) vaccine candidates formulated as an 
equimolar mixture (DiCo mix) in CoVaccine HT™ or Montanide ISA 51, as well as 
that of a PfAMA1-MSP119 fusion protein formulated in Montanide ISA 51.  
 
Methods 
Vaccine safety in rhesus macaques was monitored by animal behaviour 
observation and assessment of organ and systemic functions through clinical 
chemistry and haematology measurements. The immunogenicity of vaccine 
formulations was assessed by enzyme-linked immunosorbent assays and in vitro 
parasite growth inhibition assays with three culture-adapted P. falciparum 
strains. 
 
Results  
These data show that both adjuvants were well tolerated with only transient 
changes in a few of the chemical and haematological parameters measured. DiCo 
mix formulated in CoVaccine HT™ proved immunologically and functionally 
superior to the same candidate formulated in Montanide ISA 51. Immunological 
data from the fusion protein candidate was however difficult to interpret as four 
out of six immunised animals were non-responsive for unknown reasons.  
 
Conclusions 
The study highlights the safety and immunological benefits of DiCo mix as a 
potential human vaccine against blood stage malaria, especially when formulated 
in CoVaccine HT™, and adds to the accumulating data on the specificity 
broadening effects of DiCo mix. 
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INTRODUCTION 
The development of an effective malaria vaccine remains an important public 
health objective for disease control in endemic areas. Vaccine strategies that 
control or prevent blood stage infection may be most desirable since blood stage 
parasites are responsible for clinical symptoms of the disease. Current 
knowledge of Plasmodium falciparum, the parasite responsible for the most 
severe form of disease suggests that a potentially effective vaccine would likely 
include multiple antigens, preferably expressed in different stages of the 
parasite’s life cycle. Essential P. falciparum antigens that are currently being 
considered as subunit vaccine candidates include apical membrane antigen 1 
(AMA1) and merozoite surface protein 1 (MSP1). AMA1 is highly polymorphic 
and is found in both merozoite and sporozoite stages of the parasite [1-4] . It is 
initially expressed as an 83 kDa precursor protein in the micronemes and 
undergoes an N-terminal prosequence cleavage to form the 66 kDa antigen at the 
same site [5]. AMA1 translocates to the parasite membrane surface at the time of 
red cell invasion, and plays a key role in the invasion process [5-9]. The AMA1 
ectodomain, which is the vaccine target, is shed as 44 and 48 kDa alternate 
antigens before the parasite enters the red cell [5,10]. The ectodomain has 16 
cysteine residues that form disulphide bonds to divide the antigen’s tertiary 
structure into three different but interactive domains [11].  
MSP1, another important vaccine candidate, is the parasite major surface antigen 
that also plays a role in the red cell invasion process and is dimorphic [12-15]. 
MSP1 is expressed as a precursor protein of approximately 200 kDa on the 
surface of developing merozoites [16]. It is proteolytically processed into several 
fragments at the time of schizont rupture and red cell invasion. The 42 kDa 
fragment, which is a vaccine candidate, is subsequently processed into 33 kDa 
and 19 kDa fragments [17,18]. The 19 kDa fragment (MSP119), which is a major 
vaccine target, remains anchored to the merozoite surface and can be detected in 
early red cell stages of the parasite [19,20]. All other MSP1 fragments are shed as 
a peptide complex prior to red cell invasion.  
These antigens have demonstrable vaccine properties in rodent and non-human 
primate models as well as in in vitro systems [21-27]. Their vaccine potential, 
which is exhibited mainly through antibody-mediated mechanisms [28,29], is 
however limited by allelic polymorphism [24,26,30-32]. Multi-allele vaccination 
studies, mostly in rabbits and rodents, have however shown promise in 
overcoming the strain-specific effects of polymorphism on immune responses to 
these antigens. This strategy informed the design, expression and purification of 
three Diversity-Covering (DiCo) P. falciparum AMA1 (PfAMA1) antigens based on 
the sequences of 355 naturally occurring PfAMA1 alleles [33]. The DiCo vaccine 
candidate is an equimolar mixture (DiCo mix) of the three DiCo antigens, hence 
apart from the design strategy which is to cover polymorphism, mixing of the 
three DiCo antigens cover polymorphism on a second level. DiCo mix formulated 
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with either Montanide ISA 51 or CoVaccine HT™ as adjuvant has been shown to 
induce rabbit humoral responses with similar high inhibitory capacities against 
multiple parasite strains in vitro [33,34]. Another strategy for dampening the 
effects of polymorphism on PfAMA1 responses is to combine PfAMA1 candidates 
with other highly immunogenic candidates that show limited polymorphism. 
This second strategy may involve mixing of the separately expressed and 
purified vaccine component antigens, or the expression and purification of 
component antigens as a single chimeric protein. In one such study, rabbits were 
immunised with PfMSP119 (Welcome strain) and PfAMA1 (domains I and II of the 
FVO strain) proteins formulated as a mixture or the expressed chimeric proteins 
in Montanide ISA720 and functionality of induced IgGs was tested against three 
parasite strains (FCR3, HB3, 3D7). IgG responses to PfAMA1 alone or the 
PfAMA1/PfMSP119 vaccine products showed signs of strain specificity in 
functional assays, while responses to products containing PfMSP119 alone 
showed limited strain-specificity [35]. Challenge studies in rodents immunised 
with a cocktail of Plasmodium chabaudi AMA1 and MSP142 antigens also showed 
a greater reduction in peak parasitaemia compared to separate immunisations 
with the single antigens [36]. Another study involving a combination vaccine that 
consists of PfAMA1 and PfMSP142 yielded responses that were directed against 
both antigens, though protection induced by the combination vaccine was not 
superior to that induced by the PfAMA1 vaccine alone [27]. 
Most pre-clinical evaluations of these immunisation strategies are done in 
rodents and rabbits. Vaccine evaluation in a monkey model, though not legally 
mandatory, may be an important step as it could yield additional data on vaccine 
safety and immunogenicity ([37]). The in vitro parasite growth inhibition assay 
may have some limitations when used for assessment and down-selection of 
potentially important candidates, whose vaccine effects might be mediated by 
any of a number of different mechanisms. It nevertheless gives some idea of in 
vivo functionality, especially for antibody responses that are known to have a 
direct blocking effect on antigen processing and/or host cell invasion. In the 
current study the capacity of the DiCo mix and PfAMA1-MSP119 candidates, 
formulated in either Montanide ISA 51 or CoVaccine HT™ as adjuvants, to induce 
functional broad-strain antibody responses in non-human primates was 
examined. The safety and tolerability of these adjuvant formulations were also 
assessed as a proxy to effects that are likely to be observed in clinical testing of 
these candidates.  
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METHODS 
 
Antigens 
All antigens were expressed as recombinant proteins in Pichia pastoris systems 
and details of gene expression and protein production have already been 
described elsewhere [33,35,38]. Natural PfAMA1 alleles comprise the full length 
ectodomain (25-545) of the CAMP [GenBank:M58545], 3D7 [GenBank:U65407), 
HB3 [GenBank:U33277] and FVO (GenBank:AJ277646] strains of P. falciparum. 
DiCo proteins consist of amino acids 97 - 545 of the AMA1 ectodomain (domains 
I, II and III, without the signal sequence). The PfAMA1-MSP119 fusion protein 
(designated AM) consists of amino acids 106 - 442 (domains I and II) of the FVO 
AMA1 ectodomain fused with a mutant form of PfMSP119 (amino acids 1526 – 
1621) of the Wellcome strain of P. falciparum [35]. All antigens were recognized 
by the reduction-sensitive rat monoclonal 4G2 antibody suggesting a correct 
folding of proteins. All antigens were devoid of N-glycosylation sites and the 
molecular size of the fusion protein product is comparable to that of any of the 
AMA1 proteins. 
 
Animal welfare and ethical clearance 
Animals used in this study were captive-bred for research purposes. 
Experimentation and housing were at the Biomedical Primate Research Centre 
(BPRC) animal facility in Rijswijk, the Netherlands, in accordance with Dutch 
laws and European Acts (directive 86/609/EEC) on animal experimentation. The 
BPRC is compliant with recommendations of the Weatherall report on the use of 
non-human primates in research [39]. The study was approved by an 
independent ethics committee at BPRC, constituted in accordance with Dutch 
law on animal experimentation. To minimize discomfort to animals, 
immunisation and blood sampling were all done under ketamine sedation. The 
study involved three experimental groups, each with six rhesus monkeys. 
Animals were assigned in a manner that ensured that age, weight and sex were 
similar amongst groups, and treatments were randomly assigned to groups. 
 
Vaccine formulation, immunisation and bleeding 
Two of the three groups of rhesus macaques were immunised with DiCo mix in 
either Montanide ISA 51 (Seppic, Paris, France) or CoVaccine HT™ (Protherics 
Medicines Development Limited, A BTG International Group Company, London, 
UK) as adjuvant, and the third group was immunised with the AM fusion protein 
formulated in Montanide ISA 51. Formulations were made under sterile 
conditions according to the respective adjuvant manufacturers’ protocols. For 
Montanide ISA 51 formulations, 276 µl of antigen solution (130 µg/ml of DiCo 
mix or 217 µg/ml of AM) was added to 324 µl of adjuvant and the mixture 
emulsified by 20 passages through a Teflon-coated 22 gauge syringe-coupling 
piece. Five hundred microlitres (500 µl) of this formulation was administered 
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per animal. For CoVaccine HT™ formulation, 300 µl of DiCo mix (120 µg/ml in 
saline) was mixed with an equal volume of adjuvant to a sucrose fatty acid 
sulphate esters (SFASEs) concentration of 20 mg/ml. Five hundred microlitres 
(500 µl) of the resulting mixture with 10 mg SFASEs was administered after 
gentle mixing. Animals were immunised intramuscularly in alternating legs on 
days 0 (left), 28 (right) and 56 (left) with either 30 µg of DiCo mix (two groups, 
designated DiCo/ISA and DiCo/HT) or 50 µg AM fusion protein (1 group, 
designated AM/ISA). Small aliquots of blood (between 2 ml and 7 ml) were taken 
on days 0, 1, 7, 14, 28, 29, 35, 42, 56, 57, 63 and 70 for clinical chemistry, 
serology and haematology, and larger volumes (up to 27 ml) were taken on Day 
70 for serology, IgG isolation and subsequent in vitro testing.  
 
Safety monitoring 
All treatment groups were monitored for safety by the assessment of local 
reactions (Draize scores), behaviour, appetite, stool and bodyweight as well as 
by clinical chemistry and haematology. Injection sites were inspected for local 
reactions on days 0, 1, 7 and 14 after each vaccination. Animals were also 
monitored on a daily basis by the caretakers and injection sites were frequently 
inspected. Clinical chemistry to assess organ and systemic functions was 
performed with a Cobas Integra 400 analyzer (Roche Diagnostics, Basel, 
Switzerland) according to standard methods and compared with normal values 
based on cumulative data from healthy animals within the same animal facility. 
Parameters measured include alkaline phosphatase, alanine transaminase, 
aspartate transaminase, bilirubin, lactate dehydrogenase, gamma glutamyl 
transpeptidase, cholesterol, glucose, iron, potassium, sodium, calcium, 
phosphate, chloride, bicarbonate, albumin, creatinine, total protein and urea. 
Haematology was performed with an automated analyser (Sysmex XT 2000iV 
platform; Goffin Meyvis, Etten-Leur, the Netherlands) and measurements were 
made for the red blood cell fraction (haemoglobin levels, erythrocyte count, 
haematocrit, mean corpuscular volume, mean corpuscular haemoglobin) and for 
the white blood cell fraction (white blood cell, lymphocyte, neutrophil, monocyte, 
eosinophil and basophil counts) as well as for platelets and mean platelet 
volume. 
Safety assessments were made before immunisation and one day, one week and 
two weeks following each immunisation. Since all parameters had returned to 
normal values by day 70, body weight was the only parameter monitored on 
days 99 and 126. 
 
Immunological assessment of vaccine responses 
Anti-AMA1 IgG levels in serum samples from blood drawn before immunisation 
on days 0, 28 and 56, as well as samples taken on days 14, 42, 70, 99 and 126 
were determined using an indirect ELISA. IgGs were measured against seven 
different PfAMA1 alleles (the three DiCo antigens and recombinant PfAMA1 
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alleles from the FVO, HB3, 3D7 and CAMP parasite strains). Anti-MSP119 IgG 
levels in the AM vaccine group were measured with MSP119 as capture antigen. 
Briefly, plates were coated with 0.5 µg/ml of the relevant antigen in PBS and 
subsequently blocked with 3% BSA in PBS with 0.05% Tween 20. Serum samples 
were diluted in PBS containing 0.1% BSA and 0.05% Tween-20. A pool of 
hyperimmune sera with high AMA1 and MSP119-specific antibody titres was 
included on each plate as a standard calibrator. Antibodies were detected with 
an affinity-purified anti-human IgG coupled to alkaline phosphatase. Plates were 
developed with 1 mg/ml para-nitrophenyl phosphate, and the absorbance at 405 
nm was measured. Antibody titres were subsequently expressed in arbitrary 
units (AU), with 1AU being equivalent to the reciprocal dilution at which an 
absorbance of 1 over background is achieved. 
Antibody functionality was assessed by in vitro growth inhibition assays using 
the FCR3 (with one prodomain amino acid difference from AMA1 of the FVO 
strain [GenBank:M34553]), NF54 (parent clone of the 3D7 clone, 
[GenBank:U65407]) and HB3 [GenBank:U33277] culture-adapted parasite 
strains as has been previously described [33,38].  Antibodies were purified from 
day 70 sera using Protein A Sepharose (GE Healthcare, Etten-Leur, The 
Netherlands) columns and used at a final concentration of 10 mg/ml. Parasite 
strains were verified by restriction fragment length analysis and cultures were 
shown to be negative for mycoplasma.  
 
Data analyses 
Clinical chemistry and haematological data assessment was based on normal 
reference values calculated from cumulative data of similar measurements in 
healthy animals within the same facility. IgG titres determined by ELISA for the 
different immunisation groups were log-transformed to achieve normality and 
compared by one-way analysis of variance (ANOVA). Tukey HSD post hoc test 
with correction for multiple comparisons was used for pair-wise comparison of 
IgG titres in the same immunisation groups against different capture antigens. 
Student t tests were used for the pair-wise comparison of GIA data between 
immunisation groups against the same parasite strain, while the Tukey HSD post 
hoc test was used to compare data for the same immunisation group against 
different strains. ELISA antibody titres and GIA data from day 70 sera (or 
purified IgG) are also presented as dotplots superimposed with boxplots 
showing the median inhibition as well as the first and third quartiles per 
treatment group. Plot symbols represent individual animals within the same 
treatment group. All graphics and analyses were performed using the R 
statistical package (R Development Core Team, 2010, version 2.12.1). 
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RESULTS 
 
Safety monitoring 
Vaccine formulations with both adjuvants were generally well tolerated. All 
animals maintained body weights within reference ranges of normal values for 
the entire duration of the study. There were also no major changes in behaviour, 
appetite or stool over the period of observation. Apart from palpable inguinal 
lymph nodes there were no notable local reactions (oedema, erythema, 
indurations) in all 18 study animals. Levels of aspartate transaminase in the 
DiCo/ISA immunisation group as well as alanine transaminase and bilirubin in 
the AM/ISA group showed slight increases on the days following immunisation 
but returned to normal levels within a week. There was an increase in creatinine 
levels a day after immunisation in the DiCo/HT group but these also returned to 
normal levels within a week. Creatinine levels in the DiCo/ISA group were 
however above normal values at the start of the study and remained at similar 
high levels throughout the observation period. Levels of blood iron decreased on 
the days following immunisation in the DiCo/HT group but also returned to 
normal levels within a week. All other measured clinical chemistry parameters 
were within normal reference ranges throughout the 70-day observation period.  
Of the parameters measured for haematology, increases in neutrophil count (and 
hence white blood cell count) were observed a day after each immunisation, but 
these again returned to normal values within a week. All other measured 
parameters were between normal ranges throughout the study. 
Generally, local reactions were limited to mild reddening of the injection site 
area, and these resolved within a few days. One animal in the AM/ISA group 
however developed stiffness in the upper leg muscle to a degree that limited 
movement of the left leg. This adverse event was first observed 14 days after the 
last immunisation (day 70) and had not resolved on day 126. Given this 
observation, which lasted for more than 56 days, the amount of discomfort to 
this animal was rated moderate to serious.  
 
ELISA antibody responses 
IgG levels against seven AMA1 alleles and MSP119 at all sampling time points 
were determined using a harmonized ELISA. The three vaccine formulations 
induced appreciable levels of antibodies against the tested antigens and titres 
against all antigens increased in a similar manner and generally peaked on day 
70, two weeks after the final vaccine injections were given. IgG titres against the 
FVO AMA1 allele at all time-points are presented in Figure 1 and day 70 titres 
against all antigens are presented in Figure 2. Beyond day 70, IgG titres in the 
two DiCo mix immunisation groups showed a decline that was statistically 
significantly lower on day 126 compared to day 70 levels (p < 0.05 for all AMA1 
antigens, Student t test). Both the anti-AMA1 and anti-MSP119 levels for the 
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AM/ISA group were however not significantly different on days 70 and 126 (p > 
0.05, Student t test). 
Vaccine-induced IgG titres against all seven AMA1 capture antigens were 
generally highest in the DiCo/HT group by day 70. A comparison of the 
geometric mean titres, either for the same immunisation group against all AMA1 
antigens, or for all groups against the same capture antigen, showed that there 
were no statistically significant differences (P > 0.05, one-way ANOVA). Anti-
AMA1 IgG titres varied most amongst animals in the AM group, with four of the 
six animals having very low IgG titres against all antigens and the other two 
having exceptionally high titres (Figure 2). 
 
 
Figure 1. Anti-FVO AMA1 IgG titres in sera of animals immunised with AMA1-based 
vaccines. Three groups of six rhesus monkeys each were immunised with PfAMA1-based 
formulations on days 0, 28 and 56. One group was immunised with DiCo mix formulated in 
CoVaccine HT™ (DiCo/HT), the second group with DiCo mix in Montanide ISA 51 (DiCo/ISA), and 
the third group with an AMA1-MSP119 fusion protein in Montanide ISA 51 (AM/ISA). IgG titres in 
samples taken prior to each immunisation, as well as in samples drawn on days 14, 42, 70, 99 and 
126, were measured by an indirect ELISA. Similar patterns were observed for IgG measurements 
against six other PfAMA1 alleles (vaccine antigens DiCo 1, DiCo 2 and DiCo 3 as well as PfAMA1 
from the HB3, 3D7 and CAMP parasite strains). For each panel, the different symbols represent 
individual animals. 
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Anti-MSP119 IgG titres were determined only for the AM group (Figure 2), and 
these were statistically comparable to anti-AMA1 IgG titres against all seven 
AMA1 capture antigens for the same group (p = 0.99, one-way ANOVA). The four 
animals with low anti-AMA1 IgG levels in this group also had the lowest anti-
MSP119 IgG levels.  
 
 
Figure 2. IgG titres in day 70 sera from all three immunisation groups. Anti-PfAMA1 titres in 
all immunisation groups were measured against seven allelic vaccine antigens (DiCo 1, DiCo 2 
and DiCo 3 as well as PfAMA1 from the FVO, HB3, 3D7 and CAMP parasite strains) while anti- 
MSP119 IgG levels in the AM/ISA group were measured against PfMSP119. For each immunisation 
group, plot symbols represent data from individual animals in all panels. Plot symbols are also 
the same as those used for the same animals in Figure 1. 
 
 
In vitro growth inhibition data  
In vitro growth inhibition assays were performed on the FCR3, HB3 and NF54 
culture-adapted strains of P. falciparum using protein G-purified IgGs from day 
70 sera. Purified IgGs were tested against each parasite strain at a final 
concentration of 10 mg/ml, and the data, presented in Figure 3, is the average of 
two independent assays per parasite strain. The amino acid sequence differences 
between the three DiCo antigens and the AMA1 alleles expressed by the P. 
falciparum strains used in assays is presented in Figure 4. All animals in the 
DiCo/HT group responded well to the vaccine by eliciting levels of IgG that 
substantially inhibited parasites, while IgGs elicited by one animal in the 
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DiCo/ISA group and four animals in the AM/ISA group had growth inhibition 
levels lower than 20% against all three strains. Growth inhibition levels for the 
AM/ISA group therefore had a very wide range. 
At 10 mg/ml, IgGs from the DiCo/HT group had mean growth inhibition (56.3%, 
57.8% and 83.7% for FVO, HB3 and NF54 strains, respectively) that was 
significantly higher than that of IgGs from the DiCo/ISA group (31.0%, 33.2% 
and 56.8% for FVO, HB3 and NF54 strains, respectively) against all three 
parasite strains (p = 0.002 for FCR3 strain, p = 0. 033 for HB3 and p = 0.006 for 
NF54, student t test). Mean growth inhibition was significantly higher for the 
DiCo/HT group compared to the AM/ISA group (32.5%) against the NF54 strain 
alone (p = 0.026), while differences between the DiCo/ISA and AM/ISA groups 
against all three strains were not statistically significant (p > 0.05 in all cases). It 
must be noted that IgGs from one animal in the DiCo/HT group completely 
inhibited the NF54 strain, with the average of the two measurements being 
above 100%, an obvious artefact. 
 
 
Figure 3. In vitro parasite growth inhibition levels of protein A-purified IgGs from day 70 
samples. IgGs were tested in triplicate at a final concentration of 10 mg/ml against the FCR3, 
HB3 and NF54 culture-adapted strains of P. falciparum. The data presented is the average of two 
independent assays, and plot symbols represent data from individual animals within the same 
immunisation group in all panels. Plot symbols are also the same as that used for the same 
animals in other figures. 
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Figure 4. Protein sequence (aa 25 – 545) alignments for DiCo antigens and parasite AMA1 
alleles. AMA1 protein sequences of malaria parasites used for in vitro growth inhibition assays 
were accessed from the GenBank database. The DiCo sequences contain point mutations at the 
cleavage (K376R) and potential N-glycosylation (N162Q, T288V, S373D, N422D, S423K, N499Q) 
sites and differ from parasite AMA1 sequences at these sites. Amino acid residues 25 to 96 
represent the prodomain of the AMA1 transmembrane protein, residues 97 – 303 represent 
domain I, residues 304 – 440 represent domain II and residues 441 – 545 represent domain III of 
the protein ectodomain. 
 
 
Comparison of mean growth inhibition per immunisation group amongst the 
three parasite strains showed that IgGs from the DICo/HT group inhibited NF54 
parasites better than the other two strains (p = 0.003 against FCR3 and p = 0.005 
against HB3, Tukey HSD). Mean inhibition for this group however did not differ 
between HB3 and FCR3 parasites (p = 0.973, Tukey HSD). Mean inhibition 
against the three parasite strains was similar for both the DiCo/ISA and AM/ISA 
groups (p = 0.85 for AM/ISA and p = 0.076 for DiCo/ISA, one-way ANOVA). In 
this study, inhibition of the growth of the NF54 parasite strain was unexpectedly 
high in comparison with the other two strains.  
 
 
DISCUSSION 
Multi-allele and multi-antigen malaria vaccine approaches have shown potential 
in inducing antibody responses with broad-strain inhibitory capacity in a 
number of rodent and rabbit studies [33,34,40]. In the current study, the 
immunological benefits of such immunisation strategies, as well as the safety of 
these formulations, were further analysed in a non-human primate model. Two 
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different adjuvants were used for vaccine formulation in this study; Montanide 
ISA 51 (w/o) is a proprietary adjuvant from Seppic (Paris, France) and has been 
used in a number of human studies [41-43]. CoVaccine HT™ (o/w) is also a 
proprietary adjuvant developed by Protherics Medicines Development Limited, a 
BTG International Group company, and has recently entered human trials [44] . 
In the current study both adjuvant formulations were well tolerated as most of 
the parameters (chemistry and haematology) measured to assess organ and 
systemic functions were well within normal values for healthy animals within 
the same facility. Palpable inguinal lymph nodes were the only local reaction to 
vaccination observed in study animals. Mean levels of alanine transaminase in 
the AM/ISA immunisation group and aspartate transaminase in the DiCo/ISA 
group increased a day after each immunisation but were back to baseline within 
a week. Transient increases were seen in individual animals in all immunisation 
groups but only those in groups immunised with Montanide ISA 51 showed 
mean levels higher beyond normal values. Hypotension and hypoxaemia induced 
following ketamine sedation have been associated with a release of these 
enzymes from the liver and heart muscle [45,46] and it is possible that 
Montanide ISA 51 enhanced this effect.  
Mean levels of creatinine for the DiCo/ISA group were high throughout the study 
period, with four of the six animals in the group showing levels above normal 
prior to the first immunisation and throughout the study. As these levels 
remained largely unchanged throughout the study, it suggests that treatments 
did not alter renal function. Increased neutrophil counts in the DiCo/HT group 
following immunisation were concomitant with decreased levels of serum iron in 
the same group. This observation has also been made in previous studies and is 
suggestive of the possibility that these events are coupled. The limited leg 
movement experienced by one animal in the AM/ISA group was most likely due 
to physical injury from needles used to deliver the vaccine or for blood sampling 
and not vaccine-related. Moreover, such an outcome has not been observed in 
earlier studies in this lab with this adjuvant. 
Previous studies with CoVaccine HT™ formulations at an SFASEs dose of 2 mg or 
10 mg in rhesus monkeys [47,48] and at 2 mg or 4 mg SFASEs in rabbits [47] 
showed no local or systemic adverse events , while only minimal transient 
adverse events were seen in a small percentage of ferrets with formulations 
containing 0.125 - 4 mg of SFASEs ([47,49]). For Montanide ISA 51, though little 
to no reactogenicity has been reported in animal studies and in some human 
studies [41,50-52], other human studies have concluded that this adjuvant, with 
its current composition, might not be suitable for use in humans due to high 
reactogenicity [42,43]. 
Mean antibody responses against the AM/ISA vaccine were statistically similar 
on day 70 and 126 while responses against the two DiCo mix groups had 
declined significantly by day 126. This was due mainly to the exceptionally high 
titres in two of the six animals in the AM/ISA group (Figure 1) and does not 
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reflect a more durable IgG response against the AM fusion protein compared to 
DiCo mix, especially since the four low responders in the AM group also showed 
titre decreases on day 126. The AM/ISA vaccine also induced appreciable levels 
of anti-MSP119 IgG, especially in the two animals that also had the highest anti-
AMA1 IgGs in this group. Vaccine design studies with MSP119 fusion proteins 
have shown that IgG responses induced against the MSP119 component increase 
several fold compared to IgG responses to formulations with MSP119 alone 
[35,53], suggesting that fusion enhances antibody formation against the MSP119 
component.  
Observations in ELISA were in agreement with the in vitro growth inhibition data 
as animals with high IgG levels had correspondingly high GIA activities and vice 
versa. Purified IgGs from all animals in the DiCo/HT group showed high mean 
growth inhibition of the three parasite strains compared to inhibition by IgGs in 
animals from the DiCo/ISA group (Figure 3). This suggests that the CoVaccine 
HT™ formulation was functionally superior and that this adjuvant may be most 
suitable for inducing the required high titres of functional IgGs. Inhibition of all 
three strains was similar for all IgGs from the DiCo/ISA or AM/ISA immunisation 
groups (Figure 3). Inhibition of NF54 parasites by IgGs from the DiCo/HT group 
was however slightly higher compared to that of the two other strains (Figure 3). 
This can however not be attributed to greater sequence similarity between NF54 
AMA1 and the DiCo antigens. Indeed the greatest sequence similarity for the 
AMA1 allele sequences indicated in Figure 4 is between the FVO AMA1 allele and 
DiCo 2 (12 amino acid differences apart from the one cleavage and six N-
glycosylation site differences). This notwithstanding, the data demonstrate the 
specificity broadening benefits of DiCo mix formulations in non-human primates, 
and adds to the accumulating data on the strain-transcending properties of the 
DiCo strategy that have been demonstrated in rabbit studies [33,34].  
Four animals in the AM/ISA group had very low IgG titres (Figure 2) with 
corresponding low inhibitory activities below 20%, especially against the HB3 
and NF54 strains (Figure 3). The other two animals in this group had high 
vaccine responses in both ELISA and GIA (Figures 1 and 2) hence the weak 
responses in the four animals cannot be due to poor immunogenicity of the 
candidate antigens. Thus these animals were most likely non-responsive to 
immunisation, and this makes it difficult to draw firm conclusions on the 
effectiveness of the AM fusion protein candidate in this study. Parasite inhibition 
studies done in vitro with antibodies raised in rabbits as well as challenge studies 
in mice have however shown that vaccines composed of AMA1 and MSP1 either 
as a mixture or a fusion protein product induced functional antibodies 
[35,36,54]. 
The data presented shows that both adjuvant formulations were well tolerated 
upon administration to rhesus macaques. The data further demonstrates the 
specificity broadening benefits of multi-allele formulations compared to single 
PfAMA1 formulation in non-human primates [55,56], and adds to the 
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accumulating data on the strain-transcending properties of the DiCo strategy. 
The three antigens, especially when formulated in CoVaccine HT™, induced IgG 
levels that inhibited multiple parasite strains in vitro. It is however difficult to 
draw firm conclusions on data from the AM fusion protein since most of the test 
animals immunised with this vaccine showed low vaccine responses. The DiCo 
antigens thus represent a unique strain-transcending strategy for developing a 
malaria blood stage vaccine with benefits for susceptible individuals in areas 
where P. falciparum is endemic. 
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ABSTRACT 
 
Background 
Establishing antibody correlates of protection against malaria in human field 
studies and clinical trials requires, amongst others, an accurate estimation of 
antibody levels. For polymorphic antigens such as apical membrane antigen 1 
(AMA1), this may be confounded by the occurrence of a large number of allelic 
variants in nature.  
 
Methods 
To test this hypothesis, plasma antibody levels in an age-stratified cohort of 
naturally exposed children from a malaria-endemic area in Southern Ghana were 
determined by indirect ELISA. Titres against four single PfAMA1 alleles were 
compared with those against three different allele mixtures presumed to have a 
wider repertoire of epitope specificities. Associations of antibody levels with the 
incidence of clinical malaria as well as with previous exposure to parasites were 
also examined. 
  
Results 
Antibody titres against PfAMA1 alleles generally increased with age/exposure 
while antibody specificity for PfAMA1 variants decreased, implying that younger 
children (≤ 5 years) elicit a more strain-specific antibody response compared to 
older children. Antibody titre measurements against the FVO and 3D7 AMA1 
alleles gave the best titre estimates as these varied least in pair-wise 
comparisons with titres against all PfAMA1 allele mixtures. There was no 
association between antibody levels against any capture antigen and clinical 
malaria incidence. Antibody levels in participants with higher parasite densities 
from previous exposure tended to be lower than the levels in participants with 
lower parasite densities, though this trend was also not statistically significant.  
 
Conclusions 
The current data shows that levels of naturally acquired antigen-specific 
antibodies, especially in infants and young children, are dependent on the 
antigenic allele used for measurement. This may be relevant to the interpretation 
of antibody titre data from measurements against single PfAMA1 alleles, 
especially in studies involving infants and young children who have experienced 
fewer infections.  
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Background 
Antibodies have a demonstrably crucial role in protection against clinical malaria 
and the measurement of malaria-specific antibodies and their correlation with 
protection against disease/infection is essential in field as well as vaccine trial 
studies. Anti-malarial antibodies participate in such effector mechanisms as 
complement-mediated parasite clearance, red cell invasion inhibition, direct 
neutralisation of parasites/toxins and antibody-mediated cellular 
inhibition/cytotoxicity [1-5].  
Antibodies are naturally induced against a host of parasite antigens, and in vivo 
protection may generally be based on the cumulative/synergistic effect of 
relevant responses rather than responses to any single antigen. Additionally, at 
the peak of an infection, high levels of the relevant antibodies, rather than their 
generation from memory may be necessary for protection [6,7]. The precise 
determination of anti-malarial antibody levels in field and vaccine studies in 
disease-endemic areas is therefore very crucial to data interpretation as well as 
for identifying antigen correlates of protection. 
For polymorphic parasite antigens, antibodies against one allelic form have been 
shown to react less with other alleles as a significant proportion of antibodies are 
directed against strain-specific epitopes.  Plasmodium falciparum apical 
membrane antigen 1 (PfAMA1), a type 1 integral membrane protein expressed in 
the merozoite and sporozoite stages of the parasite and a leading candidate for 
the development of a blood stage vaccine is one such antigen [8-15]. 
Polymorphism in PfAMA1 is due to a number of non-random point mutations 
that occur in the antigen’s ectodomain, an effect that has been associated with 
host immune pressure on the parasite [16,17]. Thus for a highly polymorphic 
antigen like apical membrane antigen 1 (AMA1), many variants of which are 
likely to be present in a single population, estimation of the true antibody levels 
can be quite tricky as antibody levels measured against any single PfAMA1 allele 
may underestimate the true levels of persisting antibodies. This hypothesis was 
tested by comparing the plasma anti-PfAMA1 antibody levels in plasma samples 
collected prior to the low transmission season in a naturally exposed population 
against four single PfAMA1 alleles and three different PfAMA1 allele mixtures. 
The antigen mixtures are expected to have a variety of unique epitopes that 
would enhance binding of the broad spectrum of polyclonal anti-AMA1 
antibodies in naturally exposed individuals. The study further assesses the 
association of antibody levels with the incidence of clinical malaria during the 
low transmission season as well as with previous exposure to parasites.  
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Methods 
 
Ethics statement 
The current study used archived human samples from a longitudinal cohort 
study conducted during the malaria seasons of 1994 and 1995. The original 
study was approved by the Ministry of Health in Ghana and ethical clearance was 
sought from the ethics committee of the Ministry of Health. Written informed 
consent was obtained from parents of participating children for the original 
study, but sample analyses in the current study were done anonymously. 
 
Study population and sampling 
A random sample of 95 archived plasma samples drawn from the previous 
longitudinal cohort study (conducted at Dodowa, an area in Southern Ghana with 
seasonal, stable transmission of mainly P. falciparum) was used in this study. A 
detailed description of the study site and sampling procedures has previously 
been published [18,19]. The original study involved a total of 300 children 
between the ages of 3 and 15 years. Blood samples were drawn from study 
participants at the beginning of the high transmission season (April 1994) as 
well as at the end of the season, prior to the beginning of the low transmission 
season (November 1994). Plasma samples used here were prepared from blood 
samples taken before the low transmission season in November 1994. Clinical 
malaria was defined as having a fever and/or an axillary temperature above 
37.5ºC, as well as parasitaemia above 5000 parasites/µl of blood. 
 
Antibody determination 
Anti-PfAMA1 antibodies titres in plasma samples were measured using an 
antigen capture ELISA. Plates were coated separately with 1µg/ml of AMA1 
alleles from the FVO (GenBank accession number AJ277646), HB3 (GenBank 
accession number U33277), 3D7 (GenBank accession number U65407) and 
CAMP (GenBank accession number M58545) parasite strains, as well as with 
1µg/ml of three different antigen mixtures; i) a mixture of three Diversity 
covering (DiCo) antigens whose design is based on the amino acid sequences of 
355 naturally occurring PfAMA1 alleles [20], ii) a mixture of the FVO, HB3, 3D7 
and CAMP alleles, designated as Four, and iii) a mixture of all seven allelic 
antigens, designated as Seven. All antigen mixtures had equal weights of the 
component alleles. All antigens were expressed in Pichia pastoris and potential 
N-Glycosylation sites were removed by methodologies that have been previously 
described [12,20-22]. Plates were blocked with 200 µl/well of 3% BSA in PBS-
Tween 20 (0.05%) for 1 hour, after which 100 µl/well of plasma (diluted 1: 200 
and titrated 3-fold over 8 duplicate wells) was added and incubated for 1 hour. 
Bound antibodies were detected by incubation with 100 µl/well of 0.8 µg/ml 
alkaline phosphatase-conjugated goat anti-human IgG for 1 hour. Colour 
development was with 1 mg/ml p-Nitrophenyl phosphate in DEA buffer (0.15% 
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MgCl2.6H2O, 0.01% diethanolamine, pH = 9.8) for 30 min and optical density 
(OD) was measured at 405 nm. ODs were subsequently expressed in arbitrary 
units (AU) by the calibrator (hyperimmune human serum pool) included on each 
ELISA plate using the 4PL-based ADAMSEL programme (Remarque©), a data 
management system that is accessible from the EMVDA website 
(www.malariaresearch.eu). One arbitrary unit (1AU) is equivalent to the 
reciprocal plasma dilution that gives an OD of 1.0 over background. 
 
Statistical analyses 
Antibody titres were log-transformed to achieve normality and stratified by age 
(3 to 5 years, 6 to 10 years and 11 to 15 years) in order to assess the effect of 
age/antigen exposure on the specificity of elicited antibodies. Antibody titres 
were compared for the same age group across capture antigens by one-way 
analysis of variance followed by Tukey Honest Significance Difference post hoc 
tests where necessary. The student t test was used to make pair-wise 
comparisons between titres of different age groups measured against the same 
capture antigen. Titres are also presented as boxplots per age group on each 
capture antigen. For each capture antigen, antibody titre variability amongst the 
different age groups was assessed by Levene’s test for homogeneity of variances. 
The log-transformed titres against different capture antigen pairs were 
subsequently compared using Tukey mean-difference (TMD) or Bland-Altman 
plots [23], which assess the degree of agreement between same sample 
measurements by different methods (here different capture antigens). Since 
titres were log-transformed, the x-axis gives the geometric mean of the two 
antibody measurements for the sample against the capture antigen pair and the 
y-axis gives the ratio of titre measurements. Plots show a bold horizontal line 
(line of equality) indicating the geometric mean of titre differences (ideally at 
titre ratio = 1 or titre difference = 0) between the antigen pair and dotted lines 
indicate the 95% limits of agreement for the paired data distribution. The 
vertical axis has been modified to show fold difference instead of the absolute 
titre difference. 
Association between antibody levels against each of the capture antigens and 
cumulative incidence of clinical malaria (with the corresponding 95% confidence 
intervals) was estimated by the Kaplan-Meier method. Clinical malaria incidence 
rate estimation included all malaria episodes that met the case definition. Data 
from all 95 children sampled for this study were included in the analyses. The 
association between antibody levels (and age group) with previous exposure to 
infection (defined as categorical variables) were assessed separately for titres 
against each capture antigen using a linear regression model. For each antigen, 
Cox regression with a robust standard error was used to estimate the rate ratio 
and its 95% confidence interval. The exposure of interest, antibody levels, was 
modelled as a continuous variable transformed to log base 2 so that rate ratios 
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indicate the decrease in incidence rate of malaria corresponding to a two-fold 
increase in antibody levels.  
Analyses and plots were made using the R statistical package (version 2.13.0, 
2011, R development core team) and STATA package (Statacorp, College Station, 
TX). 
 
 
 
 
RESULTS  
The hypothesis that measurement of antibody levels in a malaria-endemic 
population against a polymorphic antigen would be influenced by the specific 
allele used was investigated in this study. Anti-PfAMA1 antibody levels in the 
plasma of naturally exposed children was measured against four single PfAMA1 
alleles and compared with titres against three different PfAMA1 allele mixtures 
(Figure 1). Antibody levels against all capture antigens/mixtures increased with 
age and mean levels against all antigens were significantly higher in the 11-15 
year olds compared to the 3 – 5 year olds (p < 0.05, student t test). No significant 
differences were observed in antibody titres between the 6 – 10 year olds and 
the other two groups in separate comparisons (p > 0.05 in all cases, student t 
test). Antibody levels against different capture antigens/mixtures did not 
significantly differ for the same age groups (P > 0.05, one-way ANOVA).  
Results of the pair-wise comparison of antibody titres against the different 
capture antigens by TMD plots are presented in Figure 2. The more distant data 
points are from the line of equality, the greater the binding preference of the 
same antibodies for one allele over the other. On this premise, plot panels 
comparing antibody levels against single alleles indicate that younger children (3 
- 5 years) showed a trend of greater strain-specificity, characterised by the 
slightly greater spread of data points (cross or “+” symbols) compared to that of 
older children in most panels (Figure 2). This greater variability of antibody 
titres in younger children is also obvious from Figure 1 (Levene’s test, p < 0.05 
for all capture antigens except for the antigen mixtures Four and Seven).  
Titre measurements of the polyclonal pool of antibodies in naturally exposed 
individuals would require an antigen(s) that present a broad range of antibody 
epitopes, a condition that may be fulfilled with multi-allele formulations. Three 
different allele mixtures (a mixture of the three DiCo antigens, designated DM, a 
mixture of the four single alleles, designated as Four, and a mixture of all seven 
PfAMA1 alleles, designated as Seven) were used for titre measurements in this 
study. The best single alleles for antibody measurement in this population were 
determined by pair-wise comparison with titres against these allele mixtures. 
 
 
 
Measurement of antibodies against a polymorphic antigen 
121 
 
 
Figure 1. Plasma antibody titres against PfAMA1 alleles and allele mixtures. Anti-PfAMA1 
antibody titres in plasma of malaria-exposed children were measured by an indirect ELISA using 
four PfAMA1 alleles (from the FVO, HB3, 3D7 and CAMP parasite strains) and three different 
allele mixtures (DiCo mix or DM, a mixture of the four natural alleles, designated as Four, and a 
mixture of all seven alleles, designated as Seven) separately as capture antigens. Titres are 
presented for children ages 3 – 5 years (lower panel), 6 – 10 years (middle panel) and 11 – 15 
years (upper panel). Each symbol represents plasma antibody titres of a study participant. 
Boxplots show the upper and lower quartiles as well as the median of each distribution. The 
vertical axis (antibody titre) is expressed in kilo arbitrary units (kAU), with one arbitrary unit 
being equivalent to the reciprocal plasma dilution that gives an OD of 1.0 over background. 
 
 
Antibody titres measured against the FVO and 3D7 alleles were least variable as 
judged by the narrow width of 95% limits of agreement (Figure 2) in separate 
pair-wise comparisons with all allele mixtures. Limits of agreement for the pair-
wise comparison of titres against FVO and 3D7 alleles was also very narrow 
(Figure 2). The number of PfAMA1 alleles (domains I, II and III) identified in four 
countries in the Africa region and whose amino acid sequences are  similar to 
those of the four alleles used in this study are presented in Table 1. The 
sequences are part of published PfAMA1 sequences that were retrieved from 
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Figure 2. Pair-wise comparison of anti-PfAMA1 antibody titres against different capture 
antigens/mixtures. Tukey Mean-Difference (TMD) plots were used to assess the level of 
agreement between antibody titres measured against pairs of capture antigens/mixtures. Each 
point represents a plot of the difference between two log-transformed titre measurements for a 
sample against the geometric mean of the same two measurements. For each panel, the bold 
horizontal line represents the average of all the differences between titres of the same samples 
against the indicated capture antigen/antigen mixture pair while the dotted horizontal lines 
represent the 95% limits of agreement for the distribution. Plot symbols represent individual 
data points; cross (or plus) symbols are study participants aged 3 – 5 years, filled squares are 
participants between 6 – 10 years and open circles are participants between 11 – 15 years.  
 
 
GenBank as of January 2011 (Remarque, personal communication). It is clear 
that all four alleles used in this study occur at very low frequencies in these 
populations (Table 1), though the 3D7 allele seems more prevalent compared to 
the FVO allele.  
The current study also investigated the association of antibody levels with the 
cumulative incidence of clinical malaria as well as with previous exposure to 
Plasmodium parasites. Of the 95 children whose samples and clinical data were 
available for analysis, 23 had at least one clinical episode during the low 
transmission season and the incidence rate of malaria decreased with the age of 
participants (Table 2). There was however no association between antibody 
levels against any of the capture antigens and the incidence of clinical malaria 
before and after correction for age (Table 3).  
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Table 1. Number of PfAMA1 alleles with similar amino acid  
     sequences to the alleles used in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*This is the total number of PfAMA1 amino acid sequences from  
those countries based on published data as of January 2011. 
 
 
Table 2. Characteristics of study population 
Characteristics 
Number 
of 
children 
(%) 
Cumulative 
incidence  
(95%CI)  
Child-
months at 
risk  
Malaria 
cases 
Rate per 100 
child-months 
(95% CI)  
Age group 
     
   3 - 5 years 39 (41) 
20.1%  
(10, 38.1) 318.82 11 3.5 (1.9, 6.2) 
   6 - 10 years 27 (28) 
22.4%  
(10.7, 43.2) 226.63 7 3.1 (1.5, 6.5) 
  11 - 15 years 29 (31) 
17.6%  
(7.7, 37.3) 243.58 5 2.1 (0.9, 4.9) 
TOTAL 95 
19.8%  
(13, 29.7) 789.03 23 2.9 (1.9, 4.4) 
 
Clinical malaria is defined as a history of fever or temperature >= 37.5 and parasite density >= 
5000/µl 
 
 
Association of anti-AMA1 titres against the different capture antigens with 
previous exposure to parasites within the preceding 6 months of the study was 
investigated using linear regression models. Participants were grouped by their 
geometric mean parasite density into four categories and the relationship with 
antibody levels against each capture antigen assessed. Participants who had no 
detectable parasites (None, n = 10) had the lowest anti-AMA1 antibody levels 
(Figure 3).  
 
PfAMA1 
allele 
Country 
Gambia Mali Nigeria Kenya 
 
FVO 1 0 0 0 
HB3 0 1 0 0 
3D7 2 23 2 1 
CAMP 3 6 1 1 
 
*Number of 
sequences    127 923 52 143 
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Table 3. Age-adjusted incidence rate ratio (IRR) for the association  
    of anti-parasite antibody levels with malaria incidence 
 
Antibody  Antigen Crude HR (95%CI) 
HR adjusted for age 
(95%CI) 
P-value for 
adjusted HR 
IgG AMA1-FVO 1.06 (0.92, 1.22) 1.09 (0.93,1.27) 0.3 
AMA1-3D7 1.05 (0.92, 1.19) 1.08 (0.94, 1.24) 0.3 
AMA1-DM 1.05 (0.92, 1.21) 1.08 (0.93, 1.26) 0.32 
AMA1-Four 1.07 (0.93, 1.23) 1.09 (0.94, 1.27) 0.25 
AMA1-Seven 1.06 (0.92, 1.21) 1.08 (0.93, 1.26) 0.3 
 
AMA1-CAMP 1.08 (0.94, 1.24) 1.11 (0.95, 1.30) 0.19 
  AMA1-HB3 1.04 (0.91, 1.18) 1.07 (0.92,1.24) 0.39 
 
 
Participants in this group had had no infection during the preceding six months 
before the plasma samples analysed here were taken, but might have 
experienced infections prior to the start of the study. Participants who had 
experienced moderate parasite densities (two groups, 1 < 760 and 760 < 3000 
parasites/µl of blood, n = 29 and n = 28, respectively) had the highest levels of 
antibodies when compared with those of participants with no exposure within 
the preceding 6 months. Participants who had previously experienced parasite 
densities greater than 3000/µl of blood (3000+, n = 28, Figure 3) however had 
antibody levels intermediate between those of the unexposed (None) and the 
other two exposed groups (1 < 760 and 760 < 3000). Despite these trends, there 
were no significant differences in antibody levels between any two parasite 
density groups. 
 
 
DISCUSSION 
An accurate estimation of antibody levels against malaria parasite antigens is 
necessary for establishing antibody correlates of protection against malaria in 
human field studies and clinical trials. A number of parasite antigens that are 
currently being assessed as vaccine candidates show polymorphism, and the 
estimation of antibody titres using a single allelic form may be confounded by the 
occurrence of a large number of allelic variants in nature. In this study, the effect 
of antigenic polymorphism on the measured levels of anti-PfAMA1 antibodies in 
plasma samples taken before the low malaria transmission season  
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Figure 3. Geometric mean of antibody titres for study participants with different parasite 
densities. Error bars show the 95% CI of antibody titres per parasite density category. Sample 
size; n = 10 for the group “None”, n = 29 for “1<760”, n = 28 for “760 < 3000” and n = 28 for the 
group “3000+” in all panels. 
 
 
in a previous study was assessed by comparing titres against single PfAMA1 
alleles and allele mixtures. The PfAMA1 allele mixtures are expected to present a 
broad spectrum of antigenic epitopes that will be recognised by antibodies in the 
polyclonal pool. We also investigate the association of anti-PfAMA1 antibody 
levels with the cumulative incidence of clinical malaria as well as with previous 
exposure to parasites. 
For participants in any one age group, antibody levels against the different 
capture antigens/mixtures did not differ significantly. This observation is not 
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surprising as antibodies in the plasma samples from most study participants 
were most likely induced after repeated infection with diverse parasite strains 
over time. Several studies have indeed reported a large diversity of parasite 
strains within single communities in disease-endemic areas [17,24-26]. 
Genotyping of parasite strains in study participants here would have added to 
data interpretation, but this could not be done due to the unavailability of 
matching DNA samples.  
The greater variability of antibody titres (against all but the antigen mixtures 
Four and Seven) observed in younger children (Figures 1 and 2) suggests that 
individuals with fewer parasite exposures might have a greater proportion of 
strain-specific antibodies compared to individuals who have had many parasite 
infections. It is therefore possible that the use of a single allele for antibody 
measurement, especially in infants/young children or individuals with limited 
parasite exposure, may under-estimate antibody levels and such data need to be 
interpreted cautiously. The data here also suggest that though humans 
discriminate between PfAMA1 alleles and possibly other polymorphic parasite 
antigens, these effects may become less apparent with age and exposure to 
variant parasite strains. This observation is in agreement with previous 
observations in humans [27]. In a study involving participants from Papua New 
Guinea for example, Cortes et al. [28] showed that the majority of anti-PfAMA1 
antibodies directed against polymorphic epitopes were detected in younger age 
groups compared to older individuals. The development of a more cross-reactive 
profile with age/exposure may most likely be as a result of clonal imprinting, 
with antigens derived from every infection primarily boosting memory to 
previously encountered antigens. This phenomenon has been demonstrated in a 
controlled setting in rabbits after immunisation with different PfAMA1 alleles in 
sequence [29].  
Antibody measurement against a PfAMA1 allele mixture is expected to give the 
best titre estimate of polyclonal anti-PfAMA1 antibodies in the field since the 
mixture would have a large diversity of antigenic epitopes. Such an approach 
based on a practical number of alleles may be useful, especially since there is a 
high likelihood of many parasite strains occurring in a given community, and 
even when there are a limited number of strains, their specific AMA1 alleles may 
not be readily available for use as coating antigens. Three different allele 
mixtures were used for titre measurements in this study. DiCo mix (DM), one of 
the mixtures, consists of three DiCo antigens that were designed based on the 
sequences of 355 naturally occurring PfAMA1 alleles to inherently cover 
naturally occurring polymorphism in PfAMA1 [20]. The mixture has been shown 
in our laboratory to yield higher antibody titres in samples from naturally 
exposed individuals compared to titres against single natural alleles 
(unpublished data). Titres against the FVO and 3D7 AMA1 alleles were most 
comparable to titres against DM and the other two allele mixtures, suggesting 
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that the FVO and 3D7 alleles preferentially recognize a greater number of 
antibody specificities compared to the CAMP and HB3 alleles. This is against the 
observation that all four single alleles used in this study have only been found at 
very low frequencies in the Africa region (Table 1), though the 3D7 allele seems 
more prevalent compared to the FVO allele. Thus the measured levels of 
circulating antibodies in a population with multiple strain infections are 
dependent on the choice of PfAMA1 alleles used for titre measurement.   
The low prevalence of all four alleles shows the complexity involved in the 
measurement and evaluation of responses to PfAMA1 in a naturally exposed 
population as even in the current study there may still be strain-specific anti-
PfAMA1 antibodies that may not be detected by the best single alleles. It is 
however worth mentioning that the levels of naturally induced cross-reactive 
antibodies seem to be the repertoire required for cross protection [29-31], and 
current vaccine strategies aim at inducing such cross-strain antibodies. Antibody 
measurement against a single allele could therefore give an indication of the 
levels of cross-strain (protective) antibodies. Data presented in Table 3 shows no 
association between antibody levels against any of the capture antigens and the 
incidence of clinical malaria before and after correction for age. Antibody levels 
against PfAMA1 have been associated with a reduced risk of malaria incidence in 
other studies with comparable population characteristics [32-35], though titre 
measurements in these studies were made at the beginning of the high 
transmission season. Titres in this study were measured at the beginning of the 
low transmission season and it is possible that antibody-mediated clearance of 
infections during the preceding high transmission season would result in low 
antibody levels at this sampling time point. An earlier study in the same 
population measured anti-MSP119 antibodies and reported similar levels of 
antibodies at the beginning and end of the high transmission season [18]. That 
study also showed no antibody correlation with protection from disease, but the 
explanation given for the observations here, if proven, would suggest different 
decay rates for antibodies against the two antigens. The limited sample size in 
this study is also likely to reduce statistical power required to detect significant 
associations in the current study. Additionally, the in vitro functionality of 
antibodies could not be assessed as the amount of plasma available was very 
limited and assays would need to be performed with multiple strains in order to 
assess the specificity of functional antibodies. 
There was a trend of decreasing antibody levels with increasing parasite density 
from previous exposure, but this inverse association was also not statistically 
significant. This notwithstanding, the trend is in agreement with the observation 
that maintenance of immune effectors involved in conferring protection against 
disease requires the persistence of low levels of circulating parasites [27,36].  
The data presented generally suggests a cautious selection of antigens for the 
measurement of naturally induced antibody levels, especially in samples from 
individuals with limited exposure to parasites. Though the study utilized 
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archived samples taken during the 1994/1995 malaria season, the findings have 
direct relevance for the assessment of naturally acquired antibodies of broad 
specificity since titres are measured against randomly selected (allelic) antigens 
and the exact circulating strains/antigenic alleles within study populations are 
usually not taken into account. Alternatively, DiCo mix may represent an ideal 
candidate for the measurement of antibody titres in naturally exposed 
populations, especially in infants and young children as the three DiCo antigens, 
apart from the effect of mixing, have been designed to cover polymorphism that 
is seen in naturally occurring PfAMA1 alleles. The data also points to a trend of 
increasing proportion of antibodies against cross-strain epitopes with age, and 
suggest the involvement of clonal imprinting in the development of this antibody 
repertoire. Finally, though there was no association of antibody levels with either 
a reduced incidence of clinical malaria or previous exposure to parasites, 
individuals with moderate parasitaemia (< 3000/µl) had higher absolute 
antibody levels than those with parasitaemia greater than 3000/µl of blood. 
These findings are collectively relevant to the interpretation of data on 
antibodies against polymorphic antigens, especially in field studies involving 
groups with limited parasite exposure. 
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GENERAL DISCUSSION 
The search for an effective malaria vaccine has become ever important, as a 
vaccine would greatly boost current coordinated efforts at malaria control and 
prevention. This thesis focuses on the formulation of a blood stage vaccine aimed 
at reducing parasite multiplication and thereby curbing disease symptoms and 
sequelae. The vaccines described in this thesis are based on the polymorphic yet 
promising candidate apical membrane antigen 1 (AMA1), an essential antigen 
expressed by Plasmodium falciparum. The thesis investigates multi-allele vaccine 
formulation as a strategy for overcoming the effect of allelic polymorphism on 
immune responses to Plasmodium falciparum AMA1 (PfAMA1), as well as a 
dissection of the fine specificity of induced responses.  
The main conclusions of the studies described in this thesis are that i) different 
PfAMA1 alleles share epitopes to which functional cross-strain antibodies can be 
induced, ii) increasing the number of PfAMA1 alleles in a vaccine from one to 
three results in an increased proportion of such functional cross-strain 
antibodies, iii) beyond three alleles the proportion of induced cross-strain 
antibodies reaches a plateau, iv) simultaneous or sequential administration of 
three PfAMA1 alleles induces similar  proportions of cross-strain antibodies, 
even though the latter was expected to induce a greater proportion of cross-
strain antibodies since strain-specific responses would not be boosted, v) the 
proportion of cross-strain antibodies elicited by multi-allele vaccines is 
independent of the adjuvant used, though adjuvant choice determines the 
absolute levels of elicited antibodies, and vi) three in silico-designed, Pichia 
pastoris-expressed PfAMA1 antigens represent a multi-allele candidate with 
broad allelic coverage for a human blood stage vaccine. 
 
Multi-allele formulations and antibody response broadening 
Vaccines based on single AMA1 alleles have been shown to confer solid 
protection against homologous parasite strains in animal models [1-4]. The 
many PfAMA1 variants found in nature (649 alleles from a database of 1778 
published valid sequences accessed from GenBank as of January 2011) may 
however complicate the design of single allele vaccines against human malaria as 
anti-AMA1 responses show strain specificity [5,6]. Vaccines based on conserved 
epitopes, or epitopes that are shared amongst a wide diversity of parasite 
strains, are therefore necessary to eliminate the effects of strain-specificity on 
vaccine effectiveness. Allelic variation results from the extensive polymorphism 
found in PfAMA1 [7-11], and this begs the question whether there are shared 
epitopes to which functional cross strain antibodies can be induced. In chapter 2 
the finding that approximately 50% of anti-FVO AMA1 mono-specific antibodies 
recognize the 3D7 AMA1 allele, and up to 80% of these (representing 40% of 
anti-FVO mono-specific antibodies) cross-react with two other relatively distant 
PfAMA1 alleles (HB3 and CAMP) has been described. This suggests that these 
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four alleles, and possibly other PfAMA1 alleles, share epitope targets to which 
functional antibodies can be induced. Additionally, the data presented in chapter 
4 show that immunisation of groups of rabbits with three distinct PfAMA1 alleles 
(FVO, HB3 and 3D7) in different orders yield antibodies with comparable 
specificity profiles and similar in vitro functional inhibitory capacities against 
multiple parasite strains. Subsequently administered alleles most likely boosted 
responses to previous alleles, and this is a strong indication of the likely 
existence of a significant number of antibody epitopes that are shared between 
alleles. To date, only a single conserved inhibitory epitope (4G2 binding epitope 
in domain II of PfAMA1) has been described [12-14], and the observations made 
in this study point to the possibility of additional strain-independent epitopes in 
AMA1 from diverse P. falciparum lines. Data from the sequential immunisation 
study (chapter 4) also support the hypothesis of the development of an 
increasing cross-strain antibody repertoire with exposure to different parasite 
strains in an endemic population, as opposed to that involving the accumulation 
of many different strain specificities [15]. The development of a cross-strain 
antibody repertoire with age/parasite exposure in humans was also 
demonstrated in chapter 6 of this thesis. 
 
Allele requirements for achieving the broadest anti-PfAMA1 response  
Even though mixed allele vaccine formulations have shown promise for 
overcoming allelic polymorphism, the number and specific type of variant alleles 
that are required for near universal coverage are still open questions. Studies 
that utilized molecular and sero-epidemiological approaches have proposed the 
inclusion of representative PfAMA1 variants from six [16] to ten [17] allele 
families in a single formulation to achieve universal coverage. These estimates 
are based on a limited number of sequences (150 unique haplotypes and 214 
haplotypes from the two studies, respectively), and estimates could be higher if 
more sequences had been available for analyses. The work involved in evaluating 
individual alleles and the associated cost of producing individual proteins before 
formulation might however make such approaches less desirable. The findings 
described in chapter 3 of this thesis that three in silico-designed PfAMA1 
antigens (known as Diversity-Covering antigens or DiCos) formulated as a multi-
allele vaccine elicit responses that are functionally comparable with formulations 
incorporating the DiCo antigens and four other PfAMA1 alleles (seven alleles in 
all) suggests a practically relevant limit to the number of component alleles. The 
DiCo antigens were designed based on the amino acid sequences of 355 naturally 
occurring PfAMA1 alleles to cover polymorphism that occurs extensively in 
PfAMA1 and were expressed in the yeast Pichia pastoris [18]. Though vaccines 
composed of three recombinantly-expressed natural alleles were shown to have 
similar effects, a direct comparison with the DiCo mix vaccine suggested a slight 
advantage for DiCo mix in terms of immune response broadening (Chapter 4 of 
this thesis). To further reduce the work involved in evaluating antigens 
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individually before mixing, the Parasitology Department at BPRC is currently 
exploring expression systems that would allow the incorporation of all three 
DiCo sequences either as one fusion protein, or separately in the same 
expression vector such that the three proteins could be purified from yeast 
culture supernatants in an already mixed form. 
 
Choice of adjuvants for vaccine formulation 
As has been demonstrated in this thesis (chapters 3, 4 and 5), the right quality of 
antibodies (cross-strain fraction) at low titres may not be enough to achieve the 
desired, strain-independent, vaccine effect. High titres of these antibodies are 
necessary for optimal inhibition of diverse parasite strains, and this has also 
been demonstrated in an in vivo challenge study in monkeys [19]. Thus the 
selection of adjuvants for vaccine formulation is crucial, and adjuvants with high 
immuno-potentiation properties will be most desirable. It has been shown in this 
thesis (chapter 2) as well as in other studies ([20]; Remarque et al., in 
preparation) that approximately 50% of anti-FVO AMA1 antibodies cross-react 
with 3D7 AMA1 and other alleles. In theory, a single PfAMA1 allele vaccine that 
elicits very high antibody titres would be effective against a diversity of parasite 
strains since it would have high titres of the cross-strain fraction. These high 
titres may however be difficult to achieve with currently available adjuvants, and 
this theoretical titre threshold is most likely lowered by multi-allele 
formulations, which have been shown to increase the overall proportion of 
elicited cross-strain antibodies. Nevertheless, the requirement of highly potent 
adjuvants with little or no reactogenicity is still necessary for multi-allele 
formulations in order to achieve high titres of the broadest possible response. 
Currently, adjuvants that are available for use in human vaccines include 
Alhydrogel, MF59 from Novartis, AF03 from Sanofi Pasteur, the Montanides (ISA 
51, ISA 720) from Seppic and the AS adjuvant series from GlaxoSmithKline (GSK), 
with all but the Montanides having been used in registered vaccines. Of these, 
Alhydrogel and the Montanides have been used in many malaria clinical trials 
with mixed results in terms of desirability. Alhydrogel has in most instances not 
shown much promise  regarding the induction of high titres of long-lasting 
(protective) responses against PfAMA1 as well as other malarial antigens [21-
26]. Though formulations of PfAMA1 as well as other antigens with the 
Montanides have been shown to induce high titre responses, the associated high 
reactogenicity observed in some instances makes these less desirable [27-30]. 
Thus though candidate antigens may per se be good enough, their vaccine effects 
may not be fully appreciated due to the choice of adjuvant. 
While adjuvants are necessary for immune response potentiation in subunit 
vaccines, a few studies have reported that the specificity of antibody responses 
to certain parasite antigens is dependent on the type of adjuvant used for 
formulation [31,32]. In chapter 3 of this thesis, it has been shown that antibody 
responses to PfAMA1 have similar antigen specificity profiles irrespective of the 
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adjuvant used. Multi-allele formulations with at least five different adjuvants 
have been tested in the work described in this thesis, and the specificity of 
induced antibodies in all formulations as assessed by a harmonized competition 
ELISA has been generally consistent. Antibody specificity profiles are also 
comparable amongst anti-PfAMA1 responses in rabbits (chapters 2, 3 and 4) 
Rhesus monkeys (unpublished data) and humans (Remarque et al., in 
preparation), though optimal depletion of rhesus and human anti-PfAMA1 
antibodies required slightly higher concentration of competitor antigens. The 
significance of this outcome for vaccine development is that irrespective of the 
adjuvant ultimately selected for PfAMA1 formulation, the same quality of 
antibody responses is likely to be elicited.  
 
Current status of AMA1-based vaccines 
Over the last few years a number of PfAMA1-based vaccine formulations have 
entered human trials and a summary of these trials is presented in the Table 
below. Some single PfAMA1 allele vaccines, tested in naïve populations, have 
shown signs of the possibility of vaccine ineffectiveness resulting from allelic 
polymorphism ([33]; Remarque et al., in preparation). A 3D7 AMA1 single allele 
vaccine that was tested in malaria-exposed adults however showed no such 
effects [34], and this was most likely due to existing levels of anti-malarial 
antibodies developed after repeated exposure to diverse strains. There is 
currently a single PfAMA1 multi-allele vaccine (AMA1-C1) in human trials, and 
this has shown early indications of response broadening but mainly against 
parasite strains expressing the vaccine component alleles [21,24,35,36]. This 
confirms the inadequacy of two alleles for dealing with the effects of 
polymorphism in PfAMA1 responses. The developers of AMA1-C1 (NIAID/NIH, 
USA) are currently exploring the possibility of including AMA1 from the L32 
parasite strain to make a three-allele vaccine termed AMA1-C2. As has been 
described in this thesis (chapter 3), PfAMA1 vaccines composed of three alleles 
seem to yield the broadest response possible, but the addition of L32 AMA1 to 
the 3D7 and FVO alleles raises the issue of which alleles to include in a multi-
allele vaccine as L32 is a very low prevalence strain (~ 0.22%, based on 
published PfAMA1 protein sequences accessed from GenBank as of January 
2011). This argument, if proven, would indicate that apart from the number of 
alleles, the choice of alleles might also be important for achieving optimal 
vaccine responses. The DiCo mix vaccine candidate being developed by BPRC 
Rijswijk consists of three PfAMA1 alleles that have been designed specifically to 
cover polymorphism in naturally occurring PfAMA1, and are expected to induce 
very broad responses in humans. The DiCo mix candidate is scheduled to go into 
phase I trials later in 2011/2012, with earlier pre-clinical studies showing a good 
level of response broadening. 
An interesting phenomenon regarding PfAMA1 vaccine responses is the 
observed immune interference from responses to other malarial antigens.  
Chapter 7 
136 
 
 
Table. PfAMA1-based vaccines that have gone into clinical trials (from  
 published work) 
 
Candidate  Expression  Adjuvant(s)/  Trial stage(s) References 
  system  delivery system        
 
PfAMA1  E. coli  Montanide ISA 720 Phase 1  [29] 
(3D7) 
 
 
PEV301/PEV3A   Virosomes  Phase 1/2a [37,38]  
(PfAMA1)                 
 
 
 
AMA1-C1          P. pastoris  Alhydrogel  Phases 1, 2 [21,24,28,35,36,39]  
(FVO+3D7)   ± CPG7909,     
Montanide ISA 720     
   
 
FMP2.1  E. coli  AS02A,  AS01B  Phases 1, 2a [34,40,41]  
(PfAMA1-3D7)          
        
 
 
PfAMA1  P. pastoris AS02A, Alhydrogel, Phase 1           [26]  
(FVO)    Montanide ISA 720      
 
 
 
PfCP-2.9 P. pastoris Montanide ISA 720 Phase 1  [42,43]  
(MSP119-AMA1 DIII)           
 
 
AdCh63  AMA1/   Simian adenovirus/ Phase 1  Hill (in preparation) 
MVA AMA1   MVA 
 
 
Accumulating data on antibody responses in humans show that persisting levels 
of other anti-malarial antibodies in naturally exposed semi-immune adults 
interfere with the functional activity of anti-PfAMA1 responses [35,44]. Naïve 
individuals and infants are less likely to have circulating anti-malarial antibodies, 
suggesting that PfAMA1, when formulated on its own, may be best suited as a 
vaccine for infants/naïve individuals but not for semi-immune adults. 
 
 
Malaria vaccines; promises and challenges 
The acquisition of anti-disease immunity in adults living in malaria-endemic 
areas, the successful treatment of both children and adults with 
immunoglobulins purified from the sera of semi-immune adults [45-48] and the 
induction of sterile immunity with whole parasite vaccines [49,50] clearly 
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suggest the feasibility of developing a vaccine against malaria. Apart from AMA1, 
a number of other promising candidate antigens, administered either as single 
recombinant antigens, antigen mixtures or chimeric proteins have also gone into 
human trials. The most prominent of these are CSP, MSP1, MSP2, MSP3, EBA-175 
and GLURP [22,25,37,51-57], and trial outcomes have generally shown limited 
successes in terms of immunogenicity and potential efficacy.  RTS,S is by far the 
most advanced malaria vaccine in terms of protective efficacy and 
developmental stage. It consists of the C-terminal repeat region of P. falciparum 
CSP fused with the N-terminal region of the Hepatitis B virus surface antigen and 
formulated with proprietary adjuvants from GSK. RTS,S has been shown to offer 
at least 50% efficacy (time to first clinical episode) over the first 8 months of 
study follow-up and protection that persists for up to 15 months after 
vaccination of 5 – 17 month old children in two malaria-endemic areas [58,59]. 
Though modest, this outcome is encouraging, and RTS,S is currently being 
evaluated in multi-centre phase III trials in Africa. Trials are currently on-going 
at eleven locations with varying transmission intensities, and the first data from 
these trials is expected to be available by the end of 2011.  
Despite these advances, the pace of malaria vaccine development has generally 
been retarded by a number of factors aside those described for PfAMA1. Whole 
parasite approaches on the one hand have been shown to induce durable 
protection [49,50,60,61], but vaccine manufacture and delivery have presented 
unique challenges. Subunit vaccines on the other hand are relatively easier to 
manufacture and deliver, but have not as yet yielded the desired level of 
protective immunity. Responses against a number of parasite antigens are 
believed to contribute to protection from disease, but these targets are not well 
defined. Additionally, the importance of these antigens as targets of protective 
immunity seems to vary amongst individuals and is dependent on exposure to 
parasites as well as on parasite and host genotypes [62]. This lack of defined 
correlates of protective immunity implies that selection of the “best” vaccine 
candidates has been based on vaccine properties of these antigens in animal 
models, or on such antigen characteristics as their accessibility to the relevant 
immune effectors and their importance for the parasite’s survival. The lack of 
correlates of protection is also linked to the limited functional assay options for 
down-selection of the best candidates for further development, as well as with 
options for assessing vaccine trial outcomes. 
The inability of currently available adjuvants to induce durable, long-lasting 
responses presents yet another challenge to malaria vaccine development. Both 
antibody and T cell-mediated responses on their own have been shown to at 
least confer non-sterile protection from disease [46,48-50,63], and an effective 
vaccine would be expected to induce both adaptive responses. Antibody 
responses require the induction of strong CD4+ T cell responses to provide the 
necessary B cell help. Induction of functional antibody and T cell responses has 
been achieved with vectored vaccines (DNA, viruses)  that especially employ 
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heterologous prime-boost vaccination regimens [64-69]. The inclusion of toll-
like receptor (TLR) agonist as immune modulators in currently available 
adjuvants has also been employed to induce strong antibody and T cell 
responses [36,70].  
Finally, recent findings that sporozoite antigens that remain in the skin after 
parasite passage into the liver induce immune tolerance that later dampens 
protective vaccine responses [71] suggest that vaccine delivery routes as well as 
candidate antigens may need to be carefully selected. These challenges 
notwithstanding, improvements in technology and increasing understanding of 
the complex nature of the parasite offer promise for a breakthrough, and malaria 
vaccine development remains an important public health objective. 
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SUMMARY 
A vaccine against the blood stages of malaria caused by Plasmodium falciparum 
would be an important addition to the currently available arsenal for disease 
control. A handful of immunologically relevant parasite antigens are at various 
stages of pre-clinical and clinical development. Amongst these is Plasmodium 
falciparum apical membrane antigen 1 (PfAMA1), an essential antigen initially 
expressed in micronemes of asexual blood stage parasites and believed to play a 
critical role in the parasite’s invasion of red blood cells. A similar role for this 
antigen has been described in sporozoites, and this makes PfAMA1 an important 
multi-stage vaccine candidate. The immune response to PfAMA1 is mediated 
mainly by antibodies that prevent invasion of host cells by parasites. PfAMA1 
however shows extensive polymorphism, with anti-PfAMA1 antibody responses 
exhibiting strain-specificity. One proposed strategy for dealing with strain-
specificity to PfAMA1 responses has been the formulation of vaccines with a 
number of PfAMA1 alleles as components, and this is the focus of the current 
thesis.  
In chapter 2 of this thesis the mechanism underlying broadening of anti-PfAMA1 
vaccine responses through immunisation with multi-allele formulations was 
investigated by comparing responses induced in rabbits with vaccines containing 
one and three PfAMA1 alleles (from FVO, HB3 and 3D7 parasite strains). A 
harmonized competition ELISA, together with an in vitro growth inhibition assay, 
was used to show that the three-allele vaccine induces a greater proportion of 
functional cross-strain antibodies compared to single allele vaccines. Cross-
strain antibodies were induced against epitopes that are shared between the 
vaccine alleles. These would include epitopes that are conserved in all PfAMA1 
alleles as well as epitopes that are common only to the vaccine alleles. Only a 
single PfAMA1 conserved epitope has thus far been described and the findings 
here suggest there may be a couple more of such conserved epitopes. The 
findings here also suggest that increasing the number of alleles included in a 
vaccine should in theory result in an increased proportion of the induced cross-
strain antibodies, and this raises the question of how many alleles are required 
to yield the best vaccine response against a diversity of strains. 
This question was addressed in chapter 3 by comparing responses induced in 
rabbits with vaccines incorporating three (Diversity Covering antigens or DiCos, 
designed in silico based on sequences of naturally occurring PfAMA1 alleles) and 
seven (the three DiCo antigens, alleles from strains FVO, HB3, 3D7 and CAMP) 
PfAMA1 alleles. Specificity assays showed that the proportions of induced cross-
strain antibodies were comparable between the two vaccines, both formulated 
with CoVaccine HT™ as adjuvant. Functional assays with protein G-purified 
antibodies confirmed this finding, suggesting that optimal broadening of the 
antibody response is achieved with three alleles, as there is a response plateau 
beyond this number. The effect of adjuvant choice on antibody specificity was 
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also investigated in this chapter. Responses against DiCo mix formulated with 
three different adjuvants (CoVaccine HT™, Montanide ISA 51 and Montanide 
IMS) showed only marginal differences in the proportions of induced cross-
strain antibodies. Functional assays however showed no adjuvant effect on 
antibody inhibitory capacity but rather an effect of the quantity of induced 
antibodies. Antibody responses against DiCo mix in Montanide IMS were 2 – 3 
fold lower compared to formulations with the other two adjuvants and this 
resulted in corresponding low growth inhibition capacities. 
In chapter 4, sequential immunisation as a possible strategy for further 
increasing the proportion of induced cross-strain anti-PfAMA1 antibodies was 
investigated. Groups of rabbits were immunised three times with three PfAMA1 
alleles in different orders and their responses compared to those of rabbits 
immunised three times with the same alleles as a mixture. It was established that 
immunisation with three PfAMA1 alleles in sequence resulted in similar 
proportions of cross-strain antibodies as three immunisations with the allele 
mixture. The findings here were also suggestive of the accumulation of a cross-
strain antibody repertoire with increasing exposure to variant parasites in the 
field.  
In chapter 5, the safety and immunogenicity of DiCo mix vaccines formulated 
with two different adjuvants (CoVaccine HT™ and Montanide ISA 51) were 
assessed in rhesus monkeys.  Safety and immunogenicity data in non-human 
primates may give a better indication of the vaccines’ effects in humans 
compared to data generated in rabbits. Different groups of rhesus macaques 
were immunised three times with the two DiCo formulations and an AMA1-MSP1 
(AM) fusion protein candidate formulated in Montanide ISA 51. Vaccine safety 
was assessed by physical and behavioural observation of animals as well as by 
measurement of chemical and haematological parameters as indices for organ 
and systemic functions. All vaccines were well tolerated with no vaccine-related 
adverse events, and DiCo mix in CoVaccine HT™ yielded the best immunogenicity 
data as assessed by indirect ELISA and in vitro growth inhibition assays. This 
data further demonstrates the specificity broadening effects of multi-allele 
formulations, and plans are underway to secure the proprietary adjuvant 
CoVaccine HT™ for testing DiCo mix in a phase I trial in a non-endemic 
population. Data from the AM fusion protein was however difficult to interpret 
as four of the six immunised animals were non-responsive for unknown reasons. 
Chapter 6 of this thesis examined the effect of PfAMA1 allele polymorphism on 
measurement of anti-PfAMA1 titres in field studies. Antibody titres in a naturally 
exposed cohort of children between the ages of 3 and 15 years, living in an 
endemic area of southern Ghana, were measured against four PfAMA1 alleles 
(from strains FVO, HB3, 3D7 and CAMP) as well as three antigen mixtures (DiCo 
mix, a mixture of the four natural alleles as well as a mixture of all seven alleles). 
The best allele for titre measurement in this population was deduced from 
comparisons of titres against single alleles with those against allele mixtures. 
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The mixtures are expected to have a wide repertoire of epitopes that would be 
recognised by antibodies of diverse specificities present in the polyclonal pool of 
naturally exposed individuals. Apart from that, the three DiCo antigens were 
designed specifically to cover naturally occurring polymorphism when used as 
an equimolar mixture. The FVO and 3D7 alleles were found to be best for use as 
capture antigens when measuring anti-PfAMA1 titres in this population. Analysis 
of PfAMA1 protein sequence data retrieved from GenBank however showed that 
the 3D7 and CAMP alleles were most prevalent of the four alleles in the Africa 
region. Findings here also suggest that the proportion of cross-strain antibodies 
most likely increases with age/exposure to different parasite strains and 
humans, especially infants and young children with limited parasite exposure, 
might discriminate between PfAMA1 alleles. Anti-PfAMA1 titres measured 
against single PfAMA1 alleles may therefore need to be cautiously interpreted as 
they may be underestimated in such individuals. 
Chapter 7 finally presents a general discussion of the findings in this thesis 
along with the current status of malaria vaccine development. 
The data presented in this thesis shows that multi-allele formulations are an 
important strategy for PfAMA1 vaccine design, and that PfAMA1 must at least be 
a component of an effective universal multi-antigen subunit vaccine. There are 
currently a number of vaccine design strategies that aim to combine several 
proven candidates either as the recombinant DNA, as antigen mixtures or as 
fusion proteins in order to cover polymorphism as well as target different stages 
of the parasite’s lifecycle. Other challenges such as availability of potent 
adjuvants, vaccine delivery systems and delivery routes will also need further 
investigation.    
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SAMENVATTING  
Een vaccin zou een belangrijke bijdrage kunnen leveren aan de bestrijding van 
malaria tropica, veroorzaakt door Plasmodium falciparum, verantwoordelijk 
voor 95% van de mortaliteit van malaria. Momenteel zijn er maar een klein 
aantal immunologisch relevante parasietantigenen in ontwikkeling tegen de 
bloedstadia van deze belangrijke infectieziekte.  Een van deze antigenen is 
Plasmodium falciparum apicaal membraan antigen 1 (PfAMA1), wat beschouwd 
wordt als één van de meest prominente bloedstadium-vaccinkandidaten PfAMA1 
is een essentieel eiwit dat waarschijnlijk een belangrijke rol speelt in de invasie 
van rode bloedcellen. Het komt initieel tot expressie in de micronemen van de 
asexuele bloedstadia van de parasiet. Het eiwit is ook aangetoond in sporozoiten 
en het vermoeden bestaat dat PfAMA1 ook betrokken is bij de invasie van 
levercellen. Dit maakt PfAMA1 mogelijk een multi-stadium vaccinkandidaat. 
De immuunrespons tegen PfAMA1 is hoofdzakelijk antilichaam gemedieerd. 
Deze antilichamen binden aan PfAMA1 en blokkeren zo de invasie van 
gastheercellen. PfAMA1 is een polymorf eiwit (allelische variatie) en 
antilichaamresponsen tegen PfAMA1 zijn grotendeels allel-specifiek. Een 
mogelijke oplossing om allel-specificiteit van antilichaam responsen te 
verbreden is vaccinatie met een mengsel van verschillende allelen. Dit laatste is 
het onderwerp van dit proefschrift. 
In hoofdstuk 2 worden mechanismen verantwoordelijk voor de verbreding van 
de immuunrespons na vaccinatie met meerdere allelen onderzocht door de 
antilichaamresponsen van konijnen gevaccineerd met slechts één PfAMA1 allel 
te vergelijken met responsen van konijnen gevaccineerd met een mengsel van 
drie PfAMA1 allelen (van de FVO, HB3 en 3D7 P. Falciparum parasietstammen). 
Met behulp van een geharmoniseerde competitie-ELISA en een in vitro groei 
inhibitie assay (GIA) werd aangetoond dat vaccinatie met een mengsel van drie 
PfAMA1 allelen meer functionele antilichamen opwekt die met meerdere 
PfAMA1 allelen reageren (cross-strain) dan vaccinatie met een enkel allel. Het 
merendeel van de antilichamen opgewekt door gelijktijdige vaccinatie met drie 
PfAMA1 allelen reageerde met epitopen die op ieder van deze drie vaccinallelen 
voorkomen. Dit soort cross-strain epitopen kunnen ook voorkomen op PfAMA1 
allelen die niet tot de drie vaccinallelen behoren. Tot nu toe is slechts één 
geconserveerde epitoop beschreven voor  PfAMA1 en de bevindingen uit 
hoofdstuk 2 suggereren dat er mogelijk meer geconserveerde epitopen kunnen 
zijn. De bevindingen in hoofdstuk 2 suggereren ook dat de antilichaamrespons 
verbreed kan worden door het aantal allelen in een vaccin te vergroten. Dit 
resulteert in de onderzoeksvraag hoeveel en welke allelen in een PfAMA1 vaccin 
dienen te worden opgenomen. 
Deze vraag wordt behandeld in hoofdstuk 3. Hier worden antilichaamresponsen 
in konijnen geïmmuniseerd met drie synthetische allelen (Diversity Covering 
PfAMA1 Antigenen of DiCo, specifiek ontworpen om een zo breed mogelijke 
PfAMA1 herkenning te geven) vergeleken met responsen in konijnen 
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geïmmuniseerd met zeven PfAMA1 allelen (3 DiCo PfAMA1’s aangevuld met 4 
natuurlijke allelen; FVO, HB3, 3D7 en CAMP). Uit specificiteitsbepalingen bleek 
dat de proporties cross-strain antilichamen vrijwel gelijk waren voor beide 
vaccins. Dit werd bevestigd door functionele assays met proteïne G gezuiverde 
antilichamen. Deze waarnemingen suggereren dat een brede antilichaamrespons 
opgewekt kan worden met een mengsel van drie allelen en dat hierna een 
plateau bereikt wordt. De invloed van het adjuvant,  werd ook in hoofdstuk 3 
onderzocht. Antilichaamresponsen tegen DiCo mix werden vergeleken met drie 
verschillende adjuvantia (CoVaccine HT™, Montanide ISA 51 en Montanide IMS). 
Het adjuvant had slechts een marginale invloed op de breedte van de 
geïnduceerde respons, maar wel een duidelijke invloed op de 
antilichaamhoeveelheden. Met behulp van functionele assays (GIAs) werden ook 
geen verschillen in de breedte van de respons waargenomen. Wederom 
resulteerde lagere antilichaamresponses in lagere GIA titers. 
In hoofdstuk 4 wordt onderzocht of sequentiële immunisatie de proportie 
cross-strain antilichamen kan verhogen. Om dit te onderzoeken werden groepen 
konijnen drie maal geïmmuniseerd met verschillende PfAMA1 allelen in 
verschillende volgordes en vergeleken met konijnen geïmmuniseerd met een 
mengsel van de drie allelen. De resultaten wezen uit dat simultane en sequentiële 
immunisatie vergelijkbare hoeveelheden cross-strain antilichamen opleveren. De 
resultaten suggereren ook dat de hoeveelheid cross-strain antilichamen 
toeneemt na blootstelling aan variant allelen in het veld. 
In hoofdstuk 5 wordt de veiligheid en immunogeniciteit van DiCo mix 
antigenen, geformuleerd met twee verschillende adjuvantia (CoVaccine HT™ en 
Montanide ISA 51), onderzocht in resus makaken. Veiligheids- en 
immuniteitsgegevens in niet-humane primaten geven mogelijk meer informatie 
dan gegevens uit studies met konijnen. Groepen resus makaken werden drie 
keer geïmmuniseerd met twee verschillende PfAMA1 DiCo formuleringen (in 
CoVaccine HT™ en Montanide ISA51) of met een PfAMA1-MSP1-19 fusie-eiwit, 
geformuleerd in Montanide ISA51. Vaccinveiligheid wordt bepaald middels 
gedragsobservatie, inspectie van de injectieplaatsen en bepaling van klinisch 
chemische en hematologische parameters als indices voor orgaanfunctie. Alle 
vaccinformuleringen werden goed verdragen zonder dat er vaccingerelateerde 
bijwerkingen werden waargenomen. Een mengsel van drie DiCo PfAMA1 
eiwitten  in het adjuvant CoVaccine HT™ gaf de beste immunogeniciteit, bepaald 
met ELISA en met in vitro groei inhibitie bepalingen. Uit de gegevens van de 
immunisaties met het PfAMA1-MSP1-19 fusie-eiwit konden geen harde conclusies 
worden getrokken omdat vier van de zes geïmmuniseerde dieren 
onverklaarbaar lage responsen te zien gaven. De gegevens verkregen met non-
humane primaten bevestigen dat vaccinatie met multi-allel formuleringen de  
specificiteit van de respons verbreedt. Momenteel worden plannen gemaakt om 
DiCo Mix met Covaccine HT™ in een fase Ia studie in niet aan malaria 
blootgestelde volwassenen te testen. 
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In hoofdstuk 6 wordt het effect van PfAMA1 polymorfismen op 
antilichaambepalingen in malaria-endemische gebieden nagegaan. Hiervoor 
werden antilichaamtiters in een cohort van aan malaria blootgestelde Ghanese 
kinderen tussen 3 en 15 jaar bepaald met verschillende antigenen of combinaties 
daarvan. Voor dit onderzoek werden platen gecoat met een van de natuurlijke 
PfAMA1 varianten FVO, HB3, 3D7 of CAMP, of met een mengsel van antigenen 
(een mengsel van DiCo PfAMA1 eiwitten, 4 natuurlijke allelen of en mengsel van 
alle zeven PfAMA1 eiwitten). Het beste coating antigeen werd bepaald door 
titers tegen enkele allelen te vergelijken met titers tegen allelmengsels. Van de 
mengsels verwacht men dat deze een breed repertoire van potentiële epitopen 
bevatten, die door polyclonale antilichamen van aan malaria blootgestelde 
personen herkend kunnen worden. Ook werd een equimolair mengsel van de 
drie DiCo PfAMA1’s getest. PfAMA1 van de FVO en 3D7 allelen bleken een goed 
beeld te geven van de anti PfAMA1 antilichamen in de onderzochte populatie. 
Analyses van PfAMA1 eiwitsequenties uit Genbank echter wijzen erop dat de 
3D7 en CAMP allelvormen het meest prevalent zouden kunnen zijn in Afrika.  
De gegevens laten verder zien dat de hoeveelheid cross-strain antilichamen 
toeneemt met leeftijd en/of blootstelling aan verschillende varianten. Peuters en 
jonge kinderen lijken meer onderscheid te maken tussen verschillende PfAMA1 
allelen dan oudere kinderen. Het verdient daarom aanbeveling om PfAMA1 titers 
bepaald tegen slechts één variant voorzichtig te interpreteren omdat deze 
mogelijk de hoeveelheden antilichamen in jongere leeftijdsgroepen 
onderschatten. 
Hoofdstuk 7 stelt definitief een algemene bespreking van de bevindingen in 
deze thesis samen met het huidige statuut van de ontwikkeling van het 
malariavaccin. 
De gegevens in dit proefschrift maken duidelijk dat multi-allel formuleringen een 
belangrijke strategie zijn voor PfAMA1 vaccins en dat PfAMA1 een component 
van een effectief universeel multi-antigeen vaccin tegen malaria zou moeten zijn. 
Er zijn momenteel een aantal vaccinstrategieën gericht op het combineren van 
meerdere gevalideerde kandidaat antigenen zowel als DNA vaccin, 
antigeenmengsels als fusie-eiwitten om zo polymorfismen en verschillende 
levensstadia van de parasiet te bestrijden. Andere uitdagingen zoals de 
beschikbaarheid van potente adjuvantia, vaccin-delivery systemen en 
toedieningsroutes behoeven nog verder onderzoek. 
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SUPPLEMENTARY FIGURES 
 
 
 
 
 
 
 
 
 
Figure S1 of Chapter 2. Schematic presentation of strain specific and cross-reactive anti-
AMA1 antibody purification. Cross-reactive and strain-specific IgG fractions of anti-3D7 AMA1 
IgGs (A) and anti-FVO AMA1 IgGs (B) were isolated from the sera of the respective mono-specific 
AMA1-immunised rabbits. Serum IgGs were first purified over protein A sepharose columns 
before affinity fractionation.  
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Figure S2 of chapter 2. Competition ELISA using different dilutions of anti-FVO AMA1 
antibodies with FVO AMA1-coated plates. The assay involves co-incubation of a 
soluble/competitor antigen with antibodies in an antigen-coated plate such that there is 
competition between the coated and soluble/competitor antigens for binding to test antibodies. 
Protein A-purified anti-FVO AMA1 antibodies were used at dilutions equivalent to 0.2, 0.5, 1, 2, 4 
and 8 times the antibody titre (1AU, the IgG dilution that yields an OD405 of 1.0). Each dilution of 
antibody was added to FVO AMA1-coated plates with soluble/competitor AMA1 antigens from 
the 3D7, HB3, FVO and CAMP parasite strains, each titrated from 30 – 0.005 µg/ml in duplicate 
wells. Antibodies that were not depleted by the soluble/competitor antigens bound to the coated 
antigen (residual binding), and the resulting optical densities (OD) were expressed as 
percentages of ODs from reagent wells with antibody but no competitor antigens. Competitor 
antigen concentrations (log transformed) were then plotted against the percent residual binding 
for all competitor antigens. Depletion patterns for competitor/soluble FVO or sFVO (A), sHB3 (B), 
s3D7 (C) and sCAMP (D) AMA1 antigens at the different antibody dilutions are shown. 
 
